

CURRICULUM VITAE

DIMITRIOS A. MAVROUDIS, M.D., Ph.D.

Work address: Department of Medical Oncology
University Hospital of Heraklion
P.O BOX 1352, Voutes, 71110,
Heraklion, Crete, Greece

tel office: +30 2810 392438

fax: +30 2810 392802

e-mail: mavrudis@med.uoc.gr

secretary: +30 2810 392747, email: oncsec@med.uoc.gr

SEPTEMBER 2025

CURRENT AND PREVIOUS APPOINTMENTS

Chief of Medical Oncology University Hospital of Heraklion, Crete, Greece	June 2014- present
Professor of Medical Oncology Medical School, University of Crete	May 2011 – present
Associate Professor of Medical Oncology Medical School, University of Crete	January 2004 – May 2011
Assistant Professor of Laboratory Hematology Medical School University of Crete	November 2000 – December 2003
Senior Clinical Attending Department of Medical Oncology University Hospital of Heraklion Crete, Greece	March 2000 – October 2000
Clinical Associate Department of Medical Oncology University Hospital of Heraklion Crete, Greece	September 1997 – March 2000
Senior fellow - Attending Physician Bone Marrow Transplantation Unit National Heart Lung & Blood Institute National Institutes of Health, Bethesda, Maryland, USA	July 1995 - June 1997

EDUCATION AND TRAINING

Fellowship Hematology - Oncology July 1992 - June 1995

National Heart Lung & Blood Institute

National Cancer Institute

**National Institutes of Health,
Bethesda, Maryland, USA**

Chief Resident in Internal Medicine July 1991 - June 1992

Hines VA Hospital, Hines, Illinois, USA

Residency in Internal Medicine July 1990 - June 1992

Hines VA Hospital, Hines, Illinois

Loyola University Hospital,

Maywood, Illinois, USA

Internship in Internal Medicine June 1989 - June 1990

Hines VA Hospital, Hines, Illinois

Loyola University Hospital,

Maywood, Illinois, USA

Medical Degree November 1978 - January 1985

University of Athens Medical School,

Athens, Greece

BOARD CERTIFICATION

Diplomate of the American Board of Medical Specialties in Hematology November 1996

Diplomate of the American Board of Medical Specialties in Medical Oncology November 1995

Diplomate of the American Board of Internal Medicine September 1992

DOCTOR OF PHILOSOPHY

Ph.D thesis:

“In vitro separation of donor T-cells responsible for the Graft-Versus-Host reaction from donor T-cells responsible for the Graft-Versus-Leukemia reaction in allogeneic bone marrow transplantation” July 1997, University of Crete, Medical School, Heraklion, Crete, Greece.

QUALIFYING EXAMS

FLEX examinations of the State of Illinois December 1990, Skokie, Illinois

FMGEMS examination, ECFMG January 20-21, 1987, Athens, Greece
certification

PUBLICATIONS

1. Datta AR, Barrett AJ, Jiang YZ, Guimaraes A, **Mavroudis D**, van Rhee F, Gordon AA, Madrigal A. Distinct T cell populations distinguish chronic myeloid leukemia cells from lymphocytes in the same individual: a model for separating GVHD from GVL reactions. Bone Marrow Transplant 1994; 14:517-24
2. Lewalle P, Hensel N, Guimaraes A, Couriel D, Jiang YZ, **Mavroudis D**, Barrett AJ. Helper and cytotoxic lymphocyte responses to chronic myeloid leukemia: implications for adoptive immunotherapy with T cells. Brit J Haematol 1996; 92:587-94
3. Jiang YZ, Couriel D, **Mavroudis D**, Lewalle P, Malkovska V, Hensel N, Dermime S, Mollrem J, Barrett AJ. Interaction of natural killer cells with MHC class II: reversal of HLA-DR1-mediated protection of K562 transfectant from natural killer cell-mediated cytotoxicity by brefeldin-A. Immunology 1996; 87:481-6
4. **Mavroudis D**, Jiang YZ, Hensel N, Lewalle P, Couriel D, Kreitman R, Pastan I, Barrett AJ. Specific depletion of alloreactivity against haplotype mismatched related individuals by a recombinant immunotoxin: a new approach to graft-versus-host disease prophylaxis in haploidentical bone marrow transplantation. Bone Marrow Transplant 1996; 17:793-9
5. Jiang YZ, **Mavroudis D**, Dermime S, Hensel N, Couriel D, Molldrem J, Barrett AJ. Alloreactive CD4+ T lymphocytes can exert cytotoxicity to chronic myeloid leukemia cells processing and presenting exogenous antigen. Brit J Haematol 1996; 93:606-12
6. Molldrem J, Dermime S, Parker K, Jiang YZ, **Mavroudis D**, Hensel N, Fukushima P, Barrett AJ. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood 1996; 88:2450-7
7. **Mavroudis D**, Read E, Cottler-Fox M, Couriel D, Molldrem J, Carter C, Yu M, Dunbar C, Barrett J. CD34+ cell dose predicts survival, post transplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies. Blood 1996; 88:3223-9

8. Jiang YZ, Barrett AJ, Goldman JM, **Mavroudis D**. Association of natural killer cell immune recovery with a graft-versus-leukemia effect independent of graft-versus-host disease following allogeneic bone marrow transplantation. *Ann Hematol* 1997; 74:1-6
9. Jiang YZ, **Mavroudis D**, Dermime S, Molldrem J, Hensel N, Barrett AJ. Preferential usage of T cell receptor (TCR) V beta by allogeneic T cells recognizing myeloid leukemia cells: implications for separating graft-versus-leukemia effect from graft-versus-host disease. *Bone Marrow Transplant* 1997; 19:899-903
10. Dermime S, **Mavroudis D**, Jiang YZ, Hensel N, Molldrem J, Barrett AJ. Immune escape from a graft-versus-leukemia effect may play a role in the relapse of myeloid leukemias following allogeneic bone marrow transplantation. *Bone Marrow Transplant* 1997; 19:989-99
11. Molldrem J, Clave E, Jiang YZ, **Mavroudis D**, Raptis A, Hensel N, Agarwala V, Barrett AJ. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. *Blood* 1997; 90:2529-34
12. Molldrem J, Caples M, **Mavroudis D**, Plante M, Young N, Barrett AJ. Antithymocyte globulin for patients with myelodysplastic syndrome. *Brit J Haematol* 1997; 99:699-705
13. **Mavroudis D**, Barrett J. The graft-versus-leukemia effect. *Curr Opin Hematol* 1996; 3:423-9
14. **Mavroudis D**, Read EJ, Molldrem J, Raptis A, Plante M, Carter C, Phang S, Dunbar C, Barrett AJ. T cell-depleted granulocyte colony-stimulating factor (G-CSF) modified allogeneic bone marrow transplantation for hematological malignancy improves graft CD34+ cell content but is associated with delayed pancytopenia. *Bone Marrow Transplant* 1998; 21:431-40
15. Barrett AJ, **Mavroudis D**, Tisdale J, Molldrem J, Clave E, Dunbar C, Cottler-Fox M, Phang S, Carter C, O'Kunnieff P, Young N, Read EJ. T-cell depleted bone marrow transplantation and delayed T-cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect. *Bone Marrow Transplant* 1998; 21:543-51

16. **Mavroudis D**, Dermime S, Molldrem J, Jiang YZ, Raptis A, van Rhee F, Hensel N, Fellowes V, Eliopoulos G, Barrett A.J. Specific depletion of alloreactive T cells in HLA-identical siblings: a method for separating graft-versus-host and graft-versus-leukaemia reactions. *Brit J Haematol* 1998; 101:565-70
17. Molldrem J, Jiang YZ, Stetler-Stevenson M, **Mavroudis D**, Hensel N, Barrett AJ. Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles. *Brit J Haematol* 1998; 102:1314-22
18. Raptis A, Clave E, **Mavroudis D**, Molldrem J, van Rhee F, Barrett AJ. Polymorphism in CD33 and CD34 genes: a source of minor histocompatibility antigens on haemopoietic progenitor cells? *Brit J Haematol* 1998; 102:1354-8
19. Hensel N, Agarwala V, Jiang YZ, **Mavroudis D**, Molldrem J, Barrett AJ. A technique for dual determination of cytotoxic and helper lymphocyte precursor frequency by a miniaturized dye release method. *Bone Marrow Transplant* 1999; 23:71-8
20. Kouroussis C, Androulakis N, Kakolyris S, Souglakos J, Kotsakis T, **Mavroudis D**, Katsogridakis K, Vardakis N, Hatzidaki D, Samonis G, Vlachonikolis J, Georgoulis V. Dose-escalation study of docetaxel in combination with mitoxantrone as first-line treatment in patients with metastatic breast cancer. *J Clin Oncol* 1999; 17:862-9
21. **Mavroudis D**, Malamos N, Alexopoulos A, Kourousis C, Agelaki S, Sarra E, Potamianou A, Kosmas C, Rigatos G, Giannakakis T, Kalbakis K, Apostolaki F, Vlachonikolis J, Kakolyris S, Samonis G, Georgoulis V. Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: A multicenter phase II trial. *Ann Oncol* 1999; 10:211-5
22. Kouroussis C, Xydakis E, Potamianou A, Giannakakis T, Kakolyris S, Agelaki S, Sara E, Malamos N, Alexopoulos A, **Mavroudis D**, Samonis G, Papadouris S, Georgoulis V, Panagos G. Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: a multicenter dose-escalation study. *Ann*

Oncol 1999; 10:547-52

23. Raptis A, **Mavroudis D**, Suffredini A, Molldrem J, Rhee F, Childs R, Phang S, Barrett AJ. High-dose corticosteroid therapy for diffuse alveolar hemorrhage in allogeneic bone marrow stem cell transplant recipients. Bone Marrow Transplant 1999; 24:879-83
24. van Rhee F, Jiang YZ, Vigue F, Kirby M, **Mavroudis D**, Hensel NF, Agarwala V, Clave E, Childs R, Raptis A, Sloand E, Carter C, Read EJ, Barrett J. Human G-CSF-mobilized CD34-positive peripheral blood progenitor cells can stimulate allogeneic T-cell responses: implications for graft rejection in mismatched transplantation. Br J Haematol 1999; 105:1014-24
25. **Mavroudis D**, Kourousis C, Kakolyris S, Agelaki S, Kalbakis K, Androulakis N, Souglakos J, Vardakis N, Samonis G, Georgoulas V. Phase I study of the gemcitabine/oxaliplatin combination in patients with advanced solid tumors: a preliminary report. Semin Oncol 2000; 27(1 Suppl 2):25-30
26. Giannakakis T, Ziras N, Kakolyris S, **Mavroudis D**, Androulakis N, Agelaki S, Parashos M, Sarra E, Dimou T, Hatzidaki D, Vlachonikolis J, Georgoulas V. Docetaxel in combination with carboplatin for the treatment of advanced non-small cell lung carcinoma: a multicentre phase I study. Eur J Cancer 2000; 36:742-7
27. Kakolyris S, Kouroussis C, Kalbakis K, **Mavroudis D**, Souglakos J, Vardakis N, Kremos S, Georgoulas V. Salvage treatment of advanced non-small-cell lung cancer previously treated with docetaxel-based front-line chemotherapy with irinotecan (CPT-11) in combination with cisplatin. Ann Oncol 2000; 11:757-60
28. **Mavroudis D**, Kourousis C, Androulakis N, Kalbakis K, Agelaki S, Kakolyris S, Souglakos J, Sarra E, Vardakis N, Hatzidaki D, Samonis G, Georgoulas V. Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial. Am J Clin Oncol 2000; 23:341-4
29. **Mavroudis D**, Alexopoulos A, Ziras N, Malamos N, Kouroussis C, Kakolyris S, Agelaki S, Kalbakis K, Tsavaris N, Potamianou A, Rigatos G, Georgoulas V. Front-line treatment of advanced breast cancer with docetaxel and epirubicin: a multicenter phase II study. Ann Oncol 2000; 11:1249-54

30. Kakolyris S, Souglakos J, Agelaki S, Kourousis C, **Mavroudis D**, Sarra E, Malliotakis P, Georgoulas V. A dose-escalation study of irinotecan (CPT-11) in combination with cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy. *Lung Cancer* 2000; 30:193-8
31. Kouroussis C, Agelaki S, **Mavroudis D**, Souglakos J, Kakolyris S, Kalbakis K, Vardakis N, Reppa D, Hatzidaki D, Samonis G, Georgoulas V. A dose escalation study of weekly docetaxel in patients with advanced solid tumors. *Cancer Chemother Pharmacol* 2000; 46:488-92
32. Stathopoulos GP, **Mavroudis D**, Tsavaris N, Kouroussis C, Aravantinos G, Agelaki S, Kakolyris S, Rigatos S, Karabekios S, Georgoulas V. Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: A phase II study of the Greek Cooperative Group for pancreatic cancer. *Ann Oncol* 2001; 12:101-3
33. Kakolyris S, **Mavroudis D**, Tsavaris N, Souglakos J, Tsiafaki P, Kalbakis K, Agelaki S, Androulakis N, Georgoulas V. Paclitaxel in combination with carboplatin as salvage treatment in refractory small-cell lung cancer (SCLC). A multicenter phase II study. *Ann Oncol* 2001; 12:193-7
34. Kakolyris S, Souglakos J, Kouroussis C, Androulakis N, **Mavroudis D**, Kalbakis K, Kotsakis A, Vardakis N, Koukourakis M, Romanos J, Georgoulas V. A dose-finding study of irinotecan (CPT-11) plus a four-day continuous 5-fluorouracil infusion in advanced colorectal cancer. *Oncology* 2001; 60:207-13
35. **Mavroudis D**, Papadakis E, Veslemes M, Tsiafaki X, Stavrakakis J, Kouroussis C, Kakolyris S, Bania E, Jordanoglou J, Agelidou M, Vlachonikolis J, Georgoulas V. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first line treatment in patients with small cell lung cancer. *Ann Oncol* 2001; 12:463-70
36. Samonis G, Anatoliotaki M, Apostolakou H, Maraki S, **Mavroudis D**, Georgoulas V. Transient fungemia due to *Rhodotorula rubra* in a cancer patient: case report and review of the literature. *Infection* 2001; 29:173-6

37. Kouroussis C, Souglakos J, Kakolyris S, **Mavroudis D**, Malamos N, Kalbakis K, Androulakis N, Agelaki A, Vardakis N, Samonis G, Georgoulas V. Oxaliplatin in combination with infusional 5-fluorouracil and leucovorin every 2 weeks as first-line treatment in patients with advanced colorectal cancer: A phase II study. *Oncology* 2001; 61:36-41
38. Kouroussis C, Kakolyris S, **Mavroudis D**, Androulakis N, Kalbakis K, Agelaki S, Sarra E, Souglakos J, Christodoulakis M, Samonis G, Georgoulas V. A dose-finding study of the weekly administration of paclitaxel in patients with advanced solid tumors. *Am J Clin Oncol* 2001; 24:404-7
39. Alexopoulos A, Kouroussis C, Malamos N, Kakolyris S, Kalbakis K, Kosmas C, **Mavroudis D**, Agelaki S, Vlachonikolis J, Sarra E, Rigatos G, Georgoulas V. Docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor as front line chemotherapy in metastatic breast cancer: a multicenter phase II study. *Ann Oncol* 2001; 12:793-8
40. Kalbakis K, Kouroussis C, Kakolyris S, **Mavroudis D**, Souglakos J, Agelaki S, Vamvakas L, Christodoulakis M, Stylianos K, Georgoulas V. Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuous infusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with anthracycline and taxane refractory metastatic breast cancer (MBC). *Brit J Cancer* 2001; 85:798-802
41. Agelaki S, Kakolyris S, Palamidas P, Rigatos G, Kouroussis C, **Mavroudis D**, Kalbakis K, Hatzidaki D, Georgoulas V, Raptis A. A dose escalation study of topotecan in combination with epirubicin in pretreated patients with small cell lung cancer. *Lung Cancer* 2001; 34:133-9
42. Kakolyris S, Kouroussis C, Souglakos J, **Mavroudis D**, Agelaki S, Kalbakis K, Androulakis N, Vardakis N, Vamvakas L, Georgoulas V. A phase I clinical trial of topotecan given every two weeks in patients with refractory solid tumors. *Oncology* 2001; 61:265-70
43. Georgoulas V, Samonis G, Papadakis E, Alexopoulos A, Tsiadaki X, Rapti A, Veslemes M, Grigoratou T, Palamidas P, Kouroussis C, **Mavroudis D**, Kakolyris S, Giannakakis T, Vlachonikolis J. Comparison of docetaxel/cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer: early results of a randomized trial. *Lung Cancer* 2001; 34 Suppl 4:S47-51

44. **Mavroudis D.** New therapeutic approaches in non-small-cell lung carcinoma (NSCLC), stages IV] *Rev Pneumol Clin.* 2001 Nov;57(5 Pt 2):S42-5. Review
45. Vamvakas L, Kakolyris S, Kouroussis C, Kandilis K, **Mavroudis D**, Ziras N, Androulakis N, Kalbakis K, Sarra E, Souglakos J, Georgoulas V. Irinotecan (CPT-11) in combination with infusional 5-fluorouracil and leucovorin (de Gramont regimen) as first-line treatment in patients with advanced colorectal cancer: A multicenter phase II study. *Am J Clin Oncol* 2002; 25:65-70
46. Kosmas C, Agelaki S, Giannakakis T, **Mavroudis D**, Kouroussis Ch, Kalbakis K, Papadouris S, Souglakos J, Malamos N, Georgoulas V. Phase I study of vinorelbine and Carboplatin combination in patients with taxane and anthracycline pretreated advanced breast cancer. *Oncology* 2002; 62:103-9
47. Kakolyris S, Kouroussis C, Koukourakis M, **Mavroudis D**, Malas K, Vardakis N, Bozionelou V, Kalbakis K, Georgoulas V. A dose-escalation study of oxaliplatin and vinorelbine in patients with advanced solid tumors. *Oncology* 2002; 63:213-8
48. Lydaki E, Nikoloudi E, Bolonaki E, **Mavroudis D**, Kandidaki E. Altering interface detector positioning in combination with prestorage filtration to achieve a better quality of single donor platelet concentrates using the CS 3000 Plus blood separator. *J Clin Apheresis* 2002; 17:21-6
49. Souglakos J, **Mavroudis D**, Kakolyris S, Kourousis C, Vardakis N, Androulakis N, Agelaki S, Kalbakis K, Tsetis D, Athanasiadis N, Samonis G, Georgoulas V. Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial. *J Clin Oncol* 2002; 20:2651-7
50. **Mavroudis D**, Kouroussis C, Kakolyris S, Agelaki S, Kalbakis K, Androulakis N, Souglakos J, Georgoulas V. Phase I study of paclitaxel (Taxol) and pegylated liposomal doxorubicin (Caelyx) administered every two weeks in patients with advanced solid tumors. *Oncology* 2002, 62:216-22
51. Kakolyris S, Kouroussis C, Koukourakis M, Kalbakis K, **Mavroudis D**, Vardakis N, Georgoulas V. A dose-escalation study of irinotecan (CPT-11) in

combination with gemcitabine in patients with advanced non-small cell lung cancer previously treated with a cisplatin-based front line chemotherapy. *Anticancer Res* 2002; 22:1891-6

52. Stathopoulou A, Vlachonikolis I, **Mavroudis D**, Perraki M, Kouroussis Ch, Apostolaki S, Malamos N, Kakolyris S, Kotsakis A, Xenidis N, Reppa D, Georgoulas V. Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. *J Clin Oncol* 2002; 20:3404-12
53. Souglakos J, Kotsakis A, Kouroussis C, Kakolyris S, **Mavroudis D**, Kalbakis K, Agelaki S, Vlachonikolis J, Georgoulas V, Samonis G. Nonneutropenic febrile episodes associated with docetaxel-based chemotherapy in patients with solid tumors. *Cancer* 2002; 95:1326-33
54. **Mavroudis D**, Veslemes M, Kouroussis C, Tzanakis N, Ferdoutsis E, Toubis M, Ziotopoulos P, Agelidou M, Tselepatiotis E, Kalbakis K, Souglakos J, Magkanas E, Samonis G, Georgoulas V. Cisplatin-etoposide alternating with topotecan in patients with extensive stage small cell lung cancer (SCLC). A multicenter phase II study. *Lung Cancer* 2002; 38:59-63
55. Androulakis N, Kouroussis C, **Mavroudis D**, Kakolyris S, Souglakos J, Agelaki S, Kalbakis K, Malas K, Pallis A, Samonis G, Georgoulas V. Phase I study of weekly paclitaxel and liposomal doxorubicin in patients with advanced solid tumors. *Eur J Cancer* 2002; 38:1992-7
56. Solomon SR, Tran T, Carter CS, Donnelly S, Hensel N, Schindler J, Bahceci E, Chetie V, Michalek J, **Mavroudis D**, Read EJ, Vitetta ES, Barrett AJ. Optimized clinical-scale culture conditions for ex-vivo selective depletion of host-reactive donor lymphocytes: a strategy for GvHD prophylaxis in allogeneic PBSC transplantation. *Cytotherapy* 2002; 4:395-406
57. Kouroussis C, Souglakos J, **Mavroudis D**, Papadouris S, Kakolyris S, Agelaki S, Kalbakis K, Panopoulos C, Vardakis N, Sarra E, Georgoulas V. Oxaliplatin with high-dose leucovorin and infusional 5-fluorouracil in irinotecan-pretreated patients with advanced colorectal cancer. *Am J Clin Oncol* 2002; 25:627-3
58. **Mavroudis D**, Pavlakou G, Blazoyiannakis G, Veslemes M, Apostolopoulou F, Kouroussis Ch, Kakolyris S, Agelaki S, Androulakis N, Vardakis N, Magkanas

E, Samonis G, Georgoulas V. Sequential administration of cisplatin-etoposide followed by topotecan in patients with extensive stage small cell lung cancer (SCLC). A multicenter phase II study. Lung Cancer 2003; 39:71-6

59. **Mavroudis D**, Pappas P, Kouroussis C, Kakolyris S, Agelaki S, Kalbakis K, Androulakis N, Souglakos J, Vardakis N, Nikolaidou M, Samonis G, Marselos M, Georgoulas V. A dose escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors. Ann Oncol 2003; 14:304-12
60. Kouroussis C, Agelaki S, **Mavroudis D**, Kakolyris S, Androulakis N, Kalbakis K, Souglakos J, Mallas K, Bozionelou V, Pallis A, Adamtziki H, Georgoulas V. A dose escalation study of docetaxel and oxaliplatin combination in patients with metastatic breast and non-small cell lung cancer. Anticancer Res 2003; 23:785-91
61. **Mavroudis D**, Alexopoulos A, Malamos N, Ardavanis A, Kandyli C, Stavriniadis E, Kouroussis Ch, Agelaki S, Androulakis N, Bozionelou V, Georgoulas V. Salvage treatment of metastatic breast cancer with docetaxel and carboplatin. A multicenter phase II trial. Oncology 2003; 64:207-12
62. Stathopoulou A, **Mavroudis D**, Perraki M, Apostolaki S, Vlachonikolis J, Lianidou E, Georgoulas V. Molecular detection of cancer cells in the peripheral blood of patients with breast cancer: comparison of CK-19, CEA and maspin as detection markers. Anticancer Res 2003; 23:1883-90
63. Xenidis N, Vlachonikolis I, **Mavroudis D**, Perraki M, Stathopoulou A, Malamos N, Kouroussis C, Kakolyris S, Apostolaki S, Vardakis N, Lianidou E, Georgoulas V. Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer. Ann Oncol 2003; 14: 849-55
64. Pallis A, **Mavroudis D**, Androulakis N, Souglakos J, Kouroussis C, Bozionelou V, Vlachonikolis I, Georgoulas V. ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program. Lung Cancer 2003; 40: 301-7
65. Souglakos J, Androulakis N, **Mavroudis D**, Kouroussis C, Kakolyris S, Vardakis N, Kalbakis K, Pallis A, Ardavanis A, Varveris C, Georgoulas V. A

multicenter dose finding study of concurrent capecitabine and radiotherapy as adjuvant treatment for operable rectal cancer. *Int J Radiat Oncol* 2003; 56: 1284-7

66. Dimitriou H, Vorgia P, Stiakaki E, **Mavroudis D**, Markaki E, Koumantakis E, Kalmanti M. In vitro proliferative and differentiating characteristics of CD133+ and CD34+ cord blood cells in the presence of Thrombopoietin (TPO) or Erythropoietin (EPO). Potential implications for hematopoietic cell transplantation. *Leukemia Res* 2003; 27: 1143-51
67. Fountzilas G, Razis E, Tsavdaridis D, Karina M, Labropoulos S, Christodoulou C, **Mavroudis D**, Gogas H, Georgoulas V, Skarlos D. Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group. *Clin Breast Cancer*. 2003; 4: 120-5
68. Stathopoulou A, Gizi A, Perraki M, Apostolaki S, Malamos N, **Mavroudis D**, Georgoulas V, Lianidou ES. Real-time quantification of CK-19 mRNA positive cells in peripheral blood of breast cancer patients using the LightCycler system. *Clin Cancer Res*, 2003; 9:5145-51
69. Samonis G, Maraki S, Kouroussis C, **Mavroudis D**, Georgoulas V. Salmonella enterica pneumonia in a patient with lung cancer. *J Clin Microbiol*. 2003; 41:5820-2
70. Giatromanolaki A, Koukourakis MI, Kakolyris S, **Mavroudis D**, Kouroussis C, Mavroudi C, Perraki M, Sivridis E, Georgoulas V. Assessment of highly angiogenic and disseminated in the peripheral blood disease in breast cancer patients predicts for resistance to adjuvant chemotherapy and early relapse. *Int J Cancer*. 2004; 108:620-7
71. Anatoliotaki M, Valatas V, Mantadakis E, Apostolakou H, **Mavroudis D**, Georgoulas V, Rolston KV, Kontoyiannis DP, Galanakis E, Samonis G. Bloodstream infections in patients with solid tumors: associated factors, microbial spectrum and outcome. *Infection*. 2004; 32:65-71
72. Kouroussis C, **Mavroudis D**, Kakolyris S, Voloudaki A, Kalbakis K, Souglakos J, Agelaki S, Malas K, Bozionelou V, Georgoulas V. High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study. *Lung Cancer*

2004; 44:363-8

73. Kakolyris S, Souglakos J, Kouroussis C, Androulakis N, Samonis G, Vardakis N, Amarantidis K, Agelaki S, **Mavroudis D**, Xenidis N, Georgoulas V. Dose escalation study on oxaliplatin and capecitabine (Xeloda) in patients with advanced solid tumors. *Oncology* 2004; 66:253-9.
74. **Mavroudis D**, Malamos N, Polyzos A, Kouroussis Ch, Christophilakis Ch, Varthalitis I, Androulakis N, Kalbakis K, Milaki G, Georgoulas V. Front-line chemotherapy with docetaxel and gemcitabine administered every two weeks in patients with metastatic breast cancer: a multicenter phase II study. *Oncology* 2004;67:250-6
75. Bozionellou V, **Mavroudis D**, Perraki M, Papadopoulos S, Apostolaki S, Stathopoulos E, Stathopoulou A, Lianidou E, Georgoulas V. Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer. *Clin Cancer Res.* 2004; 10:8185-94
76. Stathopoulos EN, Sanidas E, Kafousi M, **Mavroudis D**, Askoxylakis J, Bozionelou V, Perraki M, Tsiftsis D, Georgoulas V. Detection of CK-19 mRNA-positive cells in the peripheral blood of breast cancer patients with histologically and immunohistochemically negative axillary lymph nodes. *Ann Oncol.* 2005; 16:240-6
77. Fountzilas G, Pectasides D, Kalogera-Fountzila A, Skarlos D, Kalofonos HP, Papadimitriou C, Bafaloukos D, Lambropoulos S, Papadopoulos S, Kourea H, Markopoulos C, Linardou H, **Mavroudis D**, Briasoulis E, Pavlidis N, Razis E, Kosmidis P, Gogas H. Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group. *Breast Cancer Res Treat.* 2005; 92:1-9
78. Georgoulas V, Agelidou A, Syrigos K, Rapti A, Agelidou M, Nikolakopoulos J, Polyzos A, Athanasiadis A, Tselepatiotis E, Androulakis N, Kalbakis K, Samonis G, **Mavroudis D**. Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study. *Br J Cancer.* 2005; 93:763-9

79. Souglakos J, Kakolyris S, Vardakis N, Androulakis N, **Mavroudis D**, Vamvakas L, Kouroussis C, Agelaki S, Saridaki Z, Georgoulas V. A dose escalating study of oxaliplatin and high dose weekly leucovorin and 5-Fluorouracil in patients with advanced solid tumors. *Cancer Invest.* 2005; 23:505-10
80. Souglakos J, Pallis A, Kakolyris S, **Mavroudis D**, Androulakis N, Kouroussis C, Agelaki S, Xenidis N, Milaki G, Georgoulas V. Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: a phase II trial. *Oncology.* 2005; 69:384-90
81. Ignatiadis M, **Mavroudis D**, Veslemes M, Boukovinas J, Syrigos K, Agelidou M, Agelidou A, Gerogianni A, Pavlaku G, Tselepatiotis E, Nikolakopoulos J, Georgoulas V. Sequential versus alternating administration of cisplatin/etoposide and topotecan as first-line treatment in extensive-stage small-cell lung cancer: preliminary results of a Phase III Trial of the Hellenic Oncology Research Group. *Clin Lung Cancer.* 2005; 7:183-9
82. Souglakos J, Androulakis N, Syrigos K, Polyzos A, Ziras N, Athanasiadis A, Kakolyris S, Tsousis S, Kouroussis C, Vamvakas L, Kalykaki A, Samonis G, **Mavroudis D**, Georgoulas V. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). *Br J Cancer.* 2006; 94:798-805
83. Stathopoulou A, Ntoulia M, Perraki M, Apostolaki S, **Mavroudis D**, Malamos N, Georgoulas V, Lianidou ES. A highly specific real-time RT-PCR method for the quantitative determination of CK-19 mRNA positive cells in peripheral blood of patients with operable breast cancer. *Int J Cancer.* 2006; 119:1654-9
84. Ardavanis A, **Mavroudis D**, Kalbakis K, Malamos N, Syrigos K, Vamvakas L, Kotsakis A, Kentepozidis N, Kouroussis C, Agelaki S, Georgoulas V; Breast Cancer Committee of the Hellenic Oncology Research Group. Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: a multicentre phase II study. *Cancer Chemother Pharmacol.* 2006; 58:742-8
85. Xenidis N, Perraki M, Kafousi M, Apostolaki S, Bolonaki I, Stathopoulou A, Kalbakis K, Androulakis N, Kouroussis C, Pallis T, Christophylakis C, Argyraki

- K, Lianidou ES, Stathopoulos S, Georgoulas V, **Mavroudis D**. Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. *J Clin Oncol*. 2006; 24:3756-62
86. Souglakos J, Vamvakas L, Apostolaki S, Perraki M, Saridaki Z, Kazakou I, Pallis A, Kouroussis C, Androulakis N, Kalbakis K, Millaki G, **Mavroudis D**, Georgoulas V. Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status. *Breast Cancer Res*. 2006; 8:R36
87. Hatzidaki D, Agelaki S, **Mavroudis D**, Vlachonikolis I, Alegakis A, Georgoulas V; Lung Cancer Group of the Hellenic Oncology Research Group. A retrospective analysis of second-line chemotherapy or best supportive care in patients with advanced-stage non-small-cell lung cancer. *Clin Lung Cancer*. 2006; 8:49-55
88. Ntoulia M, Kaklamanis L, Valavanis C, Kafousi M, Stathopoulos E, Arapantoni P, **Mavroudis D**, Georgoulas V, Lianidou ES. HER-2 DNA quantification of paraffin-embedded breast carcinomas with LightCycler real-time PCR in comparison to immunohistochemistry and chromogenic in situ hybridization. *Clin Biochem*. 2006; 39:942-6
89. Ntoulia M, Stathopoulou A, Ignatiadis M, Malamos N, **Mavroudis D**, Georgoulas V, Lianidou ES. Detection of Mammaglobin A-mRNA-positive circulating tumor cells in peripheral blood of patients with operable breast cancer with nested RT-PCR. *Clin Biochem*. 2006; 39:879-8
90. Boukovinas I, Androulakis N, Vamvakas L, Papakotoulas P, Ziras N, Polyzos A, Kalykaki A, Kotsakis A, Xenidis N, Gioulmbasanis I, **Mavroudis D**, Georgoulas V. Sequential gemcitabine and cisplatin followed by docetaxel as first-line treatment of advanced urothelial carcinoma: a multicenter phase II study of the Hellenic Oncology Research Group. *Ann Oncol*. 2006; 17:1687-92
91. Petrikkos GL, Skiada A, Samonis G, **Mavroudis D**, Daikos GL. Native valve Aspergillus endocarditis in two patients with aplastic anaemia. *Scand J Infect Dis*. 2006; 38:916-20
92. **Mavroudis D**, Bolonakis I, Cornet S, Myllaki G, Kanellou P, Kotsakis A,

Galanis A, Nikoloudi I, Spyropoulou M, Menez J, Miconnet I, Niniraki M, Cordopatis P, Kosmatopoulos K, Georgoulas V. A phase I study of the optimized cryptic peptide TERT(572y) in patients with advanced malignancies. *Oncology*. 2006; 70:306-14

93. Kakolyris S, Kalbakis K, Potamianou A, Malamos N, Vamvakas L, Christophillakis C, Tselepatiotis E, Giassas S, **Mavroudis D**, Amarantidis K, Georgoulas V. Salvage chemotherapy with gemcitabine and oxaliplatin in heavily pretreated patients with metastatic breast cancer: a multicenter phase II study. *Oncology*. 2006; 70:273-9
94. Pallis AG, Christofillakis Ch, Tselepatiotis E, Agelaki S, Vamvakas L, Souglakos J, Vardakis N, Kalykaki A, Kotsakis A, Argiraki A, **Mavroudis D**, Georgoulas V. Sequential administration of docetaxel followed by maintenance gefitinib, as salvage treatment in patients with advanced NSCLC: A multicenter phase II trial. *Lung Cancer*. 2007; 55:101-7
95. Pappas P, **Mavroudis D**, Nikolaidou M, Georgoulas V, Marselos M. Coadministration of oxaliplatin does not influence the pharmacokinetics of gemcitabine. *Anticancer Drugs*. 2006; 17:1185-91
96. Souglakos J, Kalykaki A, Vamvakas L, Androulakis N, Kalbakis K, Agelaki S, Vardakis N, Tzardi M, Kotsakis AP, Gioulbasanis J, Tsetis D, Sfakiotaki G, Chatzidaki D, **Mavroudis D**, Georgoulas V. Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy. *Ann Oncol*. 2006; 18:305-10
97. Repapinou Z, Karababa P, Boussiou M, Kafarakis V, Papadaki HA, **Mavroudis D**, Eliopoulos GD, Loutradi-Anagnostou A. An improved method for the diagnostic approach of alpha(+)-thalassaemia. *Clin Lab Haematol*. 2007; 29:45-51
98. Kouloubinis A, Kaklamanis L, Ziras N, Sofroniadou S, Makaritsis K, Adamopoulos S, Revela I, Athanasiou A, **Mavroudis D**, Georgoulas V. ProANP and NT-proBNP levels to prospectively assess cardiac function in breast cancer patients treated with cardiotoxic chemotherapy. *Int J Cardiol*. 2007; 122:195-201
99. Apostolaki S, Perraki M, Pallis A, Bozionellou V, Agelaki S, Kanellou P,

- Kotsakis A, Politaki E, Kalbakis K, Kalykaki A, Vamvakas L, Georgoulas V, **Mavroudis D**. Circulating HER2 mRNA-positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: evaluation of their clinical relevance. *Ann Oncol*. 2007; 18:851-8
100. Souglakos J, Vardakis N, Androulakis N, Kakolyris S, Kouroussis Ch, **Mavroudis D**, Pallis A, Agelaki S, Kalbakis K, Georgoulas V. Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: A phase II trial. *J BUON*. 2005; 10:47-52
 101. Souglakos J, Vardakis N, Androulakis N, Kakolyris S, Kouroussis Ch, **Mavroudis D**, Pallis A, Agelaki S, Kalbakis K, Georgoulas V. Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: a phase II trial. *Dig Dis*. 2007; 25:100-5
 102. Koutsopoulos AV, **Mavroudis D**, Dambaki KI, Souglakos J, Tzortzaki EG, Drositis J, Delides GS, Georgoulas V, Stathopoulos EN. Simultaneous expression of c-erbB-1, c-erbB-2, c-erbB-3 and c-erbB-4 receptors in non-small-cell lung carcinomas: correlation with clinical outcome. *Lung Cancer*. 2007; 57:193-200
 103. Xenidis N, Markos V, Apostolaki S, Perraki M, Pallis A, Sfakiotaki G, Papadatos-Pastos D, Kalmanti L, Kafousi M, Stathopoulos E, Kakolyris S, **Mavroudis D**, Georgoulas V. Clinical relevance of circulating CK-19 mRNA-positive cells detected during the adjuvant tamoxifen treatment in patients with early breast cancer. *Ann Oncol*. 2007; 18:1623-31
 104. Kallergi G, **Mavroudis D**, Georgoulas V, Stournaras C. Phosphorylation of FAK, PI-3K, and impaired actin organization in CK-positive micrometastatic breast cancer cells. *Mol Med*. 2007 ;13:79-88
 105. Emmanouilides C, Sfakiotaki G, Androulakis N, Kalbakis K, Christophylakis C, Kalykaki A, Vamvakas L, Kotsakis A, Agelaki S, Diamandidou E, Touroutoglou N, Chatzidakis A, Georgoulas V, **Mavroudis D**, Souglakos J. Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study. *BMC Cancer*. 2007; 7:91
 106. Bozionelou V, Vamvakas L, Pappas P, Agelaki S, Androulakis N, Kalykaki A,

- Nikolaidou M, Kentepozidis N, Giassas S, Marselos M, Georgoulas V, **Mavroudis D**. A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and gemcitabine in patients with advanced solid tumours. *Br J Cancer*. 2007; 97:43-9
107. Bolonaki I, Kotsakis A, Papadimitraki E, Aggouraki D, Konsolakis G, Vagia A, Christophylakis C, Nikoloudi I, Magganis E, Galanis A, Cordopatis P, Kosmatopoulos K, Georgoulas V, **Mavroudis D**. Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide. *J Clin Oncol*. 2007; 25:2727-34
 108. Kotsakis A, Kouroussis Ch, Androulakis N, Agelaki S, Kalbakis K, Vamvakas L, Vardakis N, Kalykaki A, Polyzos A, Georgoulas V, **Mavroudis D**. A dose-escalation study of pegylated liposomal Doxorubicin and oxaliplatin in patients with advanced solid tumors. *Oncology*. 2006; 71:190-6
 109. Kalykaki A, Vamvakas L, Agelaki S, Kalbakis K, Vardakis N, Sfakiotaki G, Ignatiadis M, Saridaki Z, Karabeazis A, **Mavroudis D**, Georgoulas V. dose escalation study of gemcitabine plus pemetrexed administered biweekly in patients with solid tumors. *Oncology*. 2006; 71:197-203
 110. Stahtea XN, Roussidis AE, Kanakis I, Tzanakakis GN, Chalkiadakis G, **Mavroudis D**, Kletsas D, Karamanos NK. Imatinib inhibits colorectal cancer cell growth and suppresses stromal-induced growth stimulation, MT1-MMP expression and pro-MMP2 activation. *Int J Cancer*. 2007; 121:2808-14
 111. Georgoulas V, Androulakis N, Kotsakis A, Hatzidaki D, Syrigos K, Polyzos A, Agelidou A, Varthalitis I, Ziras N, Agelidou M, Chandrinos V, Boukovinas I, Geroyianni A, Vamvakas L, **Mavroudis D**. Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: A randomized, multicenter phase III trial. *Lung Cancer*. 2007; 59:57-63
 112. Karampeazis A, Vamvakas L, Agelaki S, Kentepozidis N, Papadimitraki E, Gioulbasanis I, Vardakis N, Ignatiadis M, **Mavroudis D**, Georgoulas V. Dose Escalation Study of Biweekly Oral Vinorelbine and Gemcitabine in Patients with Solid Tumors. *Oncology*. 2007; 71:347-53
 113. Ignatiadis M, Xenidis N, Perraki M, Apostolaki S, Politaki E, Kafousi M, Stathopoulos EN, Stathopoulou A, Lianidou E, Chlouverakis G, Sotiriou C,

Georgoulas V, **Mavroudis D**. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer. *J Clin Oncol*. 2007; 25:5194-202

114. Kalbakis K, Pappas P, Kouroussis C, Vamvakas L, Kalykaki A, Vardakis N, Nikolaidou M, Marselos M, Georgoulas V, **Mavroudis D**. A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and oxaliplatin in patients with advanced solid tumors. *Cancer Chemother Pharmacol*. 2007; 62:449-56
115. Saridaki Z, Bozionelou V, Kentepozidis N, Kotsakis A, Vardakis N, Kalykaki A, Gioulbasanis I, Karabeazis A, Vamvakas L, Georgoulas V, **Mavroudis D**. A dose escalation study of the biweekly administration of paclitaxel, oxaliplatin and capecitabine in patients with advanced solid tumors. *Oncology*. 2007; 72:45-50
116. Pallis AG, Voutsina A, Kalikaki A, Souglakos J, Briasoulis E, Murray S, Koutsopoulos A, Tripaki M, Stathopoulos E, **Mavroudis D**, Georgoulas V. 'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer. *Br J Cancer*. 2007; 97:1560-6
117. Papadopoulos S, Kouvatsas G, Skarlos D, Malamos N, Delliou E, Saratsiotou I, Ardavanis A, **Mavroudis D**, Skarpidi E, Arapantoni P, Karyda I, Patakioyta F, Aravantinos G, Razis E, Fountzilas G, Kosmidis P. Comparison of HER2 detection methods between central and regional laboratories in Greece. *Clin Breast Cancer*. 2007; 7:784-90
118. Ignatiadis M, Georgoulas V, **Mavroudis D**. Circulating tumor cells in breast cancer. *Curr Opin Obstet Gynecol*. 2008; 20:55-60
119. Ignatiadis M, Perraki M, Apostolaki S, Politaki E, Xenidis N, Kafousi M, Stathopoulos E, Lianidou E, Sotiriou C, Georgoulas V, **Mavroudis D**. Molecular detection and prognostic value of circulating cytokeratin-19 messenger RNA-positive and HER2 messenger RNA-positive cells in the peripheral blood of women with early-stage breast cancer. *Clin Breast Cancer*. 2007; 7:883-9
120. Kalykaki A, Papakotoulas P, Tsousis S, Boukovinas I, Kalbakis K, Vamvakas L, Kotsakis A, Vardakis N, Papadopoulou P, Georgoulas V, **Mavroudis D**; Hellenic Oncology Research Group. Gemcitabine plus oxaliplatin (GEMOX) in pretreated patients with advanced ovarian cancer: a multicenter phase II

study of the Hellenic Oncology Research Group (HORG). *Anticancer Res.* 2008; 28:495-500

121. Souglakos J, Boukovinas I, Taron M, Mendez P, **Mavroudis D**, Tripaki M, Hatzidaki D, Koutsopoulos A, Stathopoulos E, Georgoulas V, Rosell R. Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine. *Br J Cancer.* 2008; 98:1710-5

122. Ignatiadis M, Kallergi G, Ntoulia M, Perraki M, Apostolaki S, Kafousi M, Chlouverakis G, Stathopoulos E, Lianidou E, Georgoulas V, **Mavroudis D**. Prognostic Value of the Molecular Detection of Circulating Tumor Cells Using a Multimarker Reverse Transcription-PCR Assay for Cytokeratin 19, Mammaglobin A, and HER2 in Early Breast Cancer. *Clin Cancer Res.* 2008; 14:2593-600

123. Pallis AG, Agelaki S, Kakolyris S, Kotsakis A, Kalykaki A, Vardakis N, Papakotoulas P, Agelidou A, Geroyianni A, Agelidou M, Hatzidaki D, **Mavroudis D**, Georgoulas V; Hellenic Oncology Research Group (HORG). Chemotherapy-induced neutropenia as a prognostic factor in patients with advanced non-small cell lung cancer treated with front-line docetaxel-gemcitabine chemotherapy. *Lung Cancer.* 2008; 62:356-63

124. Boukovinas I, Souglakos J, Hatzidaki D, Kakolyris S, Ziras N, Vamvakas L, Polyzos A, Geroyianni A, Agelidou A, Agelaki S, Kalbakis K, Kotsakis A, **Mavroudis D**, Georgoulas V. Docetaxel plus gemcitabine as front-line chemotherapy in elderly patients with lung adenocarcinomas: A multicenter phase II study. *Lung Cancer.* 2009; 63:77-82

125. Kalikaki A, Koutsopoulos A, Trypaki M, Souglakos J, Stathopoulos E, Georgoulas V, **Mavroudis D**, Voutsina A. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. *Br J Cancer.* 2008 Sep 16;99(6):923-9

126. Saloustros E, **Mavroudis D**, Georgoulas V. Paclitaxel and docetaxel in the treatment of breast cancer. *Expert Opin Pharmacother.* 2008; 9:2603-16

127. Kallergi G, Agelaki S, Kalykaki A, Stournaras C, **Mavroudis D**, Georgoulas V. Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients. *Breast Cancer Res.* 2008;10:R80
128. Boukovinas I, Papadaki C, Mendez P, Taron M, **Mavroudis D**, Koutsopoulos A, Sanchez-Ronco M, Sanchez JJ, Trypaki M, Stathopoulos E, Georgoulas V, Rosell R, Souglakos J. Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients. *PLoS ONE.* 2008;3:e3695
129. Apostolaki S, Perraki M, Kallergi G, Kafousi M, Papadopoulos S, Kotsakis A, Pallis A, Xenidis N, Kalmanti L, Kalbakis K, Agelaki S, Kalykaki A, Stournaras C, Stathopoulos E, Georgoulas V, **Mavroudis D**. Detection of occult HER2 mRNA-positive tumor cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic relevance. *Breast Cancer Res Treat.* 2008; 117:525-34
130. Gioulbasanis I, Saridaki Z, Kalykaki A, Vamvakas L, Kalbakis K, Ignatiadis M, Amarantidis K, Kakolyris S, Georgoulas V, **Mavroudis D**. Gefitinib in combination with gemcitabine and vinorelbine in patients with metastatic breast cancer pre-treated with taxane and anthracycline chemotherapy: a phase I/II trial. *Anticancer Res.* 2008; 28:3019-25
131. Ignatiadis M, Georgoulas V, **Mavroudis D**. Micrometastatic disease in breast cancer: clinical implications. *Eur J Cancer.* 2008; 44:2726-36
132. Kioulafa M, Kaklamanis L, Stathopoulos E, **Mavroudis D**, Georgoulas V, Lianidou ES. Kallikrein 10 (KLK10) methylation as a novel prognostic biomarker in early breast cancer. *Ann Oncol.* 2009; 20:1020-5
133. Bozionelou V, Kalbakis K, Vamvakas L, Agelaki S, Androulakis N, Kalykaki A, Georgoulas V, **Mavroudis D**. A phase I trial of gemcitabine, docetaxel and carboplatin administered every 2 weeks as first line treatment in patients with advanced breast cancer. *Cancer Chemother Pharmacol.* 2009; 64:785-91
134. Kalikaki A, Koutsopoulos A, Trypaki M, Souglakos J, Stathopoulos E, Georgoulas V, **Mavroudis D**, Voutsina A. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. *Br J Cancer.* 2008; 99:923-9

135. Xenidis N, Ignatiadis M, Apostolaki S, Perraki M, Kalbakis K, Agelaki S, Stathopoulos EN, Chlouverakis G, Lianidou E, Kakolyris S, Georgoulas V, **Mavroudis D**. Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. *J Clin Oncol*. 2009; 27: 2177-84
136. Kalikaki A, Kanaki M, Vassalou H, Souglakos J, Voutsina A, Georgoulas V, **Mavroudis D**. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. *Clin Lung Cancer*. 2009; 10:118-23
137. Valachis A, Mauri D, Polyzos NP, **Mavroudis D**, Georgoulas V, Casazza G. Fulvestrant in the treatment of advanced breast cancer: A systematic review and meta-analysis of randomized controlled trials. *Crit Rev Oncol Hematol*. 2009 Apr 13
138. Kioulafa M, Kaklamanis L, **Mavroudis D**, Georgoulas V, Lianidou ES. Prognostic significance of RASSF1A promoter methylation in operable breast cancer. *Clin Biochem*. 2009; 42:970-5
139. Saridaki Z, Pappas P, Souglakos J, Nikolaidou M, Vardakis N, Kotsakis A, Marselos M, Georgoulas V, **Mavroudis D**. A dose escalation and pharmacokinetic study of the biweekly administration of paclitaxel, gemcitabine and oxaliplatin in patients with advanced solid tumors. *Cancer Chemother Pharmacol*. 2009; 65:121-8
140. Papadaki C, **Mavroudis D**, Trypaki M, Koutsopoulos A, Stathopoulos E, Hatzidaki D, Tsakalaki E, Georgoulas V, Souglakos J. Tumoral expression of TXR1 and TSP1 predicts overall survival of patients with lung adenocarcinoma treated with first-line docetaxel-gemcitabine regimen. *Clin Cancer Res*. 2009; 15:3827-33
141. Agelaki S, Spiliotaki M, Markomanolaki H, Kallergi G, **Mavroudis D**, Georgoulas V, Stournaras C. Caveolin-1 regulates EGFR signaling in MCF-7 breast cancer cells and enhances gefitinib-induced tumor cell inhibition.

142. Kioulafa M, Balkouranidou I, Sotiropoulou G, Kaklamanis L, **Mavroudis D**, Georgoulas V, Lianidou ES. Methylation of cystatin M promoter is associated with unfavorable prognosis in operable breast cancer. *Int J Cancer*. 2009; 125:2887-92
143. Theodoropoulos PA, Polioudaki H, Agelaki S, Kallergi G, Saridaki Z, **Mavroudis D**, Georgoulas V. Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. *Cancer Lett*. 2010 Feb 1;288(1):99-106. Epub 2009 Jul 19
144. Daskalaki A, Agelaki S, Perraki M, Apostolaki S, Xenidis N, Stathopoulos E, Kontopodis E, Hatzidaki D, **Mavroudis D**, Georgoulas V. Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer. *Br J Cancer*. 2009; 101:589-97
145. Polyzos A, Malamos N, Boukovinas I, Adamou A, Ziras N, Kalbakis K, Kakolyris S, Syrigos K, Papakotoulas P, Kouroussis C, Karvounis N, Vamvakas L, Christophyllakis C, Athanasiadis A, Varthalitis I, Georgoulas V, **Mavroudis D**. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). *Breast Cancer Res Treat*. 2009 Jul 28.
146. Gialeli Ch, Kletsas D, **Mavroudis D**, Kalofonos HP, Tzanakakis GN, Karamanos NK. Targeting epidermal growth factor receptor in solid tumors: critical evaluation of the biological importance of therapeutic monoclonal antibodies. *Curr Med Chem*. 2009; 16:3797-804
147. Saloustros E, Zaganas I, Mavridis M, Vamvakas L, Plaitakis A, Georgoulas V, **Mavroudis D**. Anti-CV2 associated cerebellar degeneration after complete response to chemoradiation of head and neck carcinoma. *J Neurooncol*. 2010 Apr;97(2):291-4. Epub 2009 Oct 2
148. Kalikaki A, Koutsopoulos A, Hatzidaki D, Trypaki M, Kontopodis E, Stathopoulos E, **Mavroudis D**, Georgoulas V, Voutsina A. Clinical outcome of patients with non-small cell lung cancer receiving front-line

chemotherapy according to EGFR and K-RAS mutation status. *Lung Cancer*. 2010 Jul;69(1):110-5. Epub 2009 Oct 24

149. Saloustros E, Androulakis N, Vamvakas L, **Mavroudis D**, Georgoulas V. Favorable clinical course of patients experiencing bevacizumab-induced proteinuria. *Case Rep Oncol*. 2010 Oct 12;3(3):368-71

150. **Mavroudis D**, Papakotoulas P, Ardavanis A, Syrigos K, Kakolyris S, Ziras N, Kouroussis C, Malamos N, Polyzos A, Christophyllakis C, Kentepozidis N, Georgoulas V; on behalf of the Breast Cancer Investigators of the Hellenic Oncology Research Group. Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer. *Ann Oncol*. 2010 Jan;21(1):48-54. Epub 2009 Nov 11

151. Kallergi G, Markomanolaki H, Giannoukaraki V, Papadaki MA, Strati A, Lianidou E, Georgoulas V, **Mavroudis D**, Agelaki S. Hypoxia-inducible factor-1 alpha and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients. *Breast Cancer Res*. 2009;11(6):R84. Epub 2009 Nov 17

152. Valachis A, Polyzos NP, Georgoulas V, **Mavroudis D**, Mauri D. Lack of evidence for fracture prevention in early breast cancer bisphosphonate trials: A meta-analysis. *Gynecol Oncol*. 2010 Apr;117(1):139-45. Epub 2010 Jan 12. Review

153. Valachis A, Polyzos NP, Patsopoulos NA, Georgoulas V, **Mavroudis D**, Mauri D. Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials. *Breast Cancer Res Treat*. 2010 Jul;122(1):1-7. Epub 2010 Jan 9. Review

154. Saloustros E, **Mavroudis D**. Cytokeratin-19 positive circulating tumor cells in early breast cancer prognosis. *Future Oncology* in press

155. Saloustros E, **Mavroudis D**. Letter to the Editor for article by Esserman L, Shieh Y, Thompson I. Rethinking Screening for Breast Cancer and Prostate Cancer. *JAMA*. 2009; 302(15):1685-1692

156. Mauri D, Valachis A, Polyzos NP, Tsali L, **Mavroudis D**, Georgoulas V, Casazza G. Does adjuvant bisphosphonate in early breast cancer modify the natural course of the disease? A meta-analysis of randomized controlled trials. *J Natl Compr Canc Netw*. 2010 Mar;8(3):279-86
157. Valachis A, Mauri D, Polyzos NP, **Mavroudis D**, Georgoulas V, Casazza G. Partial breast irradiation or whole breast radiotherapy for early breast cancer: a meta-analysis of randomized controlled trials. *Breast J*. 2010 May-Jun;16(3):245-51
158. Katopodis O, Polyzos A, Kentepozidis N, Giassas S, Rovithi M, Bozionelou V, Kalbakis K, Vamvakas L, **Mavroudis D**, Georgoulas V. Second-line chemotherapy with Capecitabine (Xeloda) and Docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial. *Cancer Chemother Pharmacol*. 2010 Apr 29
159. Saridaki Z, Papadatos-Pastos D, Tzardi M, **Mavroudis D**, Bairaktari E, Arvanity H, Stathopoulos E, Georgoulas V, Souglakos J. BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients' outcome. *Br J Cancer*. 2010 Jun 8;102(12):1762-8
160. Karachaliou N, Saloustros E, Vamvakas L, **Mavroudis D**, Georgoulas V. Proteinuria and favourable clinical response in a patient receiving paclitaxel + bevacizumab for metastatic breast cancer. *Ann Oncol*. 2010 Aug;21(8):1729-30
161. Baka S, Agelaki S, Kotsakis A, Veslemes M, Papakotoulas P, Agelidou M, Agelidou A, Tsaroucha E, Pavlaku G, Gerogianni A, Androulakis N, Vamvakas L, Kalbakis K, **Mavroudis D**, Georgoulas V. Phase III study comparing sequential versus alternate administration of cisplatin-etoposide and topotecan as first-line treatment in small cell lung cancer. *Anticancer Res*. 2010 Jul;30(7):3031-8
162. Lianidou ES, **Mavroudis D**, Sotiropoulou G, Agelaki S, Pantel K. What's new on circulating tumor cells? A meeting report. *Breast Cancer Res*. 2010;12(4):307
163. Polyzos A, Kalbakis K, Kentepozidis N, Giassas S, Kalykaki A, Vardakis N, Bozionelou V, Saloustros E, Kontopodis E, Georgoulas V, Mavroudis D. Salvage treatment in metastatic breast cancer with weekly paclitaxel and

bevacizumab. Cancer Chemother Pharmacol. 2010 Oct 5

164. Gioulbasanis I, Baracos VE, Giannousi Z, Xyrafas A, Martin L, Georgoulas V, **Mavroudis D**. Baseline nutritional evaluation in metastatic lung cancer patients: Mini Nutritional Assessment versus weight loss history. Ann Oncol. 2010 Oct 11
165. **Mavroudis D**. Circulating cancer cells. Ann Oncol. 2010 Oct;21 Suppl 7:vii95-vii100
166. Kotsakis A, Agelaki S, Vardakis N, Stathopoulos G, Vamvakas L, Kalykaki A, Kentepozidis N, Kontopodis E, Sfakiotaki G, **Mavroudis D**, Georgoulas V. A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer. Cancer Chemother Pharmacol. 2010 Nov 11
167. Vardakis N, Messaritakis I, Papadaki C, Agoglossakis G, Sfakianaki M, Saridaki Z, Apostolaki S, Koutroubakis I, Perraki M, Hatzidaki D, **Mavroudis D**, Georgoulas V, Souglakos J. Prognostic Significance of the Detection of Peripheral Blood CEACAM5mRNA-Positive Cells by Real Time Polymerase Chain Reaction in Operable Colorectal Cancer. Clin Cancer Res. 2011 Jan 1;17(1):165-73
168. Papadaki C, Tsaroucha E, Kaklamanis L, Lagoudaki E, Trypaki M, Tryfonidis K, **Mavroudis D**, Stathopoulos E, Georgoulas V, Souglakos J. Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced / metastatic non-small-cell lung cancer. Br J Cancer. 2010 Dec 14
169. Spiliotaki M, Markomanolaki H, Mela M, **Mavroudis D**, Georgoulas V, Agelaki S. Targeting the insulin-like growth factor I receptor inhibits proliferation and VEGF production of non-small cell lung cancer cells and enhances paclitaxel-mediated anti-tumor effect. Lung Cancer. 2010 Dec 27
170. Saridaki Z, Tzardi M, Papadaki C, Sfakianaki M, Pega F, Kalikaki A, Tsakalaki E, Trypaki M, Messaritakis I, Stathopoulos E, **Mavroudis D**, Georgoulas V, Souglakos J. Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patients. PLoS One. 2011 Jan 20;6(1):e15980

171. Daskalakis M, **Mavroudis D**, Sanidas E, Apostolaki S, Askoxylakis I, de Bree E, Georgoulas V, Melissas J. Assessment of the effect of surgery on the kinetics of circulating tumour cells in patients with operable breast cancer based on cytokeratin-19 mRNA detection. *Eur J Surg Oncol*. 2011 May;37(5):404-10

172. Pallis AG, Karampeazis A, Vamvakas L, Vardakis N, Kotsakis A, Bozionelou V, Kalykaki A, Hatzidaki D, **Mavroudis D**, Georgoulas V. Efficacy and treatment tolerance in older patients with NSCLC: a meta-analysis of five phase III randomized trials conducted by the Hellenic Oncology Research Group. *Ann Oncol*. 2011 Nov;22(11):2448-55. Epub 2011 Mar 10

173. Saridaki Z, Malamos N, Kourakos P, Polyzos A, Ardavanis A, Androulakis N, Kalbakis K, Vamvakas L, Georgoulas V, **Mavroudis D**. A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer. *Cancer Chemother Pharmacol*. 2012 Jan;69(1):35-42. Epub 2011 May 18

174. Gioulbasanis I, Georgoulas P, Vlachostergios PJ, Baracos V, Ghosh S, Giannousi Z, Papandreou CN, **Mavroudis D**, Georgoulas V. Mini Nutritional Assessment (MNA) and biochemical markers of cachexia in metastatic lung cancer patients: Interrelations and associations with prognosis. *Lung Cancer*. 2011;74:516-20

175. Kallergi G, Papadaki MA, Politaki E, **Mavroudis D**, Georgoulas V, Agelaki S. Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. *Breast Cancer Res*. 2011;13:R59

176. Saloustros E, Perraki M, Apostolaki S, Kallergi G, Xyrafas A, Kalbakis K, Agelaki S, Kalykaki A, Georgoulas V, **Mavroudis D**. Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse. *Breast Cancer Res*. 2011;13:R60

177. Boukovinas I, Androulakis N, Kentepozidis N, Polyzos A, Papakotoulas P, Ziras N, Kotsakis A, Vardakis N, Karampeazis A, Markos V, Kostakopoulos A, Constantinides CA, Samonis G, **Mavroudis D**, Georgoulas V. Chemotherapy with gemcitabine, cisplatin, and docetaxel in the treatment for patients with muscle-invasive bladder cancer: a multicenter phase II study of the Hellenic Oncology Research Group(HORG). *Cancer Chemother Pharmacol*. 2012 Feb;69(2):351-6. Epub 2011 Jul 12

178. Saloustros E, Kalbakis K, Vardakis N, Kalykaki A, Milaki G, Rovithi M, Agelaki S, Saridaki Z, Georgoulas V, **Mavroudis D**. Metronomic vinorelbine plus bevacizumab as salvage therapy for patients with metastatic breast cancer. *J BUON*. 2011;16:215-8

179. Valachis A, Mauri D, Polyzos NP, Chlouverakis G, **Mavroudis D**, Georgoulas V. Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: A systematic review and meta-analysis. *Breast*. 2011 Dec;20(6):485-90. Epub 2011 Jul 23. Review

180. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. *Lancet*. 2011 Aug 27;378(9793):771-84. Epub 2011 Jul 28.

181. Vetsika EK, Konsolakis G, Aggouraki D, Kotsakis A, Papadimitraki E, Christou S, Menez-Jamet J, Kosmatopoulos K, Georgoulas V, **Mavroudis D**. Immunological responses in cancer patients after vaccination with the therapeutic telomerase-specific vaccine Vx-001. *Cancer Immunol Immunother*. 2012 Feb;61(2):157-68. Epub 2011 Aug 20

182. Kotsakis A, Vetsika EK, Christou S, Hatzidaki D, Vardakis N, Aggouraki D, Konsolakis G, Georgoulas V, Christophyllakis C, Cordopatis P,

Kosmatopoulos K, **Mavroudis D**. Clinical outcome of patients with various advanced cancer types vaccinated with an optimized cryptic human telomerase reverse transcriptase (TERT) peptide: results of an expanded phase II study. *Ann Oncol*. 2012 Feb;23(2):442-9. Epub 2011 Aug 25

183. Pallis AG, Boukovinas I, Ardavanis A, Varthalitis I, Malamos N, Georgoulas V, **Mavroudis D**. A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer. *Ann Oncol*. 2012 May;23(5):1164-9.
184. Giannousi Z, Gioulbasanis I, Pallis AG, Xyrafas A, Dalliani D, Kalbakis K, Papadopoulos V, **Mavroudis D**, Georgoulas V, Papandreou CN. Nutritional status, acute phase response and depression in metastatic lung cancer patients: correlations and association prognosis. *Support Care Cancer*. 2012 Aug;20(8):1823-9.
185. Strati A, Markou A, Parisi C, Politaki E, **Mavroudis D**, Georgoulas V, Lianidou E. Gene expression profile of circulating tumor cells in breast cancer by RT-qPCR. *BMC Cancer*. 2011;11:422
186. Vetsika EK, Papadimitraki E, Aggouraki D, Konsolakis G, Mela ME, Kotsakis A, Christou S, Patramani S, Alefantinou M, Kaskara A, Christophyllakis C, Kosmatopoulos K, Georgoulas V, **Mavroudis D**. Sequential Administration of the Native TERT572 Cryptic Peptide Enhances the Immune Response Initiated by its Optimized Variant TERT572Y in Cancer Patients. *J Immunother*. 2011;34:641-50
187. Saloustros E, **Mavroudis D**. Case 17-2011: a woman with a mass in the breast and overlying skin changes. *N Engl J Med*. 2011;365:1259-60
188. Gioulbasanis I, Patrikidou A, Kitikidou K, Papadimitriou K, Vlachostergios PJ, Tsatsanis C, Margioris AN, Papandreou CN, **Mavroudis D**, Georgoulas V. Baseline plasma levels of interleukin-8 in stage IV non-small-cell lung cancer patients: relationship with nutritional status and prognosis. *Nutr Cancer*. 2012;64(1):41-7. Epub 2011 Nov 18

189. Jacquín JP, Jones S, Magné N, Chapelle C, Ellis P, Janni W, **Mavroudis D**, Martín M, Laporte S. Docetaxel-containing adjuvant chemotherapy in patients with early stage breast cancer. Consistency of effect independent of nodal and biomarker status: a meta-analysis of 14 randomized clinical trials. *Breast Cancer Res Treat.* 2012 Aug;134(3):903-13.
190. Karachaliou N, Kouroussis C, Papakotoulas P, Kalbakis K, Tryfonidis K, Vardakis N, Poppis E, Georgoulas V, **Mavroudis D**. A multicenter phase II trial of docetaxel plus gemcitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer. *Cancer Chemother Pharmacol.* 2012 May;69(5):1345-52.
191. Georgoulas V, Bozionelou V, Agelaki S, Perraki M, Apostolaki S, Kallergi G, Kalbakis K, Xyrafas A, **Mavroudis D**. Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK19 mRNA-positive circulating tumor cells: results of a randomized phase II study. *Ann Oncol.* 2012 Jul;23(7):1744-50.
192. Papadaki C, Sfakianaki M, Ioannidis G, Lagoudaki E, Trypaki M, Tryfonidis K, **Mavroudis D**, Stathopoulos E, Georgoulas V, Souglakos J. ERCC1 and BRAC1 mRNA Expression Levels in the Primary Tumor Could Predict the Effectiveness of the Second-Line Cisplatin-Based Chemotherapy in Pretreated Patients with Metastatic Non-small Cell Lung Cancer. *J Thorac Oncol.* 2012 Apr;7(4):663-71

193. Saloustros E, **Mavroudis D**. CTCs in Primary Breast Cancer (II). Recent Results Cancer Res. 2012;195:187-92.
194. Androulakis N, Agelaki S, Perraki M, Apostolaki S, Bozionelou V, Pallis A, Kalbakis K, Xyrafas A, **Mavroudis D**, Georgoulas V. Clinical relevance of circulating CK-19mRNA-positive tumour cells before front-line treatment in patients with metastatic breast cancer. Br J Cancer. 2012 Jun 5;106(12):1917-25.
195. Karachaliou N, Ziras N, Syrigos K, Tryfonidis K, Papadimitraki E, Kontopodis E, Bozionelou V, Kalykaki A, Georgoulas V, **Mavroudis D**. A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer. Cancer Chemother Pharmacol. 2012 Jul;70(1):169-76.
196. Voutsina A, Tzardi M, Kalikaki A, Zafeiriou Z, Papadimitraki E, Papadakis M, **Mavroudis D**, Georgoulas V. Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer. Mod Pathol. 2013 Feb;26(2):302-13.
197. Laliotis A, Vrekoussis T, Kafousi M, Sanidas E, Askoxilakis J, Melissas J, **Mavroudis D**, Castanas E, Stathopoulos EN. Immunohistochemical study of pElk-1 expression in human breast cancer: Association with breast cancer

biologic profile and clinicopathologic features. *Breast*. 2013 Feb;22(1):89-95.

198. Saridaki Z, Androulakis N, Vardakis N, Vamvakas L, Kabouraki E, Kalbakis K, Hatzidaki D, Voutsina A, **Mavroudis D**, Georgoulas V, Souglakos J. A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial. *Br J Cancer*. 2012 Dec 4;107(12):1932-7.

199. Xenidis N, Perraki M, Apostolaki S, Agelaki S, Kalbakis K, Vardakis N, Kalykaki A, Xyrafas A, Kakolyris S, **Mavroudis D**, Georgoulas V. Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumour cells in patients with early breast cancer. *Br J Cancer*. 2013 Feb 19;108(3):549-56.

200. Karampeazis A, Voutsina A, Souglakos J, Kentepozidis N, Giassas S, Christofillakis C, Kotsakis A, Papakotoulas P, Rapti A, Agelidou M, Agelaki S, Vamvakas L, Samonis G, **Mavroudis D**, Georgoulas V. Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: A Hellenic Oncology Research Group (HORG) randomized phase 3 study. *Cancer*. 2013 Aug 1;119(15):2754-64

201. Lianidou ES, **Mavroudis D**, Georgoulas V. Clinical challenges in the molecular characterization of circulating tumour cells in breast cancer. *Br J Cancer*. 2013 Jun 25;108(12):2426-32

202. Kallergi G, Konstantinidis G, Markomanolaki H, Papadaki MA, **Mavroudis D**, Stournaras C, Georgoulas V, Agelaki S. Apoptotic Circulating Tumor Cells (CTCs) in early and metastatic breast cancer patients. *Mol Cancer Ther*. 2013 Sep;12(9):1886-95.

203. Vassalou H, Stathopoulos E, Fiolitaki G, Koutsopoulos A, Voutsina A, Georgoulas V, **Mavroudis D**. Excision-repair-cross-complement-1 protein as a prognostic factor in patients with advanced non-small cell lung cancer treated with platinum-based first-line chemotherapy. *Lung Cancer*. 2013 Nov;82(2):324-9.

204. Karachaliou N, Papadaki C, Lagoudaki E, Trypaki M, Sfakianaki M, Koutsopoulos A, **Mavroudis D**, Stathopoulos E, Georgoulas V, Souglakos J. Predictive Value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOPO-IIA, TOPOIIB and C-MYC Genes in Patients with Small Cell Lung Cancer (SCLC) Who Received First Line Therapy with Cisplatin and Etoposide. *PLoS One*. 2013 Sep 13;8(9):e74611.

205. Tryfonidis K, Boukovinas I, Xenidis N, Christophyllakis C, Papakotoulas P, Politaki E, Malamos N, Polyzos A, Kakolyris S, Georgoulas V, **Mavroudis D**; Hellenic Oncology Research Group (HORG). A multicenter phase I-II study of docetaxel plus epirubicin plus bevacizumab as first-line treatment in women with HER2-negative metastatic breast cancer. *Breast*. 2013 Dec;22(6):1171-7.

206. Lianidou ES, **Mavroudis D**, Pantel K. Advances in circulating tumor cells (ACTC): from basic research to clinical practice. *Breast Cancer Res*. 2013 Dec 5;15(6):319.

207. Saridaki Z, Tzardi M, Sfakianaki M, Papadaki C, Voutsina A, Kalykaki A, Messaritakis I, Mpananis K, **Mavroudis D**, Stathopoulos E, Georgoulas V, Souglakos J. BRAFV600E Mutation Analysis in Patients with Metastatic Colorectal Cancer (mCRC) in Daily Clinical Practice: Correlations with Clinical Characteristics, and Its Impact on Patients' Outcome. *PLoS One*. 2013 Dec 18;8(12):e84604.

208. Kalykaki A, Agelaki S, Kallergi G, Xyrafas A, **Mavroudis D**, Georgoulas V.

Elimination of EGFR-expressing circulating tumor cells in patients with metastatic breast cancer treated with gefitinib. *Cancer Chemother Pharmacol.* 2014 Apr;73(4):685-93.

209. Bidard FC, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, **Mavroudis D**, Grisanti S, Generali D, Garcia-Saenz JA, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, de Lascoiti AF, De Mattos-Arruda L, Ignatiadis M, Lebofsky R, van Laere SJ, Meier-Stiegen F, Sandri MT, Vidal-Martinez J, Politaki E, Consoli F, Bottini A, Diaz-Rubio E, Krell J, Dawson SJ, Raimondi C, Rutten A, Janni W, Munzone E, Carañana V, Agelaki S, Almici C, Dirix L, Solomayer EF, Zorzino L, Johannes H, Reis-Filho JS, Pantel K, Pierga JY, Michiels S. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. *Lancet Oncol.* 2014 Apr;15(4):406-14.

210. Fostira F, Konstantopoulou I, **Mavroudis D**, Tryfonopoulos D, Yannoukakos D, Voutsinas GE. Genetic evaluation based on family history and Her2 status correctly identifies TP53 mutations in very early onset breast cancer cases. *Clin Genet.* 2015 Apr;87(4):383-7

211. Ignatiadis M, Riethdorf S, Bidard FC, Vaucher I, Khazour M, Rothé F, Metallo J, Rouas G, Payne RE, Coombes R, Teufel I, Andergassen U, Apostolaki S, Politaki E, **Mavroudis D**, Bessi S, Pestrin M, Di Leo A, Campion M, Reinholz M, Perez E, Piccart M, Borgen E, Naume B, Jimenez J, Aura C, Zorzino L, Cassatella M, Sandri M, Mostert B, Sleijfer S, Kraan J, Janni W, Fehm T, Rack B, Terstappen L, Repollet M, Pierga JY, Miller C, Sotiriou C, Michiels S, Pantel K. International study on inter-reader variability for circulating tumor cells in breast cancer. *Breast Cancer Res.* 2014 Apr 23;16(2):R43.

212. Tryfonidis K, Kafousi M, Perraki M, Apostolaki S, Agelaki S, Georgoulas V,

Stathopoulos E, **Mavroudis D**. Detection of circulating cytokeratin-19 mRNA-positive cells in the blood and the mitotic index of the primary tumor have independent prognostic value in early breast cancer. Clin Breast Cancer. 2014 Dec;14(6):442-50.

213. Matikas A, Kontopodis E, Nintos G, Bilidas T, Kofteridis DP, Papadaki EZ, Lyraraki E, Kanatsouli K, **Mavroudis D**. A case of herpes simplex-associated encephalitis after brain irradiation for lung cancer metastases. Anticancer Res. 2014 Aug;34(8):4411-4.
214. Kotsakis A, Papadimitraki E, Vetsika EK, Aggouraki D, Dermitzaki EK, Hatzidaki D, Kentepozidis N, **Mavroudis D**, Georgoulas V. A phase II trial evaluating the clinical and immunologic response of HLA-A2(+) non-small cell lung cancer patients vaccinated with an hTERT cryptic peptide. Lung Cancer. 2014 Oct;86(1):59-66.
215. Kalikaki A, Politaki H, Souglakos J, Apostolaki S, Papadimitraki E, Georgoulia N, Tzardi M, **Mavroudis D**, Georgoulas V, Voutsina A. KRAS genotypic changes of circulating tumor cells during treatment of patients with metastatic colorectal cancer. PLoS One. 2014 Aug 19;9(8):e104902.
216. Papadaki MA, Kallergi G, Zafeiriou Z, Manouras L, Theodoropoulos PA, **Mavroudis D**, Georgoulas V, Agelaki S. Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer. BMC Cancer. 2014 Sep 3;14:651.
217. Papadaki C, Sfakianaki M, Lagoudaki E, Giagkas G, Ioannidis G, Trypaki M, Tsakalaki E, Voutsina A, Koutsopoulos A, **Mavroudis D**, Georgoulas V, Souglakos J. PKM2 as a biomarker for chemosensitivity to front-line platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer. Br J Cancer. 2014 Oct 28;111(9):1757-64.

218. Georgoulas V, Apostolaki S, Bozionelou V, Politaki E, Perraki M, Georgoulia N, Kalbakis K, Kotsakis A, Xyrafas A, Agelaki S, **Mavroudis D**. Effect of front-line chemotherapy on circulating CK-19 mRNA-positive cells in patients with metastatic breast cancer. *Cancer Chemother Pharmacol*. 2014 Dec;74(6):1217-25.
219. Kontopodis E, Kentepozidis N, Christophyllakis Ch, Boukovinas I, Kalykaki A, Kalbakis K, Vamvakas L, Agelaki S, Kotsakis A, Vardakis N, Georgoulas V, **Mavroudis D**. Docetaxel, gemcitabine and bevacizumab as salvage chemotherapy for HER-2-negative metastatic breast cancer. *Cancer Chemother Pharmacol*. 2015 Jan;75(1):153-60
220. Saloustros E, Malamos N, Boukovinas I, Kakolyris S, Kouroussis C, Athanasiadis A, Ziras N, Kentepozidis N, Makrantonakis P, Polyzos A, Christophyllakis C, Georgoulas V, **Mavroudis D**. Dose-dense paclitaxel versus docetaxel following FEC as adjuvant chemotherapy in axillary node-positive early breast cancer: a multicenter randomized study of the Hellenic Oncology Research Group (HORG). *Breast Cancer Res Treat*. 2014 Dec;148(3):591-7.
221. Spiliotaki M, **Mavroudis D**, Kapranou K, Markomanolaki H, Kallergi G, Koinis F, Kalbakis K, Georgoulas V, Agelaki S. Evaluation of proliferation and apoptosis markers in circulating tumor cells of women with early breast cancer who are candidates for tumor dormancy. *Breast Cancer Res*. 2014 Nov 29;16(6):485..
222. Vetsika EK, Koinis F, Gioulbasani M, Aggouraki D, Koutoulaki A, Skalidaki E, **Mavroudis D**, Georgoulas V, Kotsakis A. A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients. *J Immunol Res*. 2014;2014:659294.

223. Kalikaki A, Voutsina A, Koutsopoulos A, Papadaki C, Sfakianaki M, Yachnakis E, Xyrafas A, Kotsakis A, Agelaki S, Souglakos J, **Mavroudis D**, Georgoulas V. ERCC1 SNPs as Potential Predictive Biomarkers in Non-Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy. *Cancer Invest.* 2015 Apr;33(4):107-13.
224. Kotsakis A, Kentepozidis N, Emmanouilidis Ch, Polyzos A, Agelidou A, Vaslamatzis M, Chandrinos V, Agelaki S, Vamvakas L, Kalbakis K, Katsaounis P, Stoltidis D, Nintos G, Hatzidaki D, Vetsika EK, **Mavroudis D**, Georgoulas V. Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous non-small cell lung cancer: A multicenter randomized phase II trial of the Hellenic Oncology Research Group (HORG). *Lung Cancer.* 2015 Apr;88(1):57-62.
225. Matikas A, **Mavroudis D**. Beyond CTLA-4: novel immunotherapy strategies for metastatic melanoma. *Future Oncol.* 2015;11(6):997-1009.
226. **Mavroudis D**, Saloustros E, Malamos N, Kakolyris S, Boukovinas I, Papakotoulas P, Kentepozidis N, Ziras N, Georgoulas V; Breast Cancer Investigators of Hellenic Oncology Research Group (HORG), Athens, Greece.. Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG). *Ann Oncol.* 2015 Jul;26(7):1333-40.
227. Polioudaki H, Agelaki S, Chiotaki R, Politaki E, **Mavroudis D**, Matikas A, Georgoulas V, Theodoropoulos PA. Variable expression levels of keratin and vimentin reveal differential EMT status of circulating tumor cells and correlation with clinical characteristics and outcome of patients with metastatic breast cancer. *BMC Cancer.* 2015 May 13;15:399.
228. Agelaki S, Kalykaki A, Markomanolaki H, Papadaki MA, Kallergi G, Hatzidaki D, Kalbakis K, **Mavroudis D**, Georgoulas V. Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast

Cancer. PLoS One. 2015 Jun 17;10(6):e0123683.

229. Nikolaou C, Matikas A, Papavasilopoulou M, **Mavroudis D**, Vamvakas L. Prolonged Complete Response in a Patient with Metastatic Pancreatic Adenocarcinoma after FOLFIRINOX Chemotherapy and Maintenance with FOLFIRI. Case Rep Oncol Med. 2015;2015:659624.
230. Kallergi G, Agelaki S, Papadaki MA, Nasias D, Matikas A, **Mavroudis D**, Georgoulas V. Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients. Breast Cancer Res. 2015 Aug 19;17:113.
231. Bamias A, Peroukidis S, Stamatopoulou S, Tzannis K, Koutsoukos K, Andreadis C, Bozionelou V, Pistalimatzian N, Papatsoris A, Stravodimos K, Varthalitis I, Karamouzis M, Milaki G, Agorastos A, Kentepozidis N, Androulakis N, Bompolaki I, Kalofonos H, **Mavroudis D**, Dimopoulos MA. Utilization of Systemic Chemotherapy in Advanced Urothelial Cancer: A Retrospective Collaborative Study by the Hellenic Genitourinary Cancer Group (HGUCG). Clin Genitourin Cancer. 2016 Apr;14(2):e153-9.
232. Kontopodis E, Kotsakis A, Kentepozidis N, Syrigos K, Ziras N, Moutsos M, Filippa G, Mala A, Vamvakas L, **Mavroudis D**, Georgoulas V, Agelaki S. A phase II, open-label trial of bortezomib (VELCADE®) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer. Cancer Chemother Pharmacol. 2016 May;77(5):949-56.
233. **Mavroudis D**, Matikas A, Malamos N, Papakotoulas P, Kakolyris S, Boukovinas I, Athanasiadis A, Kentepozidis N, Ziras N, Katsaounis P, Saloustros E, Georgoulas V; Breast Cancer Investigators of the Hellenic Oncology Research Group (HORG), Athens, Greece.. Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive

early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG). *Ann Oncol*. 2016 Oct;27(10):1873-8.

234. Kotsakis A, Matikas A, Koinis F, Kentepozidis N, Varthalitis I, Karavassilis V, Samantas E, Katsaounis P, Dermitzaki EK, Hatzidaki D, **Mavroudis D**, Georgoulas V. A multicentre phase II trial of cabazitaxel in patients with advanced non-small-cell lung cancer progressing after docetaxel-based chemotherapy. *Br J Cancer*. 2016 Sep 27;115(7):784-8.
235. Stratigos M, Matikas A, Voutsina A, **Mavroudis D**, Georgoulas V. Targeting angiogenesis in small cell lung cancer. *Transl Lung Cancer Res*. 2016 Aug;5(4):389-400.
236. **Mavroudis D**. The tAnGo fell short of inspiring the audience. *Lancet Oncol*. 2017 May 4. pii: S1470-2045(17)30311-X.
237. **Mavroudis D**, Saloustros E, Boukovinas I, Papakotoulas P, Kakolyris S, Ziras N, Christophylakis C, Kentepozidis N, Fountzilas G, Rigas G, Varthalitis I, Kalbakis K, Agelaki S, Hatzidaki D, Georgoulas V. Sequential vs concurrent epirubicin and docetaxel as adjuvant chemotherapy for high-risk, node-negative, early breast cancer: an interim analysis of a randomised phase III study from the Hellenic Oncology Research Group. *Br J Cancer*. 2017 Jul 11;117(2):164-170.
238. Matikas A, Voutsina A, Lagoudaki E, Hatzidaki D, Trypaki M, Stoupis G, Tzardi M, **Mavroudis D**, Georgoulas V. Detection of KRAS Exon 2 Mutations in Circulating Tumor Cells Isolated by the ISET System from Patients with RAS Wild Type Metastatic Colorectal Cancer. *Transl Oncol*. 2017 Aug;10(4):693-698.
239. Spiliotaki M, **Mavroudis D**, Kokotsaki M, Vetsika EK, Stoupis I, Matikas A, Kallergi G, Georgoulas V, Agelaki S. Expression of insulin-like growth factor-1 receptor in circulating tumor cells of patients with breast cancer is associated with patient outcomes. *Mol Oncol*. 2018 Jan;12(1):21-32.

240. Saloustros E, Nikolaou M, Kalbakis K, Polyzos A, Christofillakis C, Kentepozidis N, Pistamaltzian N, Kourousis C, Vamvakas L, Georgoulas V, **Mavroudis D**. Weekly Paclitaxel and Carboplatin Plus Bevacizumab as First-Line Treatment of Metastatic Triple-Negative Breast Cancer. A Multicenter Phase II Trial by the Hellenic Oncology Research Group. Clin Breast Cancer. 2018 Feb;18(1):88-94.
241. Politaki E, Agelaki S, Apostolaki S, Hatzidaki D, Strati A, Koinis F, Perraki M, Saloustrou G, Stoupis G, Kallergi G, Spiliotaki M, Skaltsi T, Lianidou E, Georgoulas V, **Mavroudis D**. A Comparison of Three Methods for the Detection of Circulating Tumor Cells in Patients with Early and Metastatic Breast Cancer. Cell Physiol Biochem. 2017;44(2):594-606.
242. Messaritakis I, Stogiannitsi M, Koulouridi A, Sfakianaki M, Voutsina A, Sotiriou A, Athanasakis E, Xynos E, **Mavroudis D**, Tzardi M, Souglakos J. Evaluation of the detection of Toll-like receptors (TLRs) in cancer development and progression in patients with colorectal cancer. PLoS One. 2018 Jun 8;13(6):e0197327.
243. Papadaki C, Stratigos M, Markakis G, Spiliotaki M, Mastrostamatis G, Nikolaou C, **Mavroudis D**, Agelaki S. Circulating microRNAs in the early prediction of disease recurrence in primary breast cancer. Breast Cancer Res. 2018 Jul 11;20(1):72.
244. Papadaki MA, Stoupis G, Theodoropoulos PA, **Mavroudis D**, Georgoulas V, Agelaki S. Circulating tumor cells with stemness and epithelial-to-mesenchymal transition features are chemoresistant and predictive of poor outcome in metastatic breast cancer. Mol Cancer Ther. 2018 Nov 6. pii: molcanther.0584.2018.
245. Cazzaniga ME, Ciruelos E, Fabi A, Garcia-Saenz J, Lindman H, **Mavroudis D**, Schem C, Steger G, Timotheadou E, Zaman K, Torri V; MACBETH Group. Metastatic or locally advanced breast cancer patients: towards an expert consensus on nab-paclitaxel treatment in HER2-negative tumours- the MACBETH project. Cancer Chemother Pharmacol. 2018 Nov 20.
246. Milne RL, Kuchenbaecker KB, Michailidou K, Beesley J, Kar S, Lindström S, Hui S, Lemaçon A, Soucy P, Dennis J, Jiang X, Rostamianfar A, Finucane H, Bolla MK, McGuffog L, Wang Q, Aalfs CM; ABCTB Investigators, Adams M, Adlard J, Agata S, Ahmed S, Ahsan H, Aittomäki K, Al-Ejeh F, Allen J, Ambrosone CB, Amos CI, Andrulis IL, Anton-Culver H, Antonenkova NN,

Arndt V, Arnold N, Aronson KJ, Auber B, Auer PL, Ausems MGEM, Azzollini J, Bacot F, Balmaña J, Barile M, Barjhoux L, Barkardottir RB, Barrdahl M, Barnes D, Barrowdale D, Baynes C, Beckmann MW, Benitez J, Bermisheva M, Bernstein L, Bignon YJ, Blazer KR, Blok MJ, Blomqvist C, Blot W, Bobolis K, Boeckx B, Bogdanova NV, Bojesen A, Bojesen SE, Bonanni B, Børresen- Dale AL, Bozsik A, Bradbury AR, Brand JS, Brauch H, Brenner H, Bressac-de Paillerets B, Brewer C, Brinton L, Broberg P, Brooks-Wilson A, Brunet J, Brüning T, Burwinkel B, Buys SS, Byun J, Cai Q, Caldés T, Caligo MA, Campbell I, Canzian F, Caron O, Carracedo A, Carter BD, Castelao JE, Castera L, Caux-Moncoutier V, Chan SB, Chang-Claude J, Chanock SJ, Chen X, Cheng TD, Chiquette J, Christiansen H, Claes KBM, Clarke CL, Conner T, Conroy DM, Cook J, Cordina-Duverger E, Cornelissen S, Coupier I, Cox A, Cox DG, Cross SS, Cuk K, Cunningham JM, Czene K, Daly MB, Damiola F, Darabi H, Davidson R, De Leeneer K, Devilee P, Dicks E, Diez O, Ding YC, Ditsch N, Doheny KF, Domchek SM, Dorfling CM, Dörk T, Dos- Santos-Silva I, Dubois S, Dugué PA, Dumont M, Dunning AM, Durcan L, Dwek M, Dworniczak B, Eccles D, Eeles R, Ehrencrona H, Eilber U, Ejlersen B, Ekici AB, Eliassen AH; EMBRACE, Engel C, Eriksson M, Fachal L, Faivre L, Fasching PA, Faust U, Figueroa J, Flesch-Janys D, Fletcher O, Flyger H, Foulkes WD, Friedman E, Fritschi L, Frost D, Gabrielson M, Gaddam P, Gammon MD, Ganz PA, Gapstur SM, Garber J, Garcia-Barberan V, García- Sáenz JA, Gaudet MM, Gauthier-Villars M, Gehrig A; GEMO Study Collaborators, Georgoulas V, Gerdes AM, Giles GG, Glendon G, Godwin AK, Goldberg MS, Goldgar DE, González-Neira A, Goodfellow P, Greene MH, Alnæs GIG, Grip M, Gronwald J, Grundy A, Gschwantler-Kaulich D, Guénel P, Guo Q, Haeberle L, Hahnen E, Haiman CA, Håkansson N, Hallberg E, Hamann U, Hamel N, Hankinson S, Hansen TVO, Harrington P, Hart SN, Hartikainen JM, Healey CS; HEBON, Hein A, Helbig S, Henderson A, Heyworth J, Hicks B, Hillemanns P, Hodgson S, Hogervorst FB, Hollestelle A, Hoening MJ, Hoover B, Hopper JL, Hu C, Huang G, Hulick PJ, Humphreys K, Hunter DJ, Imyanitov EN, Isaacs C, Iwasaki M, Izatt L, Jakubowska A, James P, Janavicius R, Janni W, Jensen UB, John EM, Johnson N, Jones K, Jones M, Jukkola-Vuorinen A, Kaaks R, Kabisch M, Kaczmarek K, Kang D, Kast K; kConFab/AOCS Investigators, Keeman R, Kerin MJ, Kets CM, Keupers M, Khan S, Khusnutdinova E, Kiiski JI, Kim SW, Knight JA, Konstantopoulou I, Kosma VM, Kristensen VN, Kruse TA, Kwong A, Lænkholm AV, Laitman Y, Lalloo F, Lambrechts D, Landsman K, Lasset C, Lazaro C, Le Marchand L, Lecarpentier J, Lee A, Lee E, Lee JW, Lee MH, Lejbkowitz F, Lesueur F, Li J, Lilyquist J, Lincoln A, Lindblom A, Lissowska J, Lo WY, Loibl S, Long J, Loud JT, Lubinski J, Luccarini C, Lush M, MacInnis RJ, Maishman T, Makalic E, Kostovska IM, Malone KE, Manoukian S, Manson JE, Margolin S, Martens JWM, Martinez ME, Matsuo K, **Mavroudis D**, Mazoyer S, McLean C, Meijers-Heijboer H, Menéndez P, Meyer J, Miao H, Miller A, Miller N, Mitchell G, Montagna M, Muir K, Mulligan AM, Mulot C, Nadesan S, Nathanson KL; NBSC Collaborators, Neuhausen SL, Nevanlinna H, Nevelsteen I, Niederacher D, Nielsen SF, Nordestgaard BG, Norman A, Nussbaum RL, Olah E, Olopade OI, Olson JE, Olswold C, Ong KR, Oosterwijk JC, Orr N,

Osorio A, Pankratz VS, Papi L, Park-Simon TW, Paulsson-Karlsson Y, Lloyd R, Pedersen IS, Peissel B, Peixoto A, Perez JIA, Peterlongo P, Peto J, Pfeiler G, Phelan CM, Pinchev M, Plaseska-Karanfilska D, Poppe B, Porteous ME, Prentice R, Presneau N, Prokofieva D, Pugh E, Pujana MA, Pylkäs K, Rack B, Radice P, Rahman N, Rantala J, Rappaport-Fuerhauser C, Rennert G, Rennert HS, Rhenius V, Rhiem K, Richardson A, Rodriguez GC, Romero A, Romm J, Rookus MA, Rudolph A, Ruediger T, Saloustros E, Sanders J, Sandler DP, Sangrajrang S, Sawyer EJ, Schmidt DF, Schoemaker MJ, Schumacher F, Schürmann P, Schwentner L, Scott C, Scott RJ, Seal S, Senter L, Seynaeve C, Shah M, Sharma P, Shen CY, Sheng X, Shimelis H, Shrubsole MJ, Shu XO, Side LE, Singer CF, Sohn C, Southey MC, Spinelli JJ, Spurdle AB, Stegmaier C, Stoppa-Lyonnet D, Sukiennicki G, Surowy H, Sutter C, Swerdlow A, Szabo CI, Tamimi RM, Tan YY, Taylor JA, Tejada MI, Tengström M, Teo SH, Terry MB, Tessier DC, Teulé A, Thöne K, Thull DL, Tibiletti MG, Tihomirova L, Tischkowitz M, Toland AE, Tollenaar RAEM, Tomlinson I, Tong L, Torres D, Tranchant M, Truong T, Tucker K, Tung N, Tyrer J, Ulmer HU, Vachon C, van Asperen CJ, Van Den Berg D, van den Ouweland AMW, van Rensburg EJ, Varesco L, Varon-Mateeva R, Vega A, Viel A, Vijai J, Vincent D, Vollenweider J, Walker L, Wang Z, Wang-Gohrke S, Wappenschmidt B, Weinberg CR, Weitzel JN, Wendt C, Wesseling J, Whittemore AS, Wijnen JT, Willett W, Winqvist R, Wolk A, Wu AH, Xia L, Yang XR, Yannoukakos D, Zaffaroni D, Zheng W, Zhu B, Ziogas A, Ziv E, Zorn KK, Gago-Dominguez M, Mannermaa A, Olsson H, Teixeira MR, Stone J, Offit K, Ottini L, Park SK, Thomassen M, Hall P, Meindl A, Schmutzler RK, Droit A, Bader GD, Pharoah PDP, Couch FJ, Easton DF, Kraft P, Chenevix-Trench G, García-Closas M, Schmidt MK, Antoniou AC, Simard J. Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. *Nat Genet.* 2017 Dec;49(12):1767-1778.

247. Michailidou K, Lindström S, Dennis J, Beesley J, Hui S, Kar S, Lemaçon A, Soucy P, Glubb D, Rostamianfar A, Bolla MK, Wang Q, Tyrer J, Dicks E, Lee A, Wang Z, Allen J, Keeman R, Eilber U, French JD, Qing Chen X, Fachal L, McCue K, McCart Reed AE, Ghoussaini M, Carroll JS, Jiang X, Finucane H, Adams M, Adank MA, Ahsan H, Aittomäki K, Anton-Culver H, Antonenkova NN, Arndt V, Aronson KJ, Arun B, Auer PL, Bacot F, Barrdahl M, Baynes C, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Bernstein L, Blomqvist C, Bogdanova NV, Bojesen SE, Bonanni B, Børresen-Dale AL, Brand JS, Brauch H, Brennan P, Brenner H, Brinton L, Broberg P, Brock IW, Broeks A, Brooks-Wilson A, Brucker SY, Brüning T, Burwinkel B, Butterbach K, Cai Q, Cai H, Caldés T, Canzian F, Carracedo A, Carter BD, Castelao JE, Chan TL, David Cheng TY, Seng Chia K, Choi JY, Christiansen H, Clarke CL; NBCS Collaborators, Collée M, Conroy DM, Cordina-Duverger E, Cornelissen S, Cox DG, Cox A, Cross SS, Cunningham JM, Czene K, Daly MB, Devilee P, Doheny KF, Dörk T, Dos-Santos-Silva I, Dumont M, Durcan L, Dwek M, Eccles DM, Ekici AB, Eliassen AH, Ellberg C, Elvira M, Engel C, Eriksson M, Fasching

PA, Figueroa J, Flesch-Janys D, Fletcher O, Flyger H, Fritschi L, Gaborieau V, Gabrielson M, Gago-Dominguez M, Gao YT, Gapstur SM, García-Sáenz JA, Gaudet MM, Georgoulas V, Giles GG, Glendon G, Goldberg MS, Goldgar DE, González-Neira A, Grenaker Alnæs GI, Grip M, Gronwald J, Grundy A, Guénel P, Haeberle L, Hahnen E, Haiman CA, Håkansson N, Hamann U, Hamel N, Hankinson S, Harrington P, Hart SN, Hartikainen JM, Hartman M, Hein A, Heyworth J, Hicks B, Hillemanns P, Ho DN, Hollestelle A, Hooning MJ, Hoover RN, Hopper JL, Hou MF, Hsiung CN, Huang G, Humphreys K, Ishiguro J, Ito H, Iwasaki M, Iwata H, Jakubowska A, Janni W, John EM, Johnson N, Jones K, Jones M, Jukkola-Vuorinen A, Kaaks R, Kabisch M, Kaczmarek K, Kang D, Kasuga Y, Kerin MJ, Khan S, Khusnutdinova E, Kiiski JI, Kim SW, Knight JA, Kosma VM, Kristensen VN, Krüger U, Kwong A, Lambrechts D, Le Marchand L, Lee E, Lee MH, Lee JW, Neng Lee C, Lejbkiewicz F, Li J, Lilyquist J, Lindblom A, Lissowska J, Lo WY, Loibl S, Long J, Lophatananon A, Lubinski J, Luccarini C, Lux MP, Ma ESK, MacInnis RJ, Maishman T, Makalic E, Malone KE, Kostovska IM, Mannermaa A, Manoukian S, Manson JE, Margolin S, Mariapun S, Martinez ME, Matsuo K, **Mavroudis D**, McKay J, McLean C, Meijers-Heijboer H, Meindl A, Menéndez P, Menon U, Meyer J, Miao H, Miller N, Taib NAM, Muir K, Mulligan AM, Mulot C, Neuhausen SL, Nevanlinna H, Neven P, Nielsen SF, Noh DY, Nordestgaard BG, Norman A, Olopade OI, Olson JE, Olsson H, Olswold C, Orr N, Pankratz VS, Park SK, Park-Simon TW, Lloyd R, Perez JIA, Peterlongo P, Peto J, Phillips KA, Pinchev M, Plaseska-Karanfilska D, Prentice R, Presneau N, Prokofyeva D, Pugh E, Pylkäs K, Rack B, Radice P, Rahman N, Rennert G, Rennert HS, Rhenius V, Romero A, Romm J, Ruddy KJ, Rüdiger T, Rudolph A, Ruebner M, Rutgers EJT, Saloustros E, Sandler DP, Sangrajrang S, Sawyer EJ, Schmidt DF, Schmutzler RK, Schneeweiss A, Schoemaker MJ, Schumacher F, Schürmann P, Scott RJ, Scott C, Seal S, Seynaeve C, Shah M, Sharma P, Shen CY, Sheng G, Sherman ME, Shrubsole MJ, Shu XO, Smeets A, Sohn C, Southey MC, Spinelli JJ, Stegmaier C, Stewart-Brown S, Stone J, Stram DO, Surowy H, Swerdlow A, Tamimi R, Taylor JA, Tengström M, Teo SH, Beth Terry M, Tessier DC, Thanasiythichai S, Thöne K, Tollenaar RAEM, Tomlinson I, Tong L, Torres D, Truong T, Tseng CC, Tsugane S, Ulmer HU, Ursin G, Untch M, Vachon C, van Asperen CJ, Van Den Berg D, van den Ouweland AMW, van der Kolk L, van der Luijt RB, Vincent D, Vollenweider J, Waisfisz Q, Wang-Gohrke S, Weinberg CR, Wendt C, Whittemore AS, Wildiers H, Willett W, Winqvist R, Wolk A, Wu AH, Xia L, Yamaji T, Yang XR, Har Yip C, Yoo KY, Yu JC, Zheng W, Zheng Y, Zhu B, Ziogas A, Ziv E; ABCTB Investigators; ConFab/AOCS Investigators, Lakhani SR, Antoniou AC, Droit A, Andrulis IL, Amos CI, Couch FJ, Pharoah PDP, Chang-Claude J, Hall P, Hunter DJ, Milne RL, García-Closas M, Schmidt MK, Chanock SJ, Dunning AM, Edwards SL, Bader GD, Chenevix-Trench G, SimNature. 2017 Nov 2;551(7678):92-94. doi: 10.1038/nature24284. Epub 2017 Oct 23.ard J, Kraft P, Easton DF. Association analysis identifies 65 new breast cancer risk loci.

248. Wu L, Shi W, Long J, Guo X, Michailidou K, Beesley J, Bolla MK, Shu XO, Lu Y, Cai Q, Al-Ejeh F, Rozali E, Wang Q, Dennis J, Li B, Zeng C, Feng H, Gusev A, Barfield RT, Andrulis IL, Anton-Culver H, Arndt V, Aronson KJ, Auer PL, Barrdahl M, Baynes C, Beckmann MW, Benitez J, Bermisheva M, Blomqvist C, Bogdanova NV, Bojesen SE, Brauch H, Brenner H, Brinton L, Broberg P, Brucker SY, Burwinkel B, Caldés T, Canzian F, Carter BD, Castelao JE, Chang-Claude J, Chen X, Cheng TD, Christiansen H, Clarke CL; NBCS Collaborators, Collée M, Cornelissen S, Couch FJ, Cox D, Cox A, Cross SS, Cunningham JM, Czene K, Daly MB, Devilee P, Doheny KF, Dörk T, Dos-Santos-Silva I, Dumont M, Dwek M, Eccles DM, Eilber U, Eliassen AH, Engel C, Eriksson M, Fachal L, Fasching PA, Figueroa J, Flesch-Janys D, Fletcher O, Flyger H, Fritschi L, Gabrielson M, Gago-Dominguez M, Gapstur SM, García-Closas M, Gaudet MM, Ghoussaini M, Giles GG, Goldberg MS, Goldgar DE, González-Neira A, Guénel P, Hahnen E, Haiman CA, Håkansson N, Hall P, Hallberg E, Hamann U, Harrington P, Hein A, Hicks B, Hillemanns P, Hollestelle A, Hoover RN, Hopper JL, Huang G, Humphreys K, Hunter DJ, Jakubowska A, Janni W, John EM, Johnson N, Jones K, Jones ME, Jung A, Kaaks R, Kerin MJ, Khusnutdinova E, Kosma VM, Kristensen VN, Lambrechts D, Le Marchand L, Li J, Lindström S, Lissowska J, Lo WY, Loibl S, Lubinski J, Luccarini C, Lux MP, MacInnis RJ, Maishman T, Kostovska IM, Mannermaa A, Manson JE, Margolin S, **Mavroudis D**, Meijers-Heijboer H, Meindl A, Menon U, Meyer J, Mulligan AM, Neuhausen SL, Nevanlinna H, Neven P, Nielsen SF, Nordestgaard BG, Olopade OI, Olson JE, Olsson H, Peterlongo P, Peto J, Plaseska-Karanfilska D, Prentice R, Presneau N, Pyrkäs K, Rack B, Radice P, Rahman N, Rennert G, Rennert HS, Rhenius V, Romero A, Romm J, Rudolph A, Saloustros E, Sandler DP, Sawyer EJ, Schmidt MK, Schmutzler RK, Schneeweiss A, Scott RJ, Scott CG, Seal S, Shah M, Shrubsole MJ, Smeets A, Southey MC, Spinelli JJ, Stone J, Surowy H, Swerdlow AJ, Tamimi RM, Tapper W, Taylor JA, Terry MB, Tessier DC, Thomas A, Thöne K, Tollenaar RAEM, Torres D, Truong T, Untch M, Vachon C, Van Den Berg D, Vincent D, Waisfisz Q, Weinberg CR, Wendt C, Whittemore AS, Wildiers H, Willett WC, Winqvist R, Wolk A, Xia L, Yang XR, Ziogas A, Ziv E; kConFab/AOCS Investigators, Dunning AM, Pharoah PDP, Simard J, Milne RL, Edwards SL, Kraft P, Easton DF, Chenevix-Trench G, Zheng W. A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. *Nat Genet.* 2018 Jul;50(7):968-978.
249. Mavaddat N, Michailidou K, Dennis J, Lush M, Fachal L, Lee A, Tyrer JP, Chen TH, Wang Q, Bolla MK, Yang X, Adank MA, Ahearn T, Aittomäki K, Allen J, Andrulis IL, Anton-Culver H, Antonenkova NN, Arndt V, Aronson KJ, Auer PL, Auvinen P, Barrdahl M, Beane Freeman LE, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Bernstein L, Blomqvist C, Bogdanova NV, Bojesen SE, Bonanni B, Børresen-Dale AL, Brauch H, Bremer M, Brenner H, Brentnall A, Brock IW, Brooks-Wilson A, Brucker SY, Brüning T, Burwinkel B, Campa D, Carter BD, Castelao JE, Chanock SJ, Chlebowski R, Christiansen H, Clarke CL,

Collée JM, Cordina-Duverger E, Cornelissen S, Couch FJ, Cox A, Cross SS, Czene K, Daly MB, Devilee P, Dörk T, Dos-Santos-Silva I, Dumont M, Durcan L, Dwek M, Eccles DM, Ekici AB, Eliassen AH, Ellberg C, Engel C, Eriksson M, Evans DG, Fasching PA, Figueroa J, Fletcher O, Flyger H, Försti A, Fritschi L, Gabrielson M, Gago-Dominguez M, Gapstur SM, García-Sáenz JA, Gaudet MM, Georgoulas V, Giles GG, Gilyazova IR, Glendon G, Goldberg MS, Goldgar DE, González-Neira A, Grenaker Alnæs GI, Grip M, Gronwald J, Grundy A, Guénel P, Haeberle L, Hahnen E, Haiman CA, Håkansson N, Hamann U, Hankinson SE, Harkness EF, Hart SN, He W, Hein A, Heyworth J, Hillemanns P, Hollestelle A, Hooning MJ, Hoover RN, Hopper JL, Howell A, Huang G, Humphreys K, Hunter DJ, Jakimovska M, Jakubowska A, Janni W, John EM, Johnson N, Jones ME, Jukkola-Vuorinen A, Jung A, Kaaks R, Kaczmarek K, Kataja V, Keeman R, Kerin MJ, Khusnutdinova E, Kiiski JI, Knight JA, Ko YD, Kosma VM, Koutros S, Kristensen VN, Krüger U, Kühl T, Lambrechts D, Le Marchand L, Lee E, Lejbkowitz F, Lilyquist J, Lindblom A, Lindström S, Lissowska J, Lo WY, Loibl S, Long J, Lubiński J, Lux MP, MacInnis RJ, Maishman T, Makalic E, Maleva Kostovska I, Mannermaa A, Manoukian S, Margolin S, Martens JWM, Martinez ME, **Mavroudis D**, McLean C, Meindl A, Menon U, Middha P, Miller N, Moreno F, Mulligan AM, Mulot C, Muñoz-Garzon VM, Neuhausen SL, Nevanlinna H, Neven P, Newman WG, Nielsen SF, Nordestgaard BG, Norman A, Offit K, Olson JE, Olsson H, Orr N, Pankratz VS, Park-Simon TW, Perez JIA, Pérez-Barrios C, Peterlongo P, Peto J, Pinchev M, Plaseska-Karanfilska D, Polley EC, Prentice R, Presneau N, Prokofyeva D, Purrington K, Pyrkäs K, Rack B, Radice P, Rauh-Murthy R, Rennert G, Rennert HS, Rhenius V, Robson M, Romero A, Ruddy KJ, Ruebner M, Saloustros E, Sandler DP, Sawyer EJ, Schmidt DF, Schmutzler RK, Schneeweiss A, Schoemaker MJ, Schumacher F, Schürmann P, Schwentner L, Scott C, Scott RJ, Seynaeve C, Shah M, Sherman ME, Shrubsole MJ, Shu XO, Slager S, Smeets A, Sohn C, Soucy P, Southey MC, Spinelli JJ, Stegmaier C, Stone J, Swerdlow AJ, Tamimi RM, Tapper WJ, Taylor JA, Terry MB, Thöne K, Tollenaar RAEM, Tomlinson I, Truong T, Tzardi M, Ulmer HU, Untch M, Vachon CM, van Veen EM, Vijai J, Weinberg CR, Wendt C, Whittemore AS, Wildiers H, Willett W, Winqvist R, Wolk A, Yang XR, Yannoukakos D, Zhang Y, Zheng W, Ziogas A; ABCTB Investigators; kConFab/AOCS Investigators; NBCS Collaborators, Dunning AM, Thompson DJ, Chenevix-Trench G, Chang-Claude J, Schmidt MK, Hall P, Milne RL, Pharoah PDP, Antoniou AC, Chatterjee N, Kraft P, García-Closas M, Simard J, Easton DF. Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. *Am J Hum Genet.* 2019 Jan 3;104(1):21-34.

250. Polioudaki H, Chantziou A, Kalyvianaki K, Malamos P, Notas G, **Mavroudis D**, Kampa M, Castanas E, Theodoropoulos PA. Nuclear localization of PD-L1: artifact or reality? *Cell Oncol (Dordr).* 2019 Apr;42(2):237-242.

251. Saad ED, Squifflet P, Burzykowski T, Quinaux E, Delaloge S, **Mavroudis D**, Perez E, Piccart-Gebhart M, Schneider BP, Slamon D, Wolmark N, Buyse M. Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis. *Lancet Oncol.* 2019 Mar;20(3):361-370.
252. Cristofanilli M, Pierga JY, Reuben J, Rademaker A, Davis AA, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, **Mavroudis D**, Grisanti S, Giuliano M, Garcia-Saenz JA, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, de Lascoiti AF, De Mattos-Arruda L, Ignatiadis M, Cabel L, van Laere SJ, Meier-Stiegen F, Sandri MT, Vidal-Martinez J, Politaki E, Consoli F, Generali D, Cappelletti MR, Diaz-Rubio E, Krell J, Dawson SJ, Raimondi C, Rutten A, Janni W, Munzone E, Carañana V, Agelaki S, Almici C, Dirix L, Solomayer EF, Zorzino L, Darrigues L, Reis-Filho JS, Gerratana L, Michiels S, Bidard FC, Pantel K. The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. *CritRev Oncol Hematol.* 2019 Feb;134:39-45.
253. Escala-Garcia M, Guo Q, Dörk T, Canisius S, Keeman R, Dennis J, Beesley J, Lecarpentier J, Bolla MK, Wang Q, Abraham J, Andrulis IL, Anton-Culver H, Arndt V, Auer PL, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Bernstein L, Blomqvist C, Boeckx B, Bojesen SE, Bonanni B, Børresen-Dale AL, Brauch H, Brenner H, Brentnall A, Brinton L, Broberg P, Brock IW, Brucker SY, Burwinkel B, Caldas C, Caldés T, Campa D, Canzian F, Carracedo A, Carter BD, Castela JE, Chang-Claude J, Chanock SJ, Chenevix-Trench G, Cheng TD, Chin SF, Clarke CL; NBCS Collaborators, Cordina-Duverger E, Couch FJ, Cox DG, Cox A, Cross SS, Czene K, Daly MB, Devilee P, Dunn JA, Dunning AM, Durcan L, Dwek M, Earl HM, Ekici AB, Eliassen AH, Ellberg C, Engel C, Eriksson M, Evans DG, Figueroa J, Flesch-Janys D, Flyger H, Gabrielson M, Gago-Dominguez M, Galle E, Gapstur SM, García-Closas M, García-Sáenz JA, Gaudet MM, George A, Georgoulas V, Giles GG, Glendon G, Goldgar DE, González-Neira A, Alnæs GIG, Grip M, Guénel P, Haeberle L, Hahnen E, Haiman CA, Håkansson N, Hall P, Hamann U, Hankinson S, Harkness EF, Harrington PA, Hart SN, Hartikainen JM, Hein A, Hillemanns P, Hiller L, Holleccek B, Hollestelle A, Hoening MJ, Hoover RN, Hopper JL, Howell A,

Huang G, Humphreys K, Hunter DJ, Janni W, John EM, Jones ME, Jukkola-Vuorinen A, Jung A, Kaaks R, Kabisch M, Kaczmarek K, Kerin MJ, Khan S, Khusnutdinova E, Kiiski JI, Kitahara CM, Knight JA, Ko YD, Koppert LB, Kosma VM, Kraft P, Kristensen VN, Krüger U, Kühl T, Lambrechts D, Le Marchand L, Lee E, Lejbkowitz F, Li L, Lindblom A, Lindström S, Linet M, Lissowska J, Lo WY, Loibl S, Lubiński J, Lux MP, MacInnis RJ, Maierthaler M, Maishman T, Makalic E, Mannermaa A, Manoochehri M, Manoukian S, Margolin S, Martinez ME, **Mavroudis D**, McLean C, Meindl A, Middha P, Miller N, Milne RL, Moreno F, Mulligan AM, Mulot C, Nassir R, Neuhausen SL, Newman WT, Nielsen SF, Nordestgaard BG, Norman A, Olsson H, Orr N, Pankratz VS, Park-Simon TW, Perez JIA, Pérez-Barrios C, Peterlongo P, Petridis C, Pinchev M, Prajzandanc K, Prentice R, Presneau N, Prokofieva D, Pylkäs K, Rack B, Radice P, Ramachandran D, Rennert G, Rennert HS, Rhenius V, Romero A, Roylance R, Saloustros E, Sawyer EJ, Schmidt DF, Schmutzler RK, Schneeweiss A, Schoemaker MJ, Schumacher F, Schwentner L, Scott RJ, Scott C, Seynaeve C, Shah M, Simard J, Smeets MR, Tengström M, Terry MB, Thöne K, Tollenaar RAEM, Tomlinson I, Torres D, Truong T, Turman C, Turnbull C, Ulmer HU, Untch M, Vachon C, van Asperen CJ, van den Ouweland AMW, van Veen EM, Wendt C, Whittemore AS, Willett W, Winqvist R, Wolk A, Yang XR, Zhang Y, Easton DF, Fasching PA, Nevanlinna H, Eccles DM, Pharoah PDP, Schmidt MK. Genome-wide association study of germline variants and breast cancer-specific mortality. *Br J Cancer*. 2019 Mar;120(6):647-657.

254. Papadaki C, Stoupis G, Tsalikis L, Monastirioti A, Papadaki M, Maliotis N, Stratigos M, Mastrostamatis G, **Mavroudis D**, Agelaki S. Circulating miRNAs as a marker of metastatic disease and prognostic factor in metastatic breast cancer. *Oncotarget*. 2019 Jan 29;10(9):966-981.
255. Thomopoulou K, Tzardi M, **Mavroudis D**, Souglakos I A Case Presentation of a Patient with Microsatellite Instability and BRAF Mutant Metastatic Colon Cancer and Bibliography Update. *Case Rep Oncol Med*. 2019 Feb 17;2019:4767019.
256. Sfakianaki M, Papadaki C, Tzardi M, Trypaki M, Alam S, Lagoudaki ED, Messaritakis I, Zoras O, **Mavroudis D**, Georgoulas V, Souglakos J. Loss of LKB1 Protein Expression Correlates with Increased Risk of Recurrence and

Death in Patients with Resected, Stage II or III Colon Cancer. *Cancer Res Treat.* 2019 Oct;51(4):1518-1526.

257. Ferreira MA, Gamazon ER, Al-Ejeh F, Aittomäki K, Andrulis IL, Anton-Culver H, Arason A, Arndt V, Aronson KJ, Arun BK, Asseryanis E, Azzollini J, Balmaña J, Barnes DR, Barrowdale D, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Białkowska K, Blomqvist C, Bogdanova NV, Bojesen SE, Bolla MK, Borg A, Brauch H, Brenner H, Broeks A, Burwinkel B, Caldés T, Caligo MA, Campa D, Campbell I, Canzian F, Carter J, Carter BD, Castela J, Chang-Claude J, Chanock SJ, Christiansen H, Chung WK, Claes KBM, Clarke CL; EMBRACE Collaborators; GC-HBOC Study Collaborators; GEMO Study Collaborators, Couch FJ, Cox A, Cross SS, Czene K, Daly MB, de la Hoya M, Dennis J, Devilee P, Diez O, Dörk T, Dunning AM, Dwek M, Eccles DM, Ejlertsen B, Ellberg C, Engel C, Eriksson M, Fasching PA, Fletcher O, Flyger H, Friedman E, Frost D, Gabrielson M, Gago-Dominguez M, Ganz PA, Gapstur SM, Garber J, García-Closas M, García-Sáenz JA, Gaudet MM, Giles GG, Glendon G, Godwin AK, Goldberg MS, Goldgar DE, González-Neira A, Greene MH, Gronwald J, Guénel P, Haiman CA, Hall P, Hamann U, He W, Heyworth J, Hogervorst FBL, Hollestelle A, Hoover RN, Hopper JL, Hulick PJ, Humphreys K, Imyanitov EN; ABCTB Investigators; HEBON Investigators; BCFR Investigators, Isaacs C, Jakimovska M, Jakubowska A, James PA, Janavicius R, Jankowitz RC, John EM, Johnson N, Joseph V, Karlan BY, Khusnutdinova E, Kiiski JI, Ko YD, Jones ME, Konstantopoulou I, Kristensen VN, Laitman Y, Lambrechts D, Lazaro C, Leslie G, Lester J, Lesueur F, Lindström S, Long J, Loud JT, Lubiński J, Makalic E, Mannermaa A, Manoochehri M, Margolin S, Maurer T, **Mavroudis D**, McGuffog L, Meindl A, Menon U, Michailidou K, Miller A, Montagna M, Moreno F, Moserle L, Mulligan AM, Nathanson KL, Neuhausen SL, Nevanlinna H, Nevelsteen I, Nielsen FC, Nikitina-Zake L, Nussbaum RL, Offit K, Olah E, Olopade OI, Olsson H, Osorio A, Papp J, Park-Simon TW, Parsons MT, Pedersen IS, Peixoto A, Peterlongo P, Pharoah PDP, Plaseska-Karanfilska D, Poppe B, Presneau N, Radice P, Rantala J, Rennert G, Risch HA, Saloustros E, Sanden K, Sawyer EJ, Schmidt MK, Schmutzler RK, Sharma P, Shu XO, Simard J, Singer CF, Soucy P, Southey MC, Spinelli JJ, Spurdle AB, Stone J, Swerdlow AJ, Tapper WJ, Taylor JA, Teixeira MR, Terry MB, Teulé A, Thomassen M, Thöne K, Thull DL, Tischkowitz M, Toland AE, Torres D, Truong T, Tung N, Vachon CM, van Asperen CJ, van den Ouweland AMW, van Rensburg EJ, Vega A, Viel A, Wang Q, Wappenschmidt B, Weitzel JN, Wendt C, Winqvist R, Yang XR, Yannoukakos D, Ziogas A, Kraft P, Antoniou AC, Zheng W, Easton DF, Milne RL, Beesley J, Chenevix-Trench G.

Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. *Nat Commun.* 2019 Apr 15;10(1):1741.

258. Souglakos J, Boukovinas I, Kakolyris S, Xynogalos S, Ziras N, Athanasiadis A, Androulakis N, Christopoulou A, Vaslamatzis M, Ardavanis A, Emmanouilides C, Bompoulaki I, Kourousis C, Makrantonakis P, Christofyllakis C, Athanasiadis E, Kentepozidis N, Karampeazis A, Katopodi U, Anagnosopoulos A, Papadopoulos G, Prinarakis E, Kalisperi A, **Mavroudis D**, Georgoulas V. Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project. *Ann Oncol*. 2019 Aug;30(8):1304-1310.
259. Tzanikou E, Markou A, Politaki E, Koutsopoulos A, Psyrris A, **Mavroudis D**, Georgoulas V, Lianidou E. PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study. *Mol Oncol*. 2019 Dec;13(12):2515-2530.
260. Villaruz LC, Cobo M, Syrigos K, **Mavroudis D**, Zhang W, Kim JS, Socinski MA. A phase II study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer. *Lung Cancer*. 2019 Oct;136:52-56.
261. Dörk T, Peterlongo P, Mannermaa A, Bolla MK, Wang Q, Dennis J, Ahearn T, Andrulis IL, Anton-Culver H, Arndt V, Aronson KJ, Augustinsson A, Freeman LEB, Beckmann MW, Beeghly-Fadiel A, Behrens S, Bermisheva M, Blomqvist C, Bogdanova NV, Bojesen SE, Brauch H, Brenner H, Burwinkel B, Canzian F, Chan TL, Chang-Claude J, Chanock SJ, Choi JY, Christiansen H, Clarke CL, Couch FJ, Czene K, Daly MB, Dos-Santos-Silva I, Dwek M, Eccles DM, Ekici AB, Eriksson M, Evans DG, Fasching PA, Figueroa J, Flyger H, Fritschi L, Gabrielson M, Gago-Dominguez M, Gao C, Gapstur SM, García-Closas M, García-Sáenz JA, Gaudet MM, Giles GG, Goldberg MS, Goldgar DE, Guénel P, Haeberle L, Haiman CA, Håkansson N, Hall P, Hamann U, Hartman M, Hauke J, Hein A, Hillemanns P, Hogervorst FBL, Hooning MJ, Hopper JL, Howell T, Huo D, Ito H, Iwasaki M, Jakubowska A, Janni W, John EM, Jung A, Kaaks R, Kang D, Kapoor PM, Khusnutdinova E, Kim SW, Kitahara CM, Koutros S, Kraft P, Kristensen VN, Kwong A, Lambrechts D, Marchand LL, Li J, Lindström S,

Linnet M, Lo WY, Long J, Lophatananon A, Lubiński J, Manoochehri M, Manoukian S, Margolin S, Martinez E, Matsuo K, **Mavroudis D**, Meindl A, Menon U, Milne RL, Mohd Taib NA, Muir K, Mulligan AM, Neuhausen SL, Newman WG, Offit K, Olopade OI, Olshan AF, Olson JE, Olsson H, Park SK, Park-Simon TW, Peto J, Plaseska-Karanfilska D, Pohl-Rescigno E, Presneau N, Rack B, Radice P, Rashid MU, Rennert G, Rennert HS, Romero A, Ruebner M, Saloustros E, Schmidt MK, Schmutzler RK, Schneider MO, Schoemaker MJ, Scott C, Shen CY, Shu XO, Simard J, Slager S, Smichkoska S, Southey MC, Spinelli JJ, Stone J, Surowy H, Swerdlow AJ, Tamimi RM, Tapper WJ, Teo SH, Terry MB, Toland AE, Tollenaar RAEM, Torres D, Torres-Mejía G, Troester MA, Truong T, Tsugane S, Untch M, Vachon CM, Ouweland AMWVD, Veen EMV, Vijai J, Wendt C, Wolk A, Yu JC, Zheng W, Ziogas A, Ziv E; ABCTB Investigators; NBCS Collaborators, Dunning AM, Pharoah PDP, Schindler D, Devilee P, Easton DF. Two truncating variants in FANCC and breast cancer risk. *Sci Rep*. 2019 Aug 29;9(1):12524.

262. Thomopoulou K, Manolakou S, Messaritakis I, Tzardi M, Lagoudaki E, Koutsopoulos A, Koulouris A, Kanellis G, Kalbakis K, **Mavroudis D**, Souglakos I. Brain and bone marrow metastases from rectal cancer. *Ann Gastroenterol*. 2020 Jan-Feb;33(1):95-97.
263. Fachal L, Aschard H, Beesley J, Barnes DR, Allen J, Kar S, Pooley KA, Dennis J, Michailidou K, Turman C, Soucy P, Lemaçon A, Lush M, Tyrer JP, Ghoussaini M, Moradi Marjaneh M, Jiang X, Agata S, Aittomäki K, Alonso MR, Andrulis IL, Anton-Culver H, Antonenkova NN, Arason A, Arndt V, Aronson KJ, Arun BK, Auber B, Auer PL, Azzollini J, Balmaña J, Barkardottir RB, Barrowdale D, Beeghly-Fadiel A, Benitez J, Bermisheva M, Białkowska K, Blanco AM, Blomqvist C, Blot W, Bogdanova NV, Bojesen SE, Bolla MK, Bonanni B, Borg A, Bosse K, Brauch H, Brenner H, Briceno I, Brock IW, Brooks-Wilson A, Brüning T, Burwinkel B, Buys SS, Cai Q, Caldés T, Caligo MA, Camp NJ, Campbell I, Canzian F, Carroll JS, Carter BD, Castelao JE, Chiquette J, Christiansen H, Chung WK, Claes KBM, Clarke CL; GEMO Study Collaborators; EMBRACE Collaborators, Collée JM, Cornelissen S, Couch FJ, Cox A, Cross SS, Cybulski C, Czene K, Daly MB, de la Hoya M, Devilee P, Diez O, Ding YC, Dite GS, Domchek SM, Dörk T, Dos-Santos-Silva I, Droit A, Dubois S, Dumont M, Duran M, Durcan L, Dwek M, Eccles DM, Engel C, Eriksson M, Evans DG, Fasching PA, Fletcher O, Floris G, Flyger H, Foretova L, Foulkes WD, Friedman E, Fritschi L, Frost D, Gabrielson M, Gago-Dominguez M, Gambino G, Ganz PA, Gapstur SM, Garber J, García-Sáenz JA, Gaudet MM, Georgoulas V, Giles GG, Glendon G, Godwin AK, Goldberg MS, Goldgar DE, González-Neira A, Tibiletti MG, Greene MH, Grip M,

Gronwald J, Grundy A, Guénel P, Hahnen E, Haiman CA, Håkansson N, Hall P, Hamann U, Harrington PA, Hartikainen JM, Hartman M, He W, Healey CS, Heemskerk-Gerritsen BAM, Heyworth J, Hillemanns P, Hogervorst FBL, Hollestelle A, Hoening MJ, Hopper JL, Howell A, Huang G, Hulick PJ, Imyanitov EN; KConFab Investigators; HEBON Investigators; ABCTB Investigators, Isaacs C, Iwasaki M, Jager A, Jakimovska M, Jakubowska A, James PA, Janavicius R, Jankowitz RC, John EM, Johnson N, Jones ME, Jukkola-Vuorinen A, Jung A, Kaaks R, Kang D, Kapoor PM, Karlan BY, Keeman R, Kerin MJ, Khusnutdinova E, Kiiski JI, Kirk J, Kitahara CM, Ko YD, Konstantopoulou I, Kosma VM, Koutros S, Kubelka-Sabit K, Kwong A, Kyriacou K, Laitman Y, Lambrechts D, Lee E, Leslie G, Lester J, Lesueur F, Lindblom A, Lo WY, Long J, Lophatananon A, Loud JT, Lubiński J, MacInnis RJ, Maishman T, Makalic E, Mannermaa A, Manoochehri M, Manoukian S, Margolin S, Martinez ME, Matsuo K, Maurer T, **Mavroudis D**, Mayes R, McGuffog L, McLean C, Mebirouk N, Meindl A, Miller A, Miller N, Montagna M, Moreno F, Muir K, Mulligan AM, Muñoz-Garzon VM, Muranen TA, Narod SA, Nassir R, Nathanson KL, Neuhausen SL, Nevanlinna H, Neven P, Nielsen FC, Nikitina-Zake L, Norman A, Offit K, Olah E, Olopade OI, Olsson H, Orr N, Osorio A, Pankratz VS, Papp J, Park SK, Park-Simon TW, Parsons MT, Paul J, Pedersen IS, Peissel B, Peshkin B, Peterlongo P, Peto J, Plaseska-Karanfilska D, Prajzandanc K, Prentice R, Presneau N, Prokofyeva D, Pujana MA, Pylkäs K, Radice P, Ramus SJ, Rantala J, Rau-Murthy R, Rennert G, Risch HA, Robson M, Romero A, Rossing M, Saloustros E, Sánchez-Herrero E, Sandler DP, Santamariña M, Saunders C, Sawyer EJ, Scheuner MT, Schmidt DF, Schmutzler RK, Schneeweiss A, Schoemaker MJ, Schöttker B, Schürmann P, Scott C, Scott RJ, Senter L, Seynaeve CM, Shah M, Sharma P, Shen CY, Shu XO, Singer CF, Slavin TP, Smichkoska S, Southey MC, Spinelli JJ, Spurdle AB, Stone J, Stoppa-Lyonnet D, Sutter C, Swerdlow AJ, Tamimi RM, Tan YY, Tapper WJ, Taylor JA, Teixeira MR, Tengström M, Teo SH, Terry MB, Teulé A, Thomassen M, Thull DL, Tischkowitz M, Toland AE, Tollenaar RAEM, Tomlinson I, Torres D, Torres-Mejía G, Troester MA, Truong T, Tung N, Tzardi M, Ulmer HU, Vachon CM, van Asperen CJ, van der Kolk LE, van Rensburg EJ, Vega A, Viel A, Vijai J, Vogel MJ, Wang Q, Wappenschmidt B, Weinberg CR, Weitzel JN, Wendt C, Wildiers H, Winqvist R, Wolk A, Wu AH, Yannoukakos D, Zhang Y, Zheng W, Hunter D, Pharoah PDP, Chang-Claude J, García-Closas M, Schmidt MK, Milne RL, Kristensen VN, French JD, Edwards SL, Antoniou AC, Chenevix-Trench G, Simard J, Easton DF, Kraft P, Dunning AM. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. *Nat Genet.* 2020 Jan;52(1):56-73.

264. Escala-Garcia M, Abraham J, Andrulis IL, Anton-Culver H, Arndt V, Ashworth A, Auer PL, Auvinen P, Beckmann MW, Beesley J, Behrens S, Benitez J, Bermisheva M, Blomqvist C, Blot W, Bogdanova NV, Bojesen SE, Bolla MK, Børresen-Dale AL, Brauch H, Brenner H, Brucker SY, Burwinkel B, Caldas C,

Canzian F, Chang-Claude J, Chanock SJ, Chin SF, Clarke CL, Couch FJ, Cox A, Cross SS, Czene K, Daly MB, Dennis J, Devilee P, Dunn JA, Dunning AM, Dwek M, Earl HM, Eccles DM, Eliassen AH, Ellberg C, Evans DG, Fasching PA, Figueroa J, Flyger H, Gago-Dominguez M, Gapstur SM, García-Closas M, García-Sáenz JA, Gaudet MM, George A, Giles GG, Goldgar DE, González-Neira A, Grip M, Guénel P, Guo Q, Haiman CA, Håkansson N, Hamann U, Harrington PA, Hiller L, Hoening MJ, Hopper JL, Howell A, Huang CS, Huang G, Hunter DJ, Jakubowska A, John EM, Kaaks R, Kapoor PM, Keeman R, Kitahara CM, Koppert LB, Kraft P, Kristensen VN, Lambrechts D, Le Marchand L, Lejbkowitz F, Lindblom A, Lubiński J, Mannermaa A, Manoochehri M, Manoukian S, Margolin S, Martinez ME, Maurer T, **Mavroudis D**, Meindl A, Milne RL, Mulligan AM, Neuhausen SL, Nevanlinna H, Newman WG, Olshan AF, Olson JE, Olsson H, Orr N, Peterlongo P, Petridis C, Prentice RL, Presneau N, Punie K, Ramachandran D, Rennert G, Romero A, Sachchithanathan M, Saloustros E, Sawyer EJ, Schmutzler RK, Schwentner L, Scott C, Simard J, Sohn C, Southey MC, Swerdlow AJ, Tamimi RM, Tapper WJ, Teixeira MR, Terry MB, Thorne H, Tollenaar RAEM, Tomlinson I, Troester MA, Truong T, Turnbull C, Vachon CM, van der Kolk LE, Wang Q, Winqvist R, Wolk A, Yang XR, Ziogas A, Pharoah PDP, Hall P, Wessels LFA, Chenevix-Trench G, Bader GD, Dörk T, Easton DF, Canisius S, Schmidt MK. A network analysis to identify mediators of germline-driven differences in breast cancer prognosis. *Nat Commun.* 2020 Jan 16;11(1):312.

265. Ioannidis G, Papadaki C, Lagoudaki E, Tzardi M, Trypaki M, Stathopoulos E, **Mavroudis D**, Georgoulas V, Souglakos J. Messenger-RNA Expression of Five Gemcitabine Sensitivity-related Genes Predicting Outcome in Advanced-stage Non-small Cell Lung Cancer. *Anticancer Res.* 2020 Feb;40(2):901- 913.
266. Apostolou P, Fostira F, Kouroussis C, Kalfakakou D, Delimitsou A, Agelaki S, Androulakis N, Christodoulou C, Kalbakis K, Kalykaki A, Sanidas E, Papadimitriou C, Vamvakas L, Georgoulas V, **Mavroudis D**, Yannoukakos D, Konstantopoulou I, Saloustros E. BRCA1 & BRCA2 germline testing in Cretan isolates reveals novel and strong founder effects. *Int J Cancer.* 2020 Feb 5.
267. Papadaki MA, Koutsopoulos AV, Tsoulfas PG, Lagoudaki E, Aggouraki D, Monastirioti A, Koutoulaki C, Apostolopoulou CA, Merodoulaki AC, Papadaki

C, **Mavroudis D**, Agelaki S. Clinical Relevance of Immune Checkpoints on Circulating Tumor Cells in Breast Cancer. *Cancers (Basel)*. 2020 Feb 6;12(2).

268. **Mavroudis D**, Saloustros E, Malamos N, Kakolyris S, Boukovinas I, Papakotoulas P, Kentepozidis N, Ziras N, Georgoulas V; Breast Cancer Investigators of the Hellenic Oncology Research Group (HORG), Athens, Greece. Corrigendum to Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG): *Annals of Oncology*, Volume 26, Issue 7, July 2015, Pages 1333-1340. *Ann Oncol*. 2020 Mar;31(3):444-445
269. Feng H, Gusev A, Pasaniuc B, Wu L, Long J, Abu-Full Z, Aittomäki K, Andrulis IL, Anton-Culver H, Antoniou AC, Arason A, Arndt V, Aronson KJ, Arun BK, Asseryanis E, Auer PL, Azzollini J, Balmaña J, Barkardottir RB, Barnes DR, Barrowdale D, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Białkowska K, Blanco A, Blomqvist C, Boeckx B, Bogdanova NV, Bojesen SE, Bolla MK, Bonanni B, Borg A, Brauch H, Brenner H, Briceno I, Broeks A, Brüning T, Burwinkel B, Cai Q, Caldés T, Caligo MA, Campbell I, Canisius S, Campa D, Carter BD, Carter J, Castela JE, Chang-Claude J, Chanock SJ, Christiansen H, Chung WK, Claes KBM, Clarke CL; GEMO Study Collaborators; EMBRACE Collaborators; GC-HBOC study Collaborators, Couch FJ, Cox A, Cross SS, Cybulski C, Czene K, Daly MB, de la Hoya M, De Leeneer K, Dennis J, Devilee P, Diez O, Domchek SM, Dörk T, Dos-Santos-Silva I, Dunning AM, Dwek M, Eccles DM, Ejlersen B, Ellberg C, Engel C, Eriksson M, Fasching PA, Fletcher O, Flyger H, Fostira F, Friedman E, Fritschi L, Frost D, Gabrielson M, Ganz PA, Gapstur SM, Garber J, García-Closas M, García-Sáenz JA, Gaudet MM, Giles GG, Glendon G, Godwin AK, Goldberg MS, Goldgar DE, González-Neira A, Greene MH, Gronwald J, Guénel P, Haiman CA, Hall P, Hamann U, Hake C, He W, Heyworth J, Hogervorst FBL, Hollestelle A, Hooning MJ, Hoover RN, Hopper JL, Huang G, Hulick PJ, Humphreys K, Imyanitov EN; ABCTB Investigators; HEBON Investigators; BCFR Investigators; OCGN Investigators, Isaacs C, Jakimovska M, Jakubowska A, James P, Janavicius R, Jankowitz RC, John EM, Johnson N, Joseph V, Jung A, Karlan BY, Khusnutdinova E, Kiiski JI, Konstantopoulou I, Kristensen VN, Laitman Y,

Lambrechts D, Lazaro C, Leroux D, Leslie G, Lester J, Lesueur F, Lindor N, Lindström S, Lo WY, Loud JT, Lubiński J, Makalic E, Mannermaa A, Manoochehri M, Manoukian S, Margolin S, Martens JWM, Martinez ME, Matricardi L, Maurer T, **Mavroudis D**, McGuffog L, Meindl A, Menon U, Michailidou K, Kapoor PM, Miller A, Montagna M, Moreno F, Moserle L, Mulligan AM, Muranen TA, Nathanson KL, Neuhausen SL, Nevanlinna H, Nevelsteen I, Nielsen FC, Nikitina-Zake L, Offit K, Olah E, Olopade OI, Olsson H, Osorio A, Papp J, Park-Simon TW, Parsons MT, Pedersen IS, Peixoto A, Peterlongo P, Peto J, Pharoah PDP, Phillips KA, Plaseska-Karanfilska D, Poppe B, Pradhan N, Prajzandanc K, Presneau N, Punie K, Pylkäs K, Radice P, Rantala J, Rashid MU, Rennert G, Risch HA, Robson M, Romero A, Saloustros E, Sandler DP, Santos C, Sawyer EJ, Schmidt MK, Schmidt DF, Schmutzler RK, Schoemaker MJ, Scott RJ, Sharma P, Shu XO, Simard J, Singer CF, Skytte AB, Soucy P, Southey MC, Spinelli JJ, Spurdle AB, Stone J, Swerdlow AJ, Tapper WJ, Taylor JA, Teixeira MR, Terry MB, Teulé A, Thomassen M, Thöne K, Thull DL, Tischkowitz M, Toland AE, Tollenaar RAEM, Torres D, Truong T, Tung N, Vachon CM, van Asperen CJ, van den Ouweland AMW, van Rensburg EJ, Vega A, Viel A, Vieira-Balo P, Wang Q, Wappenschmidt B, Weinberg CR, Weitzel JN, Wendt C, Winqvist R, Yang XR, Yannoukakos D, Ziogas A, Milne RL, Easton DF, Chenevix-Trench G, Zheng W, Kraft P, Jiang X. Transcriptome-wide association study of breast cancer risk by estrogen-receptor status *Genet Epidemiol*. 2020 Jul;44(5):442-468

270. Damilakis E, **Mavroudis D**, Sfakianaki M, Souglakos J. Immunotherapy in Metastatic Colorectal Cancer: Could the Latest Developments Hold the Key to Improving Patient Survival? *Cancers (Basel)*. 2020 Apr 6;12(4):889
271. Papadaki C, Manolakou S, Lagoudaki E, Pontikakis S, Ierodiakonou D, Vogiatzoglou K, Messaritakis I, Trypaki M, Giannikaki L, Sfakianaki M, Kalykaki A, **Mavroudis D**, Tzardi M, Souglakos J. Correlation of PKM2 and CD44 Protein Expression with Poor Prognosis in Platinum-Treated Epithelial Ovarian Cancer: A Retrospective Study. *Cancers (Basel)*. 2020 Apr 6;12(4):889.

272. Messaritakis I, Vogiatzoglou K, Tsantaki K, Ntreti A, Sfakianaki M, Koulouridi A, Tsiaoussis J, **Mavroudis D**, Souglakos J. The Prognostic Value of the Detection of Microbial Translocation in the Blood of Colorectal Cancer Patients *Cancers (Basel)*. 2020 Apr 24;12(4):1058.

273. Papadaki C, Monastirioti A, Rounis K, Makrakis D, Kalbakis K, Nikolaou C, **Mavroudis D**, Agelaki S. Circulating MicroRNAs Regulating DNA Damage Response and Responsiveness to Cisplatin in the Prognosis of Patients with Non-Small Cell Lung Cancer Treated with First-Line Platinum Chemotherapy. *Cancers (Basel)*. 2020 May 19;12(5):1282.
274. Messaritakis I, Koulouridi A, Sfakianaki M, Vogiatzoglou K, Gouvas N, Athanasakis E, Tsiaoussis J, Xynos E, **Mavroudis D**, Tzardi M, Souglakos J. The Role of Vitamin D Receptor Gene Polymorphisms in Colorectal Cancer Risk. *Cancers (Basel)*. 2020 May 27;12(6):1379.281.
275. Papadaki MA, Sotiriou AI, Vasilopoulou C, Filika M, Aggouraki D, Tsoulfas PG, Apostolopoulou CA, Rounis K, **Mavroudis D**, Agelaki S. Optimization of the Enrichment of Circulating Tumor Cells for Downstream Phenotypic Analysis in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-1 Immunotherapy. *Cancers (Basel)*. 2020 Jun 12;12(6):1556.
276. Liu J, Prager-van der Smitten WJC, Collée JM, Bolla MK, Wang Q, Michailidou K, Dennis J, Ahearn TU, Aittomäki K, Ambrosone CB, Andrulis IL, Anton-Culver H, Antonenkova NN, Arndt V, Arnold N, Aronson KJ, Augustinsson A, Auvinen P, Becher H, Beckmann MW, Behrens S, Bermisheva M, Bernstein L, Bogdanova NV, Bogdanova-Markov N, Bojesen SE, Brauch H, Brenner H, Briceno I, Brucker SY, Brüning T, Burwinkel B, Cai Q, Cai H, Campa D, Canzian F, Castela JE, Chang-Claude J, Chanock SJ, Choi JY, Christiaens M, Clarke CL; NBCS Collaborators, Couch FJ, Czene K, Daly MB, Devilee P, Dos-Santos-Silva I, Dwek M, Eccles DM, Eliassen AH, Fasching PA, Figueroa J, Flyger H, Fritschi L, Gago-Dominguez M, Gapstur SM, García-Closas M, García-Sáenz JA, Gaudet MM, Giles GG, Goldberg MS, Goldgar DE, Guénel P, Haiman CA, Håkansson N, Hall P,

Harrington PA, Hart SN, Hartman M, Hillemanns P, Hopper JL, Hou MF, Hunter DJ, Huo D; ABCTB Investigators, Ito H, Iwasaki M, Jakimovska M, Jakubowska A, John EM, Kaaks R, Kang D, Keeman R, Khusnutdinova E, Kim SW, Kraft P, Kristensen VN, Kurian AW, Le Marchand L, Li J, Lindblom A, Lophatananon A, Luben RN, Lubiński J, Mannermaa A, Manoochehri M, Manoukian S, Margolin S, Mariapun S, Matsuo K, Maurer T, **Mavroudis D**, Meindl A, Menon U, Milne RL, Muir K, Mulligan AM, Neuhausen SL, Nevanlinna H, Offit K, Olopade OI, Olson JE, Olsson H, Orr N, Park SK, Peterlongo P, Peto J, Plaseska-Karanfilska D, Presneau N, Rack B, Rau-Murthy R, Rennert G, Rennert HS, Rhenius V, Romero A, Ruebner M, Saloustros E, Schmutzler RK, Schneeweiss A, Scott C, Shah M, Shen CY, Shu XO, Simard J, Sohn C, Southey MC, Spinelli JJ, Tamimi RM, Tapper WJ, Teo SH, Terry MB, Torres D, Truong T, Untch M, Vachon CM, van Asperen CJ, Wolk A, Yamaji T, Zheng W, Ziogas A, Ziv E, Torres-Mejía G, Dörk T, Swerdlow AJ, Hamann U, Schmidt MK, Dunning AM, Pharoah PDP, Easton DF, Hoening MJ, Martens JWM, Hollestelle A. Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. *Sci Rep*. 2020 Jun 16;10(1):9688.

277. Sfakianaki M, Papadaki C, Tzardi M, Trypaki M, Manolakou S, Messaritakis I, Saridaki Z, Athanasakis E, **Mavroudis D**, Tsiaoussis J, Gouvas N, Souglakos J. PKM2 Expression as Biomarker for Resistance to Oxaliplatin-Based Chemotherapy in Colorectal Cancer. *Cancers (Basel)*. 2020 Jul 25;12(8):2058.
278. Rojo F, Corassa M, **Mavroudis D**, Öz AB, Biesma B, Brcic L, Pauwels P, Sailer V, Gosney J, Miljkovic D, Hader C, Wu M, Almarez T, Penault-Llorca F. International real-world study of DLL3 expression in patients with small cell lung cancer. *Lung Cancer*. 2020 Sep;147:237-243.

279. Magbanua MJM, Hendrix LH, Hyslop T, Barry WT, Winer EP, Hudis C, Toppmeyer D, Carey LA, Partridge AH, Pierga JY, Fehm T, Vidal-Martínez J, **Mavroudis D**, Garcia-Saenz JA, Stebbing J, Gazzaniga P, Manso L, Zamarchi R, Antelo ML, De Mattos-Arruda L, Generali D, Caldas C, Munzone E, Dirix L, Delson AL, Burstein H, Qadir M, Ma C, Scott JH, Bidard FC, Park JW, Rugo HS. Serial analysis of circulating tumor cells in metastatic breast cancer receiving first-line chemotherapy. *J Natl Cancer Inst.* 2020 Aug 8:djaa113.
280. Messaritakis I, Sfakianaki M, Vogiatzoglou K, Koulouridi A, Koutoulaki C, **Mavroudis D**, Tzardi M, Gouvas N, Tsiaoussis J, Souglakos J. Evaluation of the Role of Circulating Tumor Cells and Microsatellite Instability Status in Predicting Outcome of Advanced CRC Patients. *J Pers Med.* 2020 Nov 18;10(4):235.
281. Matthaïou N, Galanakis N, Kehagias E, Kontopodis N, Charalambous S, Kholcheva N, Tsetis K, **Mavroudis D**, Tsetis D. Endovascular Treatment of Malignant Superior Vena Cava Syndrome through Upper-Limb Access: A Comparison between Venous-Dedicated and Conventional Stents. *J Vasc Interv Radiol.* 2020 Dec;31(12):2066-2072.
282. Skribek M, Rounis K, Makrakis D, Agelaki S, **Mavroudis D**, De Petris L, Ekman S, Tsakonas G. Outcome of Patients with NSCLC and Brain Metastases Treated with Immune Checkpoint Inhibitors in a 'Real-Life' Setting. *Cancers (Basel).* 2020 Dec 10;12(12):3707
283. Polioudaki H, Mala A, Gkimprixi E, Papadaki MA, Chantziou A, Tzardi M, **Mavroudis D**, Agelaki S, Theodoropoulos PA. Epithelial/Mesenchymal Characteristics and PD-L1 Co-Expression in CTCs of Metastatic Breast Cancer Patients Treated with Eribulin: Correlation with Clinical Outcome. *Cancers (Basel).* 2020 Dec 11;12(12):3735

284. Michaelidou K, Koutoulaki C, Mavridis K, Vorrias E, Papadaki MA, Koutsopoulos AV, **Mavroudis D**, Agelaki S. Detection of KRAS G12/G13 Mutations in Cell Free-DNA by Droplet Digital PCR, Offers Prognostic Information for Patients with Advanced Non-Small Cell Lung Cancer. *Cells*. 2020 Nov 20;9(11):2514.
285. Papadaki MA, Sotiriou AI, Vasilopoulou C, Filika M, Aggouraki D, Tsoulfas PG, Apostolopoulou CA, Rounis K, **Mavroudis D**, Agelaki S. Optimization of the Enrichment of Circulating Tumor Cells for Downstream Phenotypic Analysis in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-1 Immunotherapy. *Cancers (Basel)*. 2020 Jun 12;12(6):1556.
289. Kramer I, Hoening MJ, Mavaddat N, Hauptmann M, Keeman R, Steyerberg EW, Giardiello D, Antoniou AC, Pharoah PDP, Canisius S, Abu-Ful Z, Andrulis IL, Anton-Culver H, Aronson KJ, Augustinsson A, Becher H, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Bogdanova NV, Bojesen SE, Bolla MK, Bonanni B, Brauch H, Bremer M, Brucker SY, Burwinkel B, Castela JE, Chan TL, Chang-Claude J, Chanock SJ, Chenevix-Trench G, Choi JY, Clarke CL; NBCS Collaborators, Collée JM, Couch FJ, Cox A, Cross SS, Czene K, Daly MB, Devilee P, Dörk T, Dos-Santos-Silva I, Dunning AM, Dwek M, Eccles DM, Evans DG, Fasching PA, Flyger H, Gago-Dominguez M, García-Closas M, García-Sáenz JA, Giles GG, Goldgar DE, González-Neira A, Haiman CA, Håkansson N, Hamann U, Hartman M, Heemskerk-Gerritsen BAM, Hollestelle A, Hopper JL, Hou MF, Howell A; ABCTB Investigators; kConFab Investigators, Ito H, Jakimovska M, Jakubowska A, Janni W, John EM, Jung A, Kang D, Kets CM, Khusnutdinova E, Ko YD, Kristensen VN, Kurian AW, Kwong A, Lambrechts D, Le Marchand L, Li J, Lindblom A, Lubiński J, Mannermaa A, Manooch M, Margolin S, Matsuo K, Mavroudis D, Meindl A, Milne RL, Mulligan AM, Muranen TA, Neuhausen SL, Nevanlinna H, Newman WG, Olshan AF, Olson JE, Olsson H, Park-Simon TW, Peto J, Petridis C, Plaseska-Karanfilska D, Presneau N, Pyrkäs K, Radice P, Rennert G, Romero A, Roylance R, Saloustros E, Sawyer EJ, Schmutzler RK,

Schwentner L, Scott C, See MH, Shah M, Shen CY, Shu XO, Siesling S, Slager S, Sohn C, Southey MC, Spinelli JJ, Stone J, Tapper WJ, Tengström M, Teo SH, Terry MB, Tollenaar RAEM, Tomlinson I, Troester MA, Vachon CM, van Ongeval C, van Veen EM, Winqvist R, Wolk A, Zheng W, Ziogas A, Easton DF, Hall P, Schmidt MK. Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. *Am J Hum Genet.* 2020 Sep 28:S0002-9297(20)30321-9.

290. Papadaki C, Thomopoulou K, Monastirioti A, Koronakis G, Papadaki MA, Rounis K, Vamvakas L, Nikolaou C, **Mavroudis D**, Agelaki S. MicroRNAs Regulating Tumor and Immune Cell Interactions in the Prediction of Relapse in Early Stage Breast Cancer. *Biomedicines.* 2021 Apr 13;9(4):421.
291. Mountzios G, Koumarianou A, Bokas A, **Mavroudis D**, Samantas E, Fergadis EG, Linardou H, Katsaounis P, Athanasiadis E, Karamouzis MV, Pentheroudakis G, Lampaki S, Froudarakis ME, Perdikouri EA, Somarakis A, Papageorgiou F, Paparepa Z, Nikolaou A, Syrigos KN. A Real-World, Observational, Prospective Study to Assess the Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations upon Progression on or after First-Line Therapy with a First- or Second-Generation EGFR Tyrosine Kinase Inhibitor in EGFR Mutation-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer: The 'LUNGFUL' Study. *Cancers (Basel).* 2021 Jun 25;13(13):3172.
292. Monastirioti A, Papadaki C, Rounis K, Kalapanida D, **Mavroudis D**, Agelaki S. A Prognostic Role for Circulating microRNAs Involved in Macrophage Polarization in Advanced Non-Small Cell Lung Cancer. *Cells.* 2021 Aug 5;10(8):1988.

293. Escala-Garcia M, Canisius S, Keeman R, Beesley J, Anton-Culver H, Arndt V, Augustinsson A, Becher H, Beckmann MW, Behrens S, Bermisheva M, Bojesen SE, Bolla MK, Brenner H, Canzian F, Castelao JE, Chang-Claude J, Chanock SJ, Couch FJ, Czene K, Daly MB, Dennis J, Devilee P, Dörk T, Dunning AM, Easton DF, Ekici AB, Eliassen AH, Fasching PA, Flyger H, Gago-Dominguez M, García-Closas M, García-Sáenz JA, Geisler J, Giles GG, Grip M, Gündert M, Hahnen E, Haiman CA, Håkansson N, Hall P, Hamann U, Hartikainen JM, Heemskerk-Gerritsen BAM, Hollestelle A, Hoppe R, Hopper JL, Hunter DJ, Jacot W, Jakubowska A, John EM, Jung AY, Kaaks R, Khusnutdinova E, Koppert LB, Kraft P, Kristensen VN, Kurian AW, Lambrechts D, Le Marchand L, Lindblom A, Luben RN, Lubiński J, Mannermaa A, Manoochehri M, Margolin S, **Mavroudis D**, Muranen TA, Nevanlinna H, Olshan AF, Olsson H, Park-Simon TW, Patel AV, Peterlongo P, Pharoah PDP, Punie K, Radice P, Rennert G, Rennert HS, Romero A, Roylance R, Rüdiger T, Ruebner M, Saloustros E, Sawyer EJ, Schmutzler RK, Schoemaker MJ, Scott C, Southey MC, Surowy H, Swerdlow AJ, Tamimi RM, Teras LR, Thomas E, Tomlinson I, Troester MA, Vachon CM, Wang Q, Winqvist R, Wolk A, Ziogas A; kConFab/AOCS Investigators, Michailidou K, Chenevix-Trench G, Bachelot T, Schmidt MK. Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis. *Sci Rep.* 2021 Oct 5;11(1):19787.
294. Morra A, Jung AY, Behrens S, Keeman R, Ahearn TU, Anton-Culver H, Arndt V, Augustinsson A, Auvinen PK, Beane Freeman LE, Becher H, Beckmann MW, Blomqvist C, Bojesen SE, Bolla MK, Brenner H, Briceno I, Brucker SY, Camp NJ, Campa D, Canzian F, Castelao JE, Chanock SJ, Choi JY, Clarke CL, Couch FJ, Cox A, Cross SS, Czene K, Dörk T, Dunning AM, Dwek M, Easton DF, Eccles DM, Egan KM, Evans DG, Fasching PA, Flyger H, Gago-Dominguez M, Gapstur SM, García-Sáenz JA, Gaudet MM, Giles GG, Grip M, Guénel P, Haiman CA, Håkansson N, Hall P, Hamann U, Han SN, Hart SN, Hartman M, Heyworth JS, Hoppe R, Hopper JL, Hunter DJ, Ito H, Jager A, Jakimovska M, Jakubowska A, Janni W, Kaaks R, Kang D, Kapoor PM, Kitahara CM, Koutros S, Kraft P, Kristensen VN, Lacey JV, Lambrechts D, Le Marchand L, Li J, Lindblom

A, Lubiński J, Lush M, Mannermaa A, Manoochehri M, Margolin S, Mariapun S, Matsuo K, **Mavroudis D**, Milne RL, Muranen TA, Newman WG, Noh DY, Nordestgaard BG, Obi N, Olshan AF, Olsson H, Park-Simon TW, Petridis C, Pharoah PDP, Plaseska-Karanfilska D, Presneau N, Rashid MU, Rennert G, Rennert HS, Rhenius V, Romero A, Saloustros E, Sawyer EJ, Schneeweiss A, Schwentner L, Scott C, Shah M, Shen CY, Shu XO, Southey MC, Stram DO, Tamimi RM, Tapper W, Tollenaar RAEM, Tomlinson I, Torres D, Troester MA, Truong T, Vachon CM, Wang Q, Wang SS, Williams JA, Winqvist R, Wolk A, Wu AH, Yoo KY, Yu JC, Zheng W, Ziogas A, Yang XR, Eliassen AH, Holmes MD, García-Closas M, Teo SH, Schmidt MK, Chang-Claude J; ABCTB Investigators; NBCS Collaborators. Breast Cancer Risk Factors and Survival by Tumor Subtype: Pooled Analyses from the Breast Cancer Association Consortium. *Cancer Epidemiol Biomarkers Prev.* 2021 Apr;30(4):623-642.

295. Rounis K, Makrakis D, Tsigkas AP, Georgiou A, Galanakis N, Papadaki C, Monastirioti A, Vamvakas L, Kalbakis K, Vardakis N, Kontogianni M, Gioulbasanis I, **Mavroudis D**, Agelaki S. Cancer cachexia syndrome and clinical outcome in patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: results from a prospective, observational study. *Transl Lung Cancer Res.* 2021 Aug;10(8):3538-3549.

296. Rounis K, Makrakis D, Papadaki C, Monastirioti A, Vamvakas L, Kalbakis K, Gourelia K, Xanthopoulos I, Tsamardinos I, **Mavroudis D**, Agelaki S. Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution study. *PLoS One.* 2021 Jun 1;16(6):e0252537.

297. Baxter JS, Johnson N, Tomczyk K, Gillespie A, Maguire S, Brough R, Fachal L, Michailidou K, Bolla MK, Wang Q, Dennis J, Ahearn TU, Andrulis IL, Anton-Culver H, Antonenkova NN, Arndt V, Aronson KJ, Augustinsson A, Becher H, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Bogdanova NV, Bojesen SE, Brenner H, Brucker SY, Cai Q, Campa D, Canzian F, Castelao JE, Chan TL, Chang-Claude J, Chanock SJ, Chenevix-Trench G, Choi JY, Clarke CL; NBCS Collaborators, Colonna S, Conroy DM, Couch FJ, Cox A, Cross SS, Czene K, Daly MB, Devilee P, Dörk T, Dossus L, Dwek M, Eccles DM, Ekici AB, Eliassen AH, Engel C, Fasching PA, Figueroa J, Flyger H, Gago-Dominguez M, Gao C, García-Closas M, García-Sáenz JA, Ghoussaini M, Giles GG, Goldberg MS, González-Neira A, Guénel P, Gündert M, Haeberle L, Hahnen E, Haiman CA, Hall P, Hamann U, Hartman M, Hatse S, Hauke J, Hollestelle A, Hoppe R, Hopper JL, Hou MF; kConFab Investigators; ABCTB Investigators, Ito H, Iwasaki M, Jager A, Jakubowska A, Janni W, John EM, Joseph V, Jung A, Kaaks R, Kang D, Keeman R, Khusnutdinova E, Kim SW, Kosma VM, Kraft P, Kristensen VN, Kubelka-Sabit K, Kurian AW, Kwong A, Lacey JV, Lambrechts D, Larson NL, Larsson SC, Le Marchand L, Lejbkiewicz F, Li J, Long J, Lophatananon A, Lubiński J, Mannermaa A, Manoochehri M, Manoukian S, Margolin S, Matsuo K, **Mavroudis D**, Mayes R, Menon U, Milne RL, Mohd Taib NA, Muir K, Muranen TA, Murphy RA, Nevanlinna H, O'Brien KM, Offit K, Olson JE, Olsson H, Park SK, Park-Simon TW, Patel AV, Peterlongo P, Peto J, Plaseska-Karanfilska D, Presneau N, Pylkäs K, Rack B, Rennert G, Romero A, Ruebner M, Rüdiger T, Saloustros E, Sandler DP, Sawyer EJ, Schmidt MK, Schmutzler RK, Schneeweiss A, Schoemaker MJ, Shah M, Shen CY, Shu XO, Simard J, Southey MC, Stone J, Surowy H, Swerdlow AJ, Tamimi RM, Tapper WJ, Taylor JA, Teo SH, Teras LR, Terry MB, Toland AE, Tomlinson I, Truong T, Tseng CC, Untch M, Vachon CM, van den Ouweland AMW, Wang SS, Weinberg CR, Wendt C, Winham SJ, Winqvist R, Wolk A, Wu AH, Yamaji T, Zheng W, Ziogas A, Pharoah PDP, Dunning AM, Easton DF, Pettitt SJ, Lord CJ, Haider S, Orr N, Fletcher O. Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element. *Am J Hum Genet.* 2021 Jul 1;108(7):1190-1203.

298. Strati A, Zavridou M, Kallergi G, Politaki E, Kuske A, Gorges TM, Riethdorf S, Joosse SA, Koch C, Bohnen AL, Mueller V, Koutsodontis G, Kontopodis E, Poulakaki N, Psyrri A, **Mavroudis D**, Georgoulas V, Pantel K, Lianidou ES. A Comprehensive Molecular Analysis of in Vivo Isolated EpCAM-Positive Circulating Tumor Cells in Breast Cancer. *Clin Chem*. 2021 Oct 1;67(10):1395-1405.
299. Koulouridi A, Messaritakis I, Theodorakis E, Chondrozoumaki M, Sfakianaki M, Gouvas N, Tsiaoussis J, **Mavroudis D**, Tzardi M, Souglakos J. Detection of Circulating Tumor Cells and Microbial DNA Fragments in Stage III Colorectal Cancer Patients under Three versus Six Months of Adjuvant Treatment. *Cancers (Basel)*. 2021 Jul 15;13(14):3552.
300. Thomopoulou K, Papadaki C, Monastiriotti A, Koronakis G, Mala A, Kalapanida D, **Mavroudis D**, Agelaki S. MicroRNAs Regulating Tumor Immune Response in the Prediction of the Outcome in Patients With Breast Cancer. *Front Mol Biosci*. 2021 Jun 9;8:668534.
301. Morra A, Escala-Garcia M, Beesley J, Keeman R, Canisius S, Ahearn TU, Andrulis IL, Anton-Culver H, Arndt V, Auer PL, Augustinsson A, Beane Freeman LE, Becher H, Beckmann MW, Behrens S, Bojesen SE, Bolla MK, Brenner H, Brüning T, Buys SS, Caan B, Campa D, Canzian F, Castela JE, Chang-Claude J, Chanock SJ, Cheng TD, Clarke CL; NBCS Collaborators, Colonna SV, Couch FJ, Cox A, Cross SS, Czene K, Daly MB, Dennis J, Dörk T, Dossus L, Dunning AM, Dwek M, Eccles DM, Ekici AB, Eliassen AH, Eriksson M, Evans DG, Fasching PA, Flyger H, Fritschi L, Gago-Dominguez M, García-Sáenz JA, Giles GG, Grip M, Guénel P, Gündert M, Hahnen E, Haiman CA, Håkansson N, Hall P, Hamann U, Hart SN, Hartikainen JM, Hartmann A, He W, Hoening MJ, Hoppe R, Hopper JL, Howell A, Hunter DJ; ABCTB Investigators; kConFab Investigators, Jager A, Jakubowska A, Janni W, John EM, Jung AY,

Kaaks R, Keupers M, Kitahara CM, Koutros S, Kraft P, Kristensen VN, Kurian AW, Lacey JV, Lambrechts D, Le Marchand L, Lindblom A, Linet M, Luben RN, Lubiński J, Lush M, Mannermaa A, Manoochehri M, Margolin S, Martens JWM, Martinez ME, **Mavroudis D**, Michailidou K, Milne RL, Mulligan AM, Muranen TA, Nevanlinna H, Newman WG, Nielsen SF, Nordestgaard BG, Olshan AF, Olsson H, Orr N, Park-Simon TW, Patel AV, Peissel B, Peterlongo P, Plaseska-Karanfilska D, Prajzandanc K, Prentice R, Presneau N, Rack B, Rennert G, Rennert HS, Rhenius V, Romero A, Roylance R, Ruebner M, Saloustros E, Sawyer EJ, Schmutzler RK, Schneeweiss A, Scott C, Shah M, Smichkoska S, Southey MC, Stone J, Surowy H, Swerdlow AJ, Tamimi RM, Tapper WJ, Teras LR, Terry MB, Tollenaar RAEM, Tomlinson I, Troester MA, Truong T, Vachon CM, Wang Q, Hurson AN, Winqvist R, Wolk A, Ziogas A, Brauch H, García-Closas M, Pharoah PDP, Easton DF, Chenevix-Trench G, Schmidt MK. Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. *Breast Cancer Res.* 2021 Aug 18;23(1):86.

302. Johnson N, Maguire S, Morra A, Kapoor PM, Tomczyk K, Jones ME, Schoemaker MJ, Gilham C, Bolla MK, Wang Q, Dennis J, Ahearn TU, Andrulis IL, Anton-Culver H, Antonenkova NN, Arndt V, Aronson KJ, Augustinsson A, Baynes C, Freeman LEB, Beckmann MW, Benitez J, Bermisheva M, Blomqvist C, Boeckx B, Bogdanova NV, Bojesen SE, Brauch H, Brenner H, Burwinkel B, Campa D, Canzian F, Castela JE, Chanock SJ, Chenevix-Trench G, Clarke CL; NBCS Collaborators, Conroy DM, Couch FJ, Cox A, Cross SS, Czene K, Dörk T, Eliassen AH, Engel C, Evans DG, Fasching PA, Figueroa J, Floris G, Flyger H, Gago-Dominguez M, Gapstur SM, García-Closas M, Gaudet MM, Giles GG, Goldberg MS, González-Neira A; AOCS Group, Guénel P, Hahnen E, Haiman CA, Håkansson N, Hall P, Hamann U, Harrington PA, Hart SN, Hoening MJ,

Hopper JL, Howell A, Hunter DJ; ABCTB Investigators; kConFab Investigators, Jager A, Jakubowska A, John EM, Kaaks R, Keeman R, Khusnutdinova E, Kitahara CM, Kosma VM, Koutros S, Kraft P, Kristensen VN, Kurian AW, Lambrechts D, Le Marchand L, Linet M, Lubiński J, Mannermaa A, Manoukian S, Margolin S, Martens JWM, **Mavroudis D**, Mayes R, Meindl A, Milne RL, Neuhausen SL, Nevanlinna H, Newman WG, Nielsen SF, Nordestgaard BG, Obi N, Olshan AF, Olson JE, Olsson H, Orban E, Park-Simon TW, Peterlongo P, Plaseska-Karanfilska D, Pylkäs K, Rennert G, Rennert HS, Ruddy KJ, Saloustros E, Sandler DP, Sawyer EJ, Schmutzler RK, Scott C, Shu XO, Simard J, Smichkoska S, Sohn C, Southey MC, Spinelli JJ, Stone J, Tamimi RM, Taylor JA, Tollenaar RAEM, Tomlinson I, Troester MA, Truong T, Vachon CM, van Veen EM, Wang SS, Weinberg CR, Wendt C, Wildiers H, Winqvist R, Wolk A, Zheng W, Ziogas A, Dunning AM, Pharoah PDP, Easton DF, Howie AF, Peto J, Dos-Santos-Silva I, Swerdlow AJ, Chang-Claude J, Schmidt MK, Orr N, Fletcher O. CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers. *Br J Cancer*. 2021 Feb;124(4):842-854.

303. Grigoriou M, Banos A, Hatzioannou A, Kloetgen A, Kouzis P, Aggouraki D, Zakopoulou R, Bamias G, Kassi E, **Mavroudis D**, Bamias A, Boumpas DT, Tsirigos A, Gogas H, Alissafi T, Verginis P. Regulatory T-cell Transcriptomic Reprogramming Characterizes Adverse Events by Checkpoint Inhibitors in Solid Tumors. *Cancer Immunol Res*. 2021 Jul;9(7):726-734.
304. Chantziou A, Theodorakis K, Polioudaki H, de Bree E, Kampa M, **Mavroudis D**, Castanas E, Theodoropoulos P. AGlycosylation Modulates Plasma Membrane Trafficking of CD24 in Breast Cancer Cells. *Int J Mol Sci*. 2021 Jul 29;22(15):8165.
305. Park HA, Neumeyer S, Michailidou K, Bolla MK, Wang Q, Dennis J, Ahearn TU, Andrulis IL, Anton-Culver H, Antonenkova NN, Arndt V, Aronson KJ, Augustinsson A, Baten A, Beane Freeman LE, Becher H, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Bogdanova NV, Bojesen SE, Brauch H, Brenner H, Brucker SY, Burwinkel B, Campa D, Canzian F, Castela JE, Chanock SJ, Chenevix-Trench G, Clarke CL; NBCS Collaborators, Conroy DM, Couch FJ, Cox A, Cross SS, Czene K, Daly MB, Devilee P, Dörk T, Dos-Santos-Silva I, Dwek M, Eccles DM, Eliassen AH, Engel C, Eriksson M, Evans DG,

Fasching PA, Flyger H, Fritschi L, García-Closas M, García-Sáenz JA, Gaudet MM, Giles GG, Glendon G, Goldberg MS, Goldgar DE, González-Neira A, Grip M, Guénel P, Hahnen E, Haiman CA, Håkansson N, Hall P, Hamann U, Han S, Harkness EF, Hart SN, He W, Heemskerk-Gerritsen BAM, Hopper JL, Hunter DJ; ABCTB Investigators; kConFab Investigators, Jager A, Jakubowska A, John EM, Jung A, Kaaks R, Kapoor PM, Keeman R, Khusnutdinova E, Kitahara CM, Koppert LB, Koutros S, Kristensen VN, Kurian AW, Lacey J, Lambrechts D, Le Marchand L, Lo WY, Lubiński J, Mannermaa A, Manoochehri M, Margolin S, Martinez ME, **Mavroudis D**, Meindl A, Menon U, Milne RL, Muranen TA, Nevanlinna H, Newman WG, Nordestgaard BG, Offit K, Olshan AF, Olsson H, Park-Simon TW, Peterlongo P, Peto J, Plaseska-Karanfilska D, Presneau N, Radice P, Rennert G, Rennert HS, Romero A, Saloustros E, Sawyer EJ, Schmidt MK, Schmutzler RK, Schoemaker MJ, Schwentner L, Scott C, Shah M, Shu XO, Simard J, Smeets A, Southey MC, Spinelli JJ, Stevens V, Swerdlow AJ, Tamimi RM, Tapper WJ, Taylor JA, Terry MB, Tomlinson I, Troester MA, Truong T, Vachon CM, van Veen EM, Vijai J, Wang S, Wendt C, Winqvist R, Wolk A, Ziogas A, Dunning AM, Pharoah PDP, Easton DF, Zheng W, Kraft P, Chang-Claude J. Mendelian randomisation study of smoking exposure in relation to breast cancer risk. *Br J Cancer*. 2021 Aug 2.

306. Koulouris A, Tsagkaris C, Messaritakis I, Gouvas N, Sfakianaki M, Trypaki M, Spyrou V, Christodoulakis M, Athanasakis E, Xynos E, Tzardi M, **Mavroudis D**, Souglakos J. Resectable Colorectal Cancer: Current Perceptions on the Correlation of Recurrence Risk, Microbiota and Detection of Genetic Mutations in Liquid Biopsies. *Cancers (Basel)*. 2021 Jul 14;13(14):3522.
307. Papadaki MA, Messaritakis I, Fiste O, Souglakos J, Politaki E, Kotsakis A, Georgoulas V, **Mavroudis D**, Agelaki S. Assessment of the Efficacy and Clinical Utility of Different Circulating Tumor Cell (CTC) Detection Assays in Patients with Chemotherapy-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC). *Int J Mol Sci*. 2021 Jan 18;22(2):925
308. Magbanua MJM, Hendrix LH, Hyslop T, Barry WT, Winer EP, Hudis C, Toppmeyer D, Carey LA, Partridge AH, Pierga JY, Fehm T, Vidal-Martínez J, **Mavroudis D**, Garcia-Saenz JA, Stebbing J, Gazzaniga P, Manso L, Zamarchi R, Antelo ML, Mattos-Arruda L, Generali D, Caldas C, Munzone E, Dirix L, Delson AL, Burstein HJ, Qadir M, Ma C, Scott JH, Bidard FC, Park JW, Rugo HS. Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy. *J Natl Cancer Inst*. 2021 Apr 6;113(4):443-452.

309. Foukakis T, Matikas A, Oikonomidou O, Andreopoulou E, **Mavroudis D**. Expert Discussion: HER2-Positive Breast Cancer. *Breast Care* (Basel). 2021 Aug;16(4):422-428. doi: 10.1159/000516965. Epub 2021 Jun 17.

310. Breast Cancer Association Consortium, Dorling L, Carvalho S, Allen J, González-Neira A, Luccarini C, Wahlström C, Pooley KA, Parsons MT, Fortuno C, Wang Q, Bolla MK, Dennis J, Keeman R, Alonso MR, Álvarez N, Herreraez B, Fernandez V, Núñez-Torres R, Osorio A, Valcich J, Li M, Törngren T, Harrington PA, Baynes C, Conroy DM, Decker B, Fachal L, Mavaddat N, Ahearn T, Aittomäki K, Antonenkova NN, Arnold N, Arveux P, Ausems MGEM, Auvinen P, Becher H, Beckmann MW, Behrens S, Bermisheva M, Białkowska K, Blomqvist C, Bogdanova NV, Bogdanova-Markov N, Bojesen SE, Bonanni B, Børresen-Dale AL, Brauch H, Bremer M, Briceno I, Brüning T, Burwinkel B, Cameron DA, Camp NJ, Campbell A, Carracedo A, Castela JE, Cessna MH, Chanock SJ, Christiansen H, Collée JM, Cordina-Duverger E, Cornelissen S, Czene K, Dörk T, Ekici AB, Engel C, Eriksson M, Fasching PA, Figueroa J, Flyger H, Försti A, Gabrielson M, Gago-Dominguez M, Georgoulas V, Gil F, Giles GG, Glendon G, Garcia EBG, Alnæs GIG, Guénel P, Hadjisavvas A, Haeberle L, Hahnen E, Hall P, Hamann U, Harkness EF, Hartikainen JM, Hartman M, He W, Heemskerk-Gerritsen BAM, Hillemanns P, Hogervorst FBL, Hollestelle A, Ho WK, Hooning MJ, Howell A, Humphreys K, Idris F, Jakubowska A, Jung A, Kapoor PM, Kerin MJ, Khusnutdinova E, Kim SW, Ko YD, Kosma VM, Kristensen VN, Kyriacou K, Lakeman IMM, Lee JW, Lee MH, Li J, Lindblom A, Lo WY, Loizidou MA, Lophatananon A, Lubiński J, MacInnis RJ, Madsen MJ, Mannermaa A, Manoochehri M, Manoukian S, Margolin S, Martinez ME, Maurer T, **Mavroudis D**, McLean C, Meindl A, Mensenkamp AR, Michailidou K, Miller N, Mohd Taib NA, Muir K, Mulligan AM, Nevanlinna H, Newman WG, Nordestgaard BG, Ng PS, Oosterwijk JC, Park SK, Park-Simon TW, Perez JIA, Peterlongo P, Porteous DJ, Prajzandanc K, Prokofyeva D, Radice P, Rashid MU, Rhenius V, Rookus MA, Rüdiger T, Saloustros E, Sawyer EJ, Schmutzler RK, Schneeweiss A, Schürmann P, Shah M, Sohn C, Southey MC, Surowy H, Suvanto M, Thanassitichai S, Tomlinson I, Torres D, Truong T, Tzardi M, Valova Y, van Asperen CJ, Van Dam RM, van den Ouweland AMW, van der Kolk LE, van Veen EM, Wendt C, Williams JA, Yang XR, Yoon SY, Zamora MP, Evans DG, de la Hoya M, Simard J, Antoniou AC, Borg Å, Andrulis IL, Chang-Claude J, García-Closas M, Chenevix-Trench G, Milne RL, Pharoah PDP, Schmidt MK, Spurdle AB, Vreeswijk MPG, Benitez J, Dunning AM, Kvist A, Teo SH, Devilee P, Easton DF. Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. *N Engl J Med*. 2021 Feb 4;384(5):428-439.

311. Morra A, Mavaddat N, Muranen TA, Ahearn TU, Allen J, Andrulis IL, Auvinen P, Becher H, Behrens S, Blomqvist C, Bojesen SE, Bolla MK, Brauch H, Camp NJ, Carvalho S, Castela J, Cessna MH, Chang-Claude J, Chenevix-Trench G; NBCS Collaborators; Czene K, Decker B, Dennis J, Dörk T, Dorling L, Dunning AM, Ekici AB, Eriksson M, Evans DG, Fasching PA, Figueroa JD, Flyger H, Gago-Dominguez M, García-Closas M, Geurts-Giele WRR, Giles GG, Guénel P, Gündert M, Hahnen E, Hall P, Hamann U, Harrington PA, He W, Heikkilä P, Hoening MJ, Hoppe R, Howell A, Humphreys K; kConFab Investigators; Jakubowska A, Jung AY, Keeman R, Kristensen VN, Lubiński J, Mannermaa A, Manooch M, Manoukian S, Margolin S, **Mavroudis D**, Milne RL, Mulligan AM, Newman WG, Park-Simon TW, Peterlongo P, Pharoah PDP, Rhenius V, Saloustros E, Sawyer EJ, Schmutzler RK, Shah M, Spurdle AB, Tomlinson I, Truong T, van Veen EM, Vreeswijk MPG, Wang Q, Wendt C, Yang XR, Nevanlinna H, Devilee P, Easton DF, Schmidt MK. The impact of coding germline variants on contralateral breast cancer risk and survival *Am J Hum Genet*. 2023 Mar 2;110(3):475-486. doi: 10.1016/j.ajhg.2023.02.003. Epub 2023 Feb 23.
312. Zaggana E, Konstantinou MP, Krasagakis GH, de Bree E, Kalpakis K, **Mavroudis D**, Krasagakis K. Merkel Cell Carcinoma-Update on Diagnosis, Management and Future Perspectives *Cancers (Basel)*. 2022 Dec 23;15(1):103. doi: 10.3390/cancers15010103.
313. de Bree E, Michelakis D, Heretis I, Kontopodis N, Spanakis K, Lagoudaki E, Tolia M, Zografakis-Sfakianakis M, Ioannou C, **Mavroudis D**. Retroperitoneal Soft Tissue Sarcoma: Emerging Therapeutic Strategies *Cancers (Basel)*. 2023 Nov 18;15(22):5469. doi: 10.3390/cancers15225469.
314. Levi H, Carmi S, Rosset S, Yerushalmi R, Zick A, Yablonski-Peretz T; BCAC Consortium; Wang Q, Bolla MK, Dennis J, Michailidou K, Lush M, Ahearn T, Andrulis IL, Anton-Culver H, Antoniou AC, Arndt V, Augustinsson A, Auvinen P, Beane Freeman L, Beckmann M, Behrens S, Bermisheva M, Bodelon C, Bogdanova NV, Bojesen SE, Brenner H, Byers H, Camp N, Castela J, Chang-Claude J, Chirlaque MD, Chung W, Clarke C; NBCS Collaborators; Collee MJ, Colonna S; CTS Consortium; Couch F, Cox A, Cross SS, Czene K, Daly M, Devilee P, Dörk T, Dossus L, Eccles DM, Eliassen AH, Eriksson M, Evans G, Fasching P, Fletcher O, Flyger H, Fritschi L, Gabrielson M, Gago-Dominguez M, García-Closas M, Garcia-Saenz JA, Genkinger J, Giles GG, Goldberg M, Guénel P, Hall P, Hamann U, He W, Hillemanns P, Hollestelle A, Hoppe R,

Hopper J; ABCTB Investigators; Jakovchevska S, Jakubowska A, Jernström H, John E, Johnson N, Jones M, Vijai J, Kaaks R, Khusnutdinova E, Kitahara C, Koutros S, Kristensen V, Kurian AW, Lacey J, Lambrechts D, Le Marchand L, Lejbkowitz F, Lindblom A, Loibl S, Lori A, Lubinski J, Mannermaa A, Manoochehri M, **Mavroudis D**, Menon U, Mulligan A, Murphy R, Nevelsteen I, Newman WG, Obi N, O'Brien K, Evaluation of European-based polygenic risk score for breast cancer in Ashkenazi Jewish women in Israel *J Med Genet.* 2023 Nov 27;60(12):1186-1197. doi: 10.1136/jmg-2023-109185.

315. Figlioli G, Billaud A, Ahearn TU, Antonenkova NN, Becher H, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Blok MJ, Bogdanova NV, Bonanni B, Burwinkel B, Camp NJ, Campbell A, Castelao JE, Cessna MH, Chanock SJ; NBCS Collaborators; Czene K, Devilee P, Dörk T, Engel C, Eriksson M, Fasching PA, Figueroa JD, Gabrielson M, Gago-Dominguez M, García-Closas M, González-Neira A, Grassmann F, Guénel P, Gündert M, Hadjisavvas A, Hahnen E, Hall P, Hamann U, Harrington PA, He W, Hillemanns P, Hollestelle A, Hoening MJ, Hoppe R, Howell A, Humphreys K; KConFab Investigators; Jager A, Jakubowska A, Khusnutdinova EK, Ko YD, Kristensen VN, Lindblom A, Lissowska J, Lubiński J, Mannermaa A, Manoukian S, Margolin S, **Mavroudis D**, Newman WG, Obi N, Panayiotidis MI, Rashid MU, Rhenius V, Rookus MA, Saloustros E, Sawyer EJ, Schmutzler RK, Shah M, Sironen R, Southey MC, Suvanto M, Tollenaar RAEM, Tomlinson I, Truong T, van der Kolk LE, van Veen EM, Wappenschmidt B, Yang XR, Bolla MK, Dennis J, Dunning AM, Easton DF, Lush M, Michailidou K, Pharoah PDP, Wang Q, Adank MA, Schmidt MK, Andrulis IL, Chang-Claude J, Nevanlinna H, Chenevix-Trench G, Evans DG, Milne RL, Radice P, Peterlongo P. FANCM missense variants and breast cancer risk: a case-control association study of 75,156 European women *Eur J Hum Genet.* 2023 May;31(5):578-587. doi: 10.1038/s41431-022-01257-w. Epub 2023 Jan 27

316. Morra A, Schreurs MAC, Andrulis IL, Anton-Culver H, Augustinsson A, Beckmann MW, Behrens S, Bojesen SE, Bolla MK, Brauch H, Broeks A, Buys SS, Camp NJ, Castelao JE, Cessna MH, Chang-Claude J, Chung WK; NBCS Collaborators; Colonna SV, Couch FJ, Cox A, Cross SS, Czene K, Daly MB, Dennis J, Devilee P, Dörk T, Dunning AM, Dwek M, Easton DF, Eccles DM, Eriksson M, Evans DG, Fasching PA, Fehm TN, Figueroa JD, Flyger H, Gabrielson M, Gago-Dominguez M, García-Closas M, García-Sáenz JA, Genkinger J, Grassmann F, Gündert M, Hahnen E, Haiman CA, Hamann U, Harrington PA, Hartikainen JM, Hoppe R, Hopper JL, Houlston RS, Howell A; ABCTB Investigators; kConFab Investigators; Jakubowska A, Janni W, Jernström H, John EM, Johnson N, Jones ME, Kristensen VN, Kurian AW,

Lambrechts D, Le Marchand L, Lindblom A, Lubiński J, Lux MP, Mannermaa A, **Mavroudis D**, Mulligan AM, Muranen TA, Nevanlinna H, Nevelsteen I, Neven P, Newman WG, Obi N, Offit K, Olshan AF, Park-Simon TW, Patel AV, Peterlongo P, Phillips KA, Plaseska-Karanfilska D, Polley EC, Presneau N, Pylkäs K, Rack B, Radice P, Rashid MU, Rhenius V, Robson M, Romero A, Saloustros E, Sawyer EJ, Schmutzler RK, Schuetze S, Scott C, Shah M, Smichk... Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival *Cancer Med.* 2023 Aug;12(15):16142-16162. doi: 10.1002/cam4.6272. Epub 2023 Jul 3.

317. Dorling L, Carvalho S, Allen J, Parsons MT, Fortuno C, González-Neira A, Heijl SM, Adank MA, Ahearn TU, Andrulis IL, Auvinen P, Becher H, Beckmann MW, Behrens S, Bermisheva M, Bogdanova NV, Bojesen SE, Bolla MK, Bremer M, Briceno I, Camp NJ, Campbell A, Castela J, Chang-Claude J, Chanock SJ, Chenevix-Trench G; NBCS Collaborators; Collée JM, Czene K, Dennis J, Dörk T, Eriksson M, Evans DG, Fasching PA, Figueroa J, Flyger H, Gabrielson M, Gago-Dominguez M, García-Closas M, Giles GG, Glendon G, Guénel P, Gündert M, Hadjisavvas A, Hahnen E, Hall P, Hamann U, Harkness EF, Hartman M, Hogervorst FBL, Hollestelle A, Hoppe R, Howell A; kConFab Investigators; SGBCC Investigators; Jakubowska A, Jung A, Khusnutdinova E, Kim SW, Ko YD, Kristensen VN, Lakeman IMM, Li J, Lindblom A, Loizidou MA, Lophatananon A, Lubiński J, Luccarini C, Madsen MJ, Mannermaa A, Manooch M, Margolin S, **Mavroudis D**, Milne RL, Mohd Taib NA, Muir K, Nevanlinna H, Newman WG, Oosterwijk JC, Park SK, Peterlongo P, Radice P, Saloustros E, Sawyer EJ, Schmutzler RK, Shah M, Sim X, Southey MC, Surowy H, Suvanto M, Tomlinson I, Torres D, Truong T, van Asperen CJ, Waltes R, Wang Q, Yang XR, Pharoah PDP, Schmidt MK,... Breast cancer risks associated with missense variants in breast cancer susceptibility genes *Genome Med.* 2022 May 18;14(1):51. doi: 10.1186/s13073-022-01052-8.
318. Rounis K, Makrakis D, Gioulbasanis I, Ekman S, De Petris L, **Mavroudis D**, Agelaki S. Cancer Cachexia and Antitumor Immunity: Common Mediators and Potential Targets for New Therapies *Life (Basel)*. 2022 Jun 12;12(6):880. doi: 10.3390/life12060880.
319. Ingen-Housz-Oro S, Elshot YS, Segura S, Marchand A, Pouessel D, Kluger N, de Barros Silva G, Ortiz-Brugues A, Aubert M, Saldana C, **Mavroudis D**, Burle E, Tournier E, Koumaki D, Sibaud V. Skin toxicity of enfortumab vedotin:

Proposal of a specific management algorithm J Eur Acad Dermatol Venereol. 2024 Jan;38(1):e99-e101. doi: 10.1111/jdv.19454. Epub 2023 Aug 29

320. Mountzios G, Planchard D, Metro G, Tsiouda D, Prelaj A, Lampaki S, Shalata W, Riudavets M, Christopoulos P, Girard N, Albarrán-Artahona V, Garcia Campelo R, Samitas K, Banna GL, Boukovinas I, Agbarya A, Koumarianou A, Perdikouri EI, Kosmidis P, Linardou H, Mauri D, **Mavroudis D**, Athanasiadis I, Kalofonos H, Xenidis N, Korantzis I, Ardavanis A, Rallis G, Bottiglieri A, Efthymiadis K, Oikonomopoulos G, Kokkalis A, Saloustros E, Tsoukalas N, Bartzis D, Economopoulou P, Psyrri A, Reck M, Lo Russo G. Molecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era: The European EXOTIC Registry JTO Clin Res Rep. 2022 Nov 20;4(1):100433. doi: 10.1016/j.jtocrr.2022.100433. eCollection 2023 Jan.
321. Makrakis D, Rounis K, Tsigkas AP, Georgiou A, Galanakis N, Tsakonas G, Ekman S, Papadaki C, Monastirioti A, Kontogianni M, Gioulbasanis I, **Mavroudis D**, Agelaki S. Effect of body tissue composition on the outcome of patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors PLoS One. 2023 Feb 10;18(2):e0277708. doi: 10.1371/journal.pone.0277708. eCollection 2023
322. Figlioli G, Billaud A, Wang Q, Bolla MK, Dennis J, Lush M, Kvist A, Adank MA, Ahearn TU, Antonenkova NN, Auvinen P, Behrens S, Bermisheva M, Bogdanova NV, Bojesen SE, Bonanni B, Brüning T, Camp NJ, Campbell A, Castela JE, Cessna MH, Nbcsc Collaborators, Czene K, Devilee P, Dörk T, Eriksson M, Fasching PA, Flyger H, Gabrielson M, Gago-Dominguez M, García-Closas M, Glendon G, Gómez García EB, González-Neira A, Grassmann F, Guénel P, Hahnen E, Hamann U, Hillemanns P, Hoening MJ, Hoppe R, Howell A, Humphreys K, kConFab Investigators, Jakubowska A, Khusnutdinova EK, Kristensen VN, Lindblom A, Loizidou MA, Lubiński J, Mannermaa A, Maurer T, **Mavroudis D**, Newman WG, Obi N, Panayiotidis MI, Radice P, Rashid MU, Rhenius V, Ruebner M, Saloustros E, Sawyer EJ, Schmidt MK, Schmutzler RK, Shah M, Southey MC, Tomlinson I, Truong T, van Veen EM, Wendt C, Yang XR, Michailidou K, Dunning AM, Pharoah PDP, Easton DF, Andrulis IL, Evans DG, Hollestelle A, Chang-Claude J, Milne RL, Peterlongo P. Spectrum and Frequency of Germline FANCM Protein-Truncating Variants in 44,803 European Female Breast Cancer Cases Cancers (Basel). 2023 Jun 23;15(13):3313. doi: 10.3390/cancers15133313.

323. Sfakianaki M, Tzardi M, Tsantaki K, Koutoulaki C, Messaritakis I, Datseri G, Moustou E, **Mavroudis D** Evaluation of Microsatellite Instability Molecular Analysis versus Immuno-Histochemical Interpretation in Malignant Neoplasms with Different Localizations Cancers (Basel). 2023 Jan 5;15(2):353. doi: 10.3390/cancers15020353
324. Breast Cancer Association Consortium; Mavaddat N, Dorling L, Carvalho S, Allen J, González-Neira A, Keeman R, Bolla MK, Dennis J, Wang Q, Ahearn TU, Andrulis IL, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Blomqvist C, Bogdanova NV, Bojesen SE, Briceno I, Brüning T, Camp NJ, Campbell A, Castela JE, Chang-Claude J, Chanock SJ, Chenevix-Trench G, Christiansen H, Czene K, Dörk T, Eriksson M, Evans DG, Fasching PA, Figueroa JD, Flyger H, Gabrielson M, Gago-Dominguez M, Geisler J, Giles GG, Guénel P, Hadjisavvas A, Hahnen E, Hall P, Hamann U, Hartikainen JM, Hartman M, Hoppe R, Howell A, Jakubowska A, Jung A, Khusnutdinova EK, Kristensen VN, Li J, Lim SH, Lindblom A, Loizidou MA, Lophatananon A, Lubinski J, Madsen MJ, Mannermaa A, Manoochehri M, Margolin S, **Mavroudis D**, Milne RL, Mohd Taib NA, Morra A, Muir K, Obi N, Osorio A, Park-Simon TW, Peterlongo P, Radice P, Saloustros E, Sawyer EJ, Schmutzler RK, Shah M, Sim X, Southey MC, Thorne H, Tomlinson I, Torres D, Truong T, Yip CH, Spurdle AB, Vreeswijk MPG, Dunning AM, García-Closas M, Pharoah PDP, Kvist A, Muranen TA, Nevanlinna H, Teo SH, Devilee P, Schmidt MK, Easton DF. Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes JAMA Oncol. 2022 Mar 1;8(3):e216744. doi: 10.1001/jamaoncol.2021.6744. Epub 2022 Mar 17.
325. Nikovia V, Chinis E, Gkantaifi A, Marketou M, Mazonakis M, Charalampakis N, **Mavroudis D**, Orfanidou KV, Varveris A, Antoniadis C, Tolia M. Current Cardioprotective Strategies for the Prevention of Radiation-Induced Cardiotoxicity in Left-Sided Breast Cancer Patients J Pers Med. 2023 Jun 24;13(7):1038. doi: 10.3390/jpm13071038.
326. Yiangou K, Mavaddat N, Dennis J, Zanti M, Wang Q, Bolla MK, Abubakar M, Ahearn TU, Andrulis IL, Anton-Culver H, Antonenkova NN, Arndt V, Aronson KJ, Augustinsson A, Baten A, Behrens S, Bermisheva M, de Gonzalez AB, Białkowska K, Boddicker N, Bodelon C, Bogdanova NV, Bojesen SE, Brantley KD, Brauch H, Brenner H, Camp NJ, Canzian F, Castela JE, Cessna MH, Chang-Claude J, Chenevix-Trench G, Chung WK; NBCS Collaborators; Colonna SV, Couch FJ, Cox A, Cross SS, Czene K, Daly MB, Devilee P, Dörk T,

Dunning AM, Eccles DM, Eliassen AH, Engel C, Eriksson M, Evans DG, Fasching PA, Fletcher O, Flyger H, Fritschi L, Gago-Dominguez M, Gentry-Maharaj A, González-Neira A, Guénel P, Hahnen E, Haiman CA, Hamann U, Hartikainen JM, Ho V, Hodge J, Hollestelle A, Honisch E, Hooning MJ, Hoppe R, Hopper JL, Howell S, Howell A; ABCTB Investigators; kConFab Investigators; Jakovchevska S, Jakubowska A, Jernström H, Johnson N, Kaaks R, Khusnutdinova EK, Kitahara CM, Koutros S, Kristensen VN, Lacey JV, Lambrechts D, Lejbkowitz F, Lindblom A, Lush M, Mannermaa A, **Mavroudis D**, Menon U, Murphy RA, Nevanlinna H, Obi N, Offit K, Park-Simon TW, Patel AV, Peng C, Peterlongo P, Pita G, Plaseska-Karanfilska D,... Differences in polygenic score distributions in European ancestry populations: implications for breast cancer risk prediction medRxiv [Preprint]. 2024 Feb 13:2024.02.12.24302043. doi: 10.1101/2024.02.12.24302043

327. Dennis J, Tyrer JP, Walker LC, Michailidou K, Dorling L, Bolla MK, Wang Q, Ahearn TU, Andrulis IL, Anton-Culver H, Antonenkova NN, Arndt V, Aronson KJ, Freeman LEB, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Bogdanova NV, Bojesen SE, Brenner H, Castela JE, Chang-Claude J, Chenevix-Trench G, Clarke CL; NBCS Collaborators; Collée JM; CTS Consortium; Couch FJ, Cox A, Cross SS, Czene K, Devilee P, Dörk T, Dossus L, Eliassen AH, Eriksson M, Evans DG, Fasching PA, Figueroa J, Fletcher O, Flyger H, Fritschi L, Gabrielson M, Gago-Dominguez M, García-Closas M, Giles GG, González-Neira A, Guénel P, Hahnen E, Haiman CA, Hall P, Hollestelle A, Hoppe R, Hopper JL, Howell A; ABCTB Investigators; kConFab/AOCS Investigators; Jager A, Jakubowska A, John EM, Johnson N, Jones ME, Jung A, Kaaks R, Keeman R, Khusnutdinova E, Kitahara CM, Ko YD, Kosma VM, Koutros S, Kraft P, Kristensen VN, Kubelka-Sabit K, Kurian AW, Lacey JV, Lambrechts D, Larson NL, Linet M, Ogrodniczak A, Mannermaa A, Manoukian S, Margolin S, **Mavroudis D**, Milne RL, Muranen TA, Murphy RA, Nevanlinna H, Olson JE, Olsson H, Park-Simon TW, Perou CM, Peterlongo P, Plaseska-Karanfilska D, Pyrkäs K, Rennert G, Saloustros E, S... Rare germline copy number variants (CNVs) and breast cancer risk Commun Biol. 2022 Jan 18;5(1):65. doi: 10.1038/s42003-021-02990-6.

328. Cazzaniga ME, Ciaccio A, Danesi R, Duhoux FP, Girmenia C, Zaman K, Lindman H, Luppi F, **Mavroudis D**, Paris I, Olubukola A, Samreen A, Schem C, Singer C, Snegovoy A. Late onset toxicities associated with the use of CDK 4/6 inhibitors in hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer patients: a multidisciplinary, pan-EU position paper regarding their optimal

management. The GIOCONDA project Front Oncol. 2023 Oct 26;13:1247270. doi: 10.3389/fonc.2023.1247270. eCollection 2023.

329. Mountzios G, Koumarianou A, Linardou H, Boutis A, **Mavroudis D**, Samantas E, Korantzis I, Athanasiadis E, Fergadis EG, Lampaki S, Georgoulas V, Baka S, Karamouzis MV, Boukovinas I, Andreadis C, Rapti A, Koulouris N, Pentheroudakis G, Froudarakis ME, Somarakis A, Anastasopoulou E, Karadimou A, Papageorgiou F, Paparepa Z, Nikolaou A, Papista C, Syrigos KN. Clinical Outcomes Beyond 1L EGFR-TKI Progression in mNSCLC: Final Results of the Real-World Study 'LUNGFUL' Anticancer Res. 2023 May;43(5):2243-2258. doi: 10.21873/anticancer.16388
330. Koulouridi A, Karagianni M, Messaritakis I, Sfakianaki M, Voutsina A, Trypaki M, Bachlitzanaki M, Koustas E, Karamouzis MV, Ntavatzikos A, Koumarianou A, Androulakis N, **Mavroudis D**, Tzardi M, Souglakos J. Prognostic Value of KRAS Mutations in Colorectal Cancer Patients Cancers (Basel). 2022 Jul 7;14(14):3320. doi: 10.3390/cancers14143320.
331. Bamias A, Zakopoulou R, Tzannis K, Sakellakis M, Koutsoukos K, Kyriazoglou A, Panagiotou A, Armylagos S, Rokas K, Gotzias D, Boulouta A, Bozionelou V, Stravodimos K, Varkarakis I, **Mavroudis D**, Dimopoulos MA. Outcomes from treatment of metastatic renal-cell carcinoma following failure of first-line anti-VEGF/VEGFR therapy: real-life evidence on the change of the treatment paradigm Anticancer Drugs. 2023 Mar 1;34(3):413-421. doi: 10.1097/CAD.0000000000001420. Epub 2022 Nov 16.
332. Morra A, Schreurs MAC, Andrulis IL, Anton-Culver H, Augustinsson A, Beckmann MW, Behrens S, Bojesen SE, Bolla MK, Brauch H, Broeks A, Buys SS, Camp NJ, Castela JE, Cessna MH, Chang-Claude J, Chung WK, Collaborators N, Colonna SV, Couch FJ, Cox A, Cross SS, Czene K, Daly MB, Dennis J, Devilee P, Dörk T, Dunning AM, Dwek M, Easton DF, Eccles DM, Eriksson M, Evans DG, Fasching PA, Fehm TN, Figueroa JD, Flyger H, Gabrielson M, Gago-Dominguez M, García-Closas M, García-Sáenz JA, Genkinger J, Grassmann F, Gündert M, Hahnen E, Haiman CA, Hamann U, Harrington PA, Hartikainen JM, Hoppe R, Hopper JL, Houlston RS, Howell A, Investigators A, Investigators K, Jakubowska A, Janni W, Jernström H, John

EM, Johnson N, Jones ME, Kristensen VN, Kurian AW, Lambrechts D, Marchand LL, Lindblom A, Lubiński J, Lux MP, Mannermaa A, **Mavroudis D**, Mulligan AM, Muranen TA, Nevanlinna H, Nevelsteen I, Neven P, Newman WG, Obi N, Offit K, Olshan AF, Park-Simon TW, Patel AV, Peterlongo P, Phillips KA, Plaseska-Karanfilska D, Polley EC, Presneau N, Pylkäs K, Rack B, Radice P, Rashid MU, Rhenius V, Robson M, Romero A, Saloustros E, Sawyer EJ, Schmutzler RK, Schuetze S, Scott C, Shah M, Smichkoska S, Southey... Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival Res Sq [Preprint]. 2023 Feb 13;rs.3.rs-2569372. doi: 10.21203/rs.3.rs-2569372/v1.

333. Monastirioti A, Papadaki C, Kalapanida D, Rounis K, Michaelidou K, Papadaki MA, **Mavroudis D**, Agelaki S. Plasma-Based microRNA Expression Analysis in Advanced Stage NSCLC Patients Treated with Nivolumab Cancers (Basel). 2022 Sep 28;14(19):4739. doi: 10.3390/cancers14194739
334. Kaltsas G, Andreadis C, Kosmidis P, **Mavroudis D**, Pazaitou-Panayiotou K, Vaslamatzis M, Athanasiadis I. A Real-world Multicenter Prospective Study of Everolimus in Pancreatic Neuroendocrine Tumors: The 'PROTOR' Study Anticancer Res. 2022 Apr;42(4):1941-1948. doi: 10.21873/anticancer.15672.
335. Papadaki C, Stratigos M, Markakis G, Spiliotaki M, Mastrostamatis G, Nikolaou C, **Mavroudis D**, Agelaki S Correction to: Circulating microRNAs in the early prediction of disease recurrence in primary breast cancer Breast Cancer Res. 2022 Jul 22;24(1):53. doi: 10.1186/s13058-022-01544-w.
336. Bachlitzanaki M, Aletras G, Bachlitzanaki E, Messaritakis I, Koukias S, Koulouridi A, Bachlitzanakis E, Kaloeidi E, Vakonaki E, Kontopodis E, Androulakis N, Chamilos G, **Mavroudis D**, Ioannou P, Kofteridis D. Evaluation of Febrile Neutropenia in Hospitalized Patients with Neoplasia Undergoing Chemotherapy Microorganisms. 2023 Oct 12;11(10):2547. doi: 10.3390/microorganisms11102547.

337. Kalpadakis S, Sifaki-Pistolla D, Symvoulakis EK, Kelefiotis-Stratidakis P, Vamvakas L, **Mavroudis D**, Lionis C. Reporting Liver Cancer Trends in the Island of Crete, Greece: Results from a Geo-Epidemiological Study *Int J Environ Res Public Health*. 2022 Aug 17;19(16):10166. doi: 10.3390/ijerph191610166.
338. Gerratana L, Pierga JY, Reuben JM, Davis AA, Wehbe FH, Dirix L, Fehm T, Nolé F, Gisbert-Criado R, **Mavroudis D**, Grisanti S, Garcia-Saenz JA, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, Bonotto M, Fernandez de Lascoiti A, De Mattos-Arruda L, Ignatiadis M, Sandri MT, Generali D, De Angelis C, Dawson SJ, Janni W, Carañana V, Riethdorf S, Solomayer EF, Puglisi F, Giuliano M, Pantel K, Bidard FC, Cristofanilli M. Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design *Simulation Oncologist*. 2022 Jul 5;27(7):e561-e570. doi: 10.1093/oncolo/oyac045
339. Carlsson G, Koumarianou A, Guren TK, Haux J, Katsaounis P, Kentepozidis N, Pfeiffer P, Brændengen M, **Mavroudis D**, Taflin H, Skintemo L, Tell R, Papadimitriou C. A phase I/II study of arfolitixorin and 5-fluorouracil in combination with oxaliplatin (plus or minus bevacizumab) or irinotecan in metastatic colorectal cancer *ESMO Open*. 2022 Oct;7(5):100589. doi: 10.1016/j.esmoop.2022.100589. Epub 2022 Sep 29
340. Messaritakis I, Koulouridi A, Boukla E, Sfakianaki M, Vogiatzoglou K, Karagianni M, Gouvas N, Tsiaoussis J, Xynos E, Athanasakis E, **Mavroudis D**, Tzardi M, Souglakos J. Investigation of Microbial Translocation, TLR and VDR Gene Polymorphisms, and Recurrence Risk in Stage III Colorectal Cancer Patients *Cancers (Basel)*. 2022 Sep 10;14(18):4407. doi: 10.3390/cancers14184407.
341. Papadaki MA, Mala A, Merodoulaki AC, Vassilakopoulou M, **Mavroudis D**, Agelaki S. Investigating the Role of CTCs with Stem/EMT-like Features in Metastatic Breast Cancer Patients Treated with Eribulin Mesylate *Future Oncol*. 2022 Sep;18(28):3151-3164. doi: 10.2217/fon-2022-0386. Epub 2022 Aug 5

342. Sifaki-Pistolla D, Poimenaki V, Fotopoulou I, Saloustros E, **Mavroudis D**, Vamvakas L, Lionis C. Significant Rise of Colorectal Cancer Incidence in Younger Adults and Strong Determinants: 30 Years Longitudinal Differences between under and over 50s Cancers (Basel). 2022 Sep 30;14(19):4799. doi: 10.3390/cancers14194799.
343. Papadaki MA, Monastirioti A, Apostolopoulou CA, Aggouraki D, Papadaki C, Michaelidou K, Vassilakopoulou M, Alexakou K, **Mavroudis D**, Agelaki S. TLR4 and pSTAT3 Expression on Circulating Tumor Cells (CTCs) and Immune Cells in the Peripheral Blood of Breast Cancer Patients: Prognostic Implications Cancers (Basel). 2022 Feb 18;14(4):1053. doi: 10.3390/cancers14041053.
344. Rounis K, Makrakis D, Papadaki C, Monastirioti A, Vamvakas L, Kalbakis K, Gourelia K, Xanthopoulos I, Tsamardinos I, **Mavroudis D**, Agelaki S., Correction: Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution study PLoS One. 2023 Nov 9;18(11):e0294382. doi: 10.1371/journal.pone.0294382. eCollection 2023.
345. Messaritakis I, Psaroudaki E, Vogiatzoglou K, Sfakianaki M, Topalis P, Iliopoulos I, **Mavroudis D**, Tsiaoussis J, Gouvas N, Tzardi M, Souglakos J. Unraveling the Role of Molecular Profiling in Predicting Treatment Response in Stage III Colorectal Cancer Patients: Insights from the IDEA International Study Cancers (Basel). 2023 Sep 30;15(19):4819. doi: 10.3390/cancers15194819.
346. Michaelidou K, Karniadakis I, Pantelaion V, Koutoulaki C, Boukla E, Folinas K, Dimaras P, Papadaki MA, Koutsopoulos AV, **Mavroudis D**, Vourlakou C, Mavridis K, Agelaki S. Rapid and reliable testing for clinically actionable EGFR mutations in non-small cell lung cancer using the Idylla™ platform: a real-world two-center experience in Greece Expert Rev Mol Diagn. 2024 Jan-Feb;24(1-2):89-98. doi: 10.1080/14737159.2024.2303320. Epub 2024 Jan 11.

347. Bafaloukos D, Kouzis P, Gouveris P, Boukovinas I, Kalbakis K, Baka S, Kyriakakis G, Moschou D, Molfeta A, Demiri S, **Mavroudis D**, Spanoudi F, Dimitriadis I, Gogas H. Real-world management practices and characteristics of patients with advanced melanoma initiated on immuno-oncology or targeted therapy in the first-line setting during the period 2015-2018 in Greece. The 'SUMMER' study: a retrospective multicenter chart review project Melanoma Res. 2024 Apr 1;34(2):152-165. doi: 10.1097/CMR.0000000000000949. Epub 2023 Dec 13.
348. Yiangou K, Mavaddat N, Dennis J, Zanti M, Wang Q, Bolla MK, Abubakar M, Ahearn TU, Andrulis IL, Anton-Culver H, Antonenkova NN, Arndt V, Aronson KJ, Augustinsson A, Baten A, Behrens S, Bermisheva M, de Gonzalez AB, Białkowska K, Boddicker N, Bodelon C, Bogdanova NV, Bojesen SE, Brantley KD, Brauch H, Brenner H, Camp NJ, Canzian F, Castelao JE, Cessna MH, Chang-Claude J, Chenevix-Trench G, Chung WK; NBCS Collaborators; Colonna SV, Couch FJ, Cox A, Cross SS, Czene K, Daly MB, Devilee P, Dörk T, Dunning AM, Eccles DM, Eliassen AH, Engel C, Eriksson M, Evans DG, Fasching PA, Fletcher O, Flyger H, Fritschi L, Gago-Dominguez M, Gentry-Maharaj A, González-Neira A, Guénel P, Hahnen E, Haiman CA, Hamann U, Hartikainen JM, Ho V, Hodge J, Hollestelle A, Honisch E, Hooning MJ, Hoppe R, Hopper JL, Howell S, Howell A; ABCTB Investigators; kConFab Investigators; Jakovchevska S, Jakubowska A, Jernström H, Johnson N, Kaaks R, Khusnutdinova EK, Kitahara CM, Koutros S, Kristensen VN, Lacey JV, Lambrechts D, Lejbkiewicz F, Lindblom A, Lush M, Mannermaa A, **Mavroudis D**, Menon U, Murphy RA, Nevanlinna H, Obi N, Offit K, Park-Simon TW, Patel AV, Peng C, Peterlongo P, Pita G, Plaseska-Karanfilska D,... Differences in polygenic score distributions in European ancestry populations: implications for breast cancer risk prediction. MedRxiv.[Preprint]. 2024 Feb 13:2024.02.12.24302043. doi: 10.1101/2024.02.12.24302043.
349. Tsiligianni I, Christodoulakis A, Monastirioti A, **Mavroudis D**, Agelaki S. The journey of lung cancer patients from symptoms to diagnosis in Greece. A mixed methods approach. NPJ Prim Care Respir Med. 2024 Apr 29;34(1):5. doi: 10.1038/s41533-024-00359-w
350. Thomopoulou K, Papadaki C, Monastirioti A, Koronakis G, Mala A, Kalapanida D, **Mavroudis D**, Agelaki S. Corrigendum: MicroRNAs regulating tumor immune response in the prediction of the outcome in patients with breast cancer. Front Mol Biosci. 2024 Apr 23;11:1413164. doi: 10.3389/fmolb.2024.1413164. eCollection 2024

351. Lagoudaki ED, Koutsopoulos AV, Sfakianaki M, Papadaki C, Manikis GC, Voutsina A, Trypaki M, Tsakalaki E, Fiolitaki G, Hatzidaki D, Yiachnakis E, Koumaki D, **Mavroudis D**, Tzardi M, Stathopoulos EN, Marias K, Georgoulas V, Souglakos J. LKB1 Loss Correlates with STING Loss and, in Cooperation with β -Catenin Membranous Loss, Indicates Poor Prognosis in Patients with Operable Non-Small Cell Lung Cancer. *Cancers (Basel)*. 2024 May 10;16(10):1818. doi: 10.3390/cancers16101818.
352. Messaritakis I, Koulouris A, Boukla E, Vogiatzoglou K, Lagkouvardos I, Intze E, Sfakianaki M, Chondrozoumaki M, Karagianni M, Athanasakis E, Xynos E, Tsiaoussis J, Christodoulakis M, Flamourakis ME, Tsagkataki ES, Giannikaki L, Chliara E, **Mavroudis D**, Tzardi M, Souglakos J. Exploring Gut Microbiome Composition and Circulating Microbial DNA Fragments in Patients with Stage II/III Colorectal Cancer: A Comprehensive Analysis. *Cancers (Basel)*. 2024 May 18;16(10):1923. doi: 10.3390/cancers16101923.
353. Davidson AL, Michailidou K, Parsons MT, Fortuno C, Bolla MK, Wang Q, Dennis J, Naven M, Abubakar M, Ahearn TU, Alonso MR, Andrulis IL, Antoniou AC, Auvinen P, Behrens S, Bermisheva MA, Bogdanova NV, Bojesen SE, Brüning T, Byers HJ, Camp NJ, Campbell A, Castelao JE, Cessna MH, Chang-Claude J, Chanock SJ, Chenevix-Trench G; NBCS Collaborators; Collée JM, Czene K, Dörk T, Eriksson M, Evans DG, Fasching PA, Figueroa JD, Flyger H, Gago-Dominguez M, García-Closas M, Glendon G, González-Neira A, Grassmann F, Gronwald J, Guénel P, Hadjisavvas A, Haeberle L, Hall P, Hamann U, Hartman M, Ho PJ, Hooning MJ, Hoppe R, Howell A; kConFab Investigators; Jakubowska A, Khusnutdinova EK, Kristensen VN, Li J, Lim J, Lindblom A, Liu J, Lophatananon A, Mannermaa A, **Mavroudis DA**, Mensenkamp AR, Milne RL, Muir KR, Newman WG, Obi N, Panayiotidis MI, Park SK, Park-Simon TW, Peterlongo P, Radice P, Rashid MU, Rhenius V, Saloustros E, Sawyer EJ, Schmidt MK, Seibold P, Shah M, Southey MC, Teo SH, Tomlinson I, Torres D, Truong T, van de Beek I, van der Hout AH, Wendt CC, Dunning AM, Pharoah PDP, Devilee P, Easton DF, James PA, Spurdle AB. Co-observation of germline pathogenic variants in breast cancer predisposition genes: Results from analysis of the BRIDGES sequencing dataset. *Am J Hum Genet*. 2024 Sep 5;111(9):2059-2069. doi: 10.1016/j.ajhg.2024.07.004. Epub 2024 Aug 2.
354. Papadaki MA, Papadaki E, Chatziavraam S, Aggouraki D, Michaelidou K, Fotsitzoudis C, Vassilakopoulou M, **Mavroudis D**, Agelaki S. Prognostic Value

of Fas/Fas Ligand Expression on Circulating Tumor Cells (CTCs) and Immune Cells in the Peripheral Blood of Patients with Metastatic Breast Cancer. *Cancers (Basel)*. 2024 Aug 23;16(17):2927. doi: 10.3390/cancers16172927.

355. Zanti M, O'Mahony DG, Parsons MT, Dorling L, Dennis J, Boddicker NJ, Chen W, Hu C, Naven M, Yiangou K, Ahearn TU, Ambrosone CB, Andrulis IL, Antoniou AC, Auer PL, Baynes C, Bodelon C, Bogdanova NV, Bojesen SE, Bolla MK, Brantley KD, Camp NJ, Campbell A, Castelao JE, Cessna MH, Chang-Claude J, Chen F, Chenevix-Trench G; NBCS Collaborators; Conroy DM, Czene K, De Nicolo A, Domchek SM, Dörk T, Dunning AM, Eliassen AH, Evans DG, Fasching PA, Figueroa JD, Flyger H, Gago-Dominguez M, García-Closas M, Glendon G, González-Neira A, Grassmann F, Hadjisavvas A, Haiman CA, Hamann U, Hart SN, Hartman MBA, Ho WK, Hodge JM, Hoppe R, Howell SJ; kConFab Investigators; Jakubowska A, Khusnutdinova EK, Ko YD, Kraft P, Kristensen VN, Lacey JV, Li J, Lim GH, Lindström S, Lophatananon A, Luccarini C, Mannermaa A, Martinez ME, **Mavroudis D**, Milne RL, Muir K, Nathanson KL, Nuñez-Torres R, Obi N, Olson JE, Palmer JR, Panayiotidis MI, Patel AV, Pharoah PDP, Polley EC, Rashid MU, Ruddy KJ, Saloustros E, Sawyer EJ, Schmidt MK, Southey MC, Tan VK, Teo SH, Teras LR, Torres D, Trentham-Dietz A, Truong T, Vachon CM, Wang Q, Weitzel JN, Yadav S, Yao S, Zirpoli GR, Cline MS, Devilee P, Tavtigian SV, Goldgar D...Analysis of more than 400,000 women provides case-control evidence for BRCA1 and BRCA2 variant classification. *MedRxiv*. [Preprint]. 2024 Sep 4:2024.09.04.24313051. doi: 10.1101/2024.09.04.24313051.
356. Yiangou K, Mavaddat N, Dennis J, Zanti M, Wang Q, Bolla MK, Abubakar M, Ahearn TU, Andrulis IL, Anton-Culver H, Antonenkova NN, Arndt V, Aronson KJ, Augustinsson A, Baten A, Behrens S, Bermisheva M, de Gonzalez AB, Białkowska K, Boddicker N, Bodelon C, Bogdanova NV, Bojesen SE, Brantley KD, Brauch H, Brenner H, Camp NJ, Canzian F, Castelao JE, Cessna MH, Chang-Claude J, Chenevix-Trench G, Chung WK; NBCS Collaborators; Colonna SV, Couch FJ, Cox A, Cross SS, Czene K, Daly MB, Devilee P, Dörk T, Dunning AM, Eccles DM, Eliassen AH, Engel C, Eriksson M, Evans DG, Fasching PA, Fletcher O, Flyger H, Fritschi L, Gago-Dominguez M, Gentry-Maharaj A, González-Neira A, Guénel P, Hahnen E, Haiman CA, Hamann U, Hartikainen JM, Ho V, Hodge J, Hollestelle A, Honisch E, Hoening MJ, Hoppe R, Hopper JL, Howell S, Howell A; ABCTB Investigators; kConFab Investigators; Jakovchevska S, Jakubowska A, Jernström H, Johnson N, Kaaks R, Khusnutdinova EK, Kitahara CM, Koutros S, Kristensen VN, Lacey JV, Lambrechts D, Lejbkowitz F, Lindblom A, Lush M, Mannermaa A, **Mavroudis D**, Menon U, Murphy RA, Nevanlinna H, Obi N, Offit K, Park-Simon TW, Patel

AV, Peng C, Peterlongo P, Pita G, Plaseska-Karanfilska D,... Polygenic score distribution differences across European ancestry populations: implications for breast cancer risk prediction. *Breast Cancer Res.* 2024 Dec 29;26(1):189. doi: 10.1186/s13058-024-01947-x.

357. Mountzios G, Lampaki S, Linardou H, Georgoulas V, **Mavroudis D**, Anevlaivis S, Charpidou A, Lykka M, Spyrtos D, Sarris EG, Somarakis A, Papista C, Glentis A, Nikolaou A, Paparepa Z, Papageorgiou F, Syrigos KN. Real-world treatment patterns in patients with non-metastatic non-small cell lung cancer in Greece: the 'EVIDENCE' study. *Future Oncol.* 2025 Feb;21(4):447-462. doi: 10.1080/14796694.2024.2442295. Epub 2025 Jan 9.
358. Starace M, Rapparini L, Cedirian S, Quadrelli F, Pampaloni F, Bruni F, Misciali C, Piraccini BM, Apalla Z, Fattore D, Segura S, Koumaki D, **Mavroudis D**, Iorizzo M, Elshot YS, Freitas-Martinez A, Sollena P, Delli F, Jaka A, Nikolaou V, Giaccherio D, Riganti J, Sibaud V. Erosive pustular dermatosis of the scalp due to EGFR inhibitors: A multicentric study by EADV task force of 'Dermatology for Cancer Patients'. *J Eur Acad Dermatol Venereol.* 2025 Feb 3. doi: 10.1111/jdv.20569. Online ahead of print.
359. Boukouris AE, Kokkinakis I, Drakos E, Sfakianaki M, Tzardi M, **Mavroudis D**, Souglakos J. Case report: a rare case of diffusely metastatic BRAF V600E-mutated colorectal cancer with concomitant infiltration of the skin and parotid gland. *Front Oncol.* 2025 Jan 28;15:1512000. doi: 10.3389/fonc.2025.1512000. eCollection 2025.
360. Hoppe R, Winter S, Lo WY, Michailidou K, Bolla MK, Keeman R, Wang Q, Dennis J, Lush M, Kalari KR, Goetz MP, Wang L, Cairns J, Weinshilboum R, Shepherd L, Chen BE, Häberle L, Ruebner M, Beckmann MW, He W, Larson NL, Armasu SM, Schroth W, Chowbay B, Khor CC, Abubakar M, Antoniou AC, Brüning T, Castela JE, Chang-Claude J, NbcS Collaborators, Dörk T, Eccles DM, Figueroa JD, Gago-Dominguez M, García-Sáenz JA, Gündert M, Hack CC, Hamann U, Han S, Hoening MJ, Huebner H, Abctb Investigators, John EM, Ko YD, Kristensen VN, Linn S, Margolin S, **Mavroudis D**, Nevanlinna H, Neven P, Obi N, Park-Simon TW, Pyrkäs K, Rashid MU, Romero A, Saloustros E, Sawyer EJ, Tapper WJ, Tomlinson I, Wendt C, Winqvist R, Dunning AM, Simard J, Hall

P, Pharoah PDP, Schwab M, Couch FJ, Czene K, Fasching PA, Easton DF, Schmidt MK, Ingle JN, Brauch H. Lessons learned from a candidate gene study investigating aromatase inhibitor treatment outcome in breast cancer. *NPJ Breast Cancer*. 2025 Feb 19;11(1):18. doi: 10.1038/s41523-025-00733-y.

361. Janni W, Friedl TWP, Yab TC, Bidard FC, Cristofanilli M, Hayes DF, Ignatiadis M, Regan MM, Alix-Panabieres C, Barlow WE, Caldas C, Carey LA, Dirix L, Fehm T, Garcia-Saenz JA, Gazzaniga P, Generali D, Gerratana L, Gisbert-Criado R, Jacot W, Jiang Z, Joosse SA, Lianidou E, López López R, Magbanua MJM, Manso L, **Mavroudis D**, Müller V, Munzone E, Pantel K, Pierga JY, Rack B, Riethdorf S, Rugo HS, Sideras K, Sleijfer S, Smerage J, Stebbing J, Terstappen LWMM, Vidal-Martínez J, Wallwiener M, Giridhar KV, Liu MC. Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis *Clin Cancer Res*. 2025 Jun 3;31(11):2196-2209. doi: 10.1158/1078-0432.CCR-24-3108. PMID: 40100138
362. Georgopoulos NS, Tolia M, Boulouta A, Kyriazoglou A, Patriarcheas V, Dimakakos E, Schizas D, Mauri D, Tsoukalas N, Chalampakakis N, De Mello RA, Antoniadis C, de Bree E, Michelakis D, Tsapakidis K, Mazonakis M, Kountourakis P, Nixon I, **Mavroudis D**, Gkantaifi A. Wound Healing Complications after Neoadjuvant Radiotherapy Combined with Targeted Therapies in Soft Tissue Sarcoma Patients. *Rev Recent Clin Trials*. 2025 Mar 28. doi: 10.2174/0115748871354960250315170817. Online ahead of print. PMID: 40176686
363. Riganti J, Torre AC, Sollena P, Koumaki D, Freites-Martinez A, Delyon J, Communie A, Starace M, Rapparini L, Lallas A, **Mavroudis D**, Suzanne D, Mazzuocolo LD, Bobos M, Sibaud V, Apalla Z. Immune Checkpoint Inhibitor-Induced Lipodystrophy. *JAMA Dermatol*. 2025 Jun 1;161(6):658-661. doi: 10.1001/jamadermatol.2025.0359. PMID: 40202750

364. Gkantaifi A, Papadopoulos C, Toumpourleka M, Marketou M, Mauri D, Giakoumettis G, **Mavroudis D**, Tolia M. A Prospective Study on the Role of Strain Echocardiography in Detecting Early Radiation-induced Cardiotoxicity in Left-sided Breast Cancer Patients *Rev Recent Clin Trials*. 2025 May 8. doi: 10.2174/0115748871338729250418152731. Online ahead of print.PMID: 40353406
365. Zanti M, O'Mahony DG, Parsons MT, Dorling L, Dennis J, Boddicker NJ, Chen W, Hu C, Naven M, Yiangou K, Ahearn TU, Ambrosone CB, Andrulis IL, Antoniou AC, Auer PL, Baynes C, Bodelon C, Bogdanova NV, Bojesen SE, Bolla MK, Brantley KD, Camp NJ, Campbell A, Castelao JE, Cessna MH, Chang-Claude J, Chen F, Chenevix-Trench G; NBCS Collaborators; Conroy DM, Czene K, De Nicolo A, Domchek SM, Dörk T, Dunning AM, Eliassen AH, Evans DG, Fasching PA, Figueroa JD, Flyger H, Gago-Dominguez M, García-Closas M, Glendon G, González-Neira A, Grassmann F, Hadjisavvas A, Haiman CA, Hamann U, Hart SN, Hartman MBA, Ho WK, Hodge JM, Hoppe R, Howell SJ; kConFab Investigators; Jakubowska A, Khusnutdinova EK, Ko YD, Kraft P, Kristensen VN, Lacey JV, Li J, Lim GH, Lindström S, Lophatananon A, Luccarini C, Mannermaa A, Martinez ME, **Mavroudis D**, Milne RL, Muir K, Nathanson KL, Nuñez-Torres R, Obi N, Olson JE, Palmer JR, Panayiotidis MI, Patel AV, Pharoah PDP, Polley EC, Rashid MU, Ruddy KJ, Saloustros E, Sawyer EJ, Schmidt MK, Southey MC, Tan VK, Teo SH, Teras LR, Torres D, Trentham-Dietz A, Truong T, Vachon CM, Wang Q, Weitzel JN, Yadav S, Yao S, Zirpoli GR, Cline MS, Devilee P, Tavtigian SV, Goldgar D. Analysis of more than 400,000 women provides case-control evidence for BRCA1 and BRCA2 variant classification. *Nat Commun*. 2025 May 25;16(1):4852. doi: 10.1038/s41467-025-59979-6.PMID: 40413188
366. Boukouris AE, Michaelidou K, Joosse SA, Charpidou A, **Mavroudis D**, Syrigos KN, Agelaki S. A comprehensive overview of minimal residual disease in the management of early-stage and locally advanced non-small cell lung cancer. *NPJ Precis Oncol*. 2025 Jun 13;9(1):178. doi: 10.1038/s41698-025-00984-9. PMID: 40514443

367. Papadaki C, Mortoglou M, Boukouris AE, Gourelia K, Markaki M, Lagoudaki E, Koutsopoulos A, Tsamardinos I, **Mavroudis D**, Agelaki S. MicroRNA Expression Analysis and Biological Pathways in Chemoresistant Non-Small Cell Lung Cancer. *Cancers (Basel)*. 2025 Jul 29;17(15):2504. doi: 10.3390/cancers17152504.PMID: 40805201
368. Semitekolou M, Paschalidis N, Lo Tartaro D, Tsitsopoulou A, Stamou P, Mavroudis A, Markaki E, Varveri A, Morianos I, Lavigne M, Fotsitzoudis C, Magkouta S, Dede K, Kalomenidis I, Samitas K, Potaris K, Cossarizza A, **Mavroudis D**, De Biasi S, Verginis P. Blood immunomap for prediction of responses to anti-PD-1 immunotherapy in metastatic non-small cell lung cancer. *iScience*. 2025 Jun 2;28(9):112804. doi: 10.1016/j.isci.2025.112804. eCollection 2025 Sep 19.PMID: 40860257